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Father Willitun
try011 are oldfather William", the young surgeon said,
"andyour colonfrom polyps isfree.
Yet most ofyour siblings are known to be dead -
A really badfamily tree. "
." In myyouth"father William replied with a grin,
"1 was told that a gene had mutated,
That all who carried this dominant gene
To polyps and cancer were fated
I sought advice from a medicalfriend,
Who sighed and said-"without doubt
YOUT only escape from an untimely end
Is to have your intestine right out".
" It seemed rather bad luck- I was then but nineteen-
So I went andconsulted a quack.
Who too/c afirm grip on my dominant gene
Andpromptly mutated it back"
"This", said the surgeon, "is something quite new
And before we ascribe a19' merit
We must see ifthe claims ofthisfelloware true,
And observe whatyour children inherit".
Dukes C. Familial intestinal polyposis. Ann Royal Coll Surg Eng. 1952; 293-304.
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Abstract
Colorectal cancer is the most common cause of death due to malignancy in non-
smokers in the western world In 1995 there were 1,757 cases of colon cancer in Ireland.
Most colon cancer is sporadic, however ten percent of cases occur where there is •
previous family history of the disease. In an attempt to Wlderstand the tumorigenic
pathway in Irish colon cancer patients, a number of genes associated with colorectal
cancer development were analysed in Irish sporadic and HNPCC colon cancer patients.
The hereditary fonns of colon cancer include Familial adenomatous polyposis coli
(FAP) and Hereditary Non-Polyposis Colon Cancer (HNPCC). Genetic analysis of the
gene responsible for FAP, (the APe gene) has been previously perfonned on Irish
families, however the genetic analysis of HNPCC families is limited. In III attempt to
determine the mutation spectrum in Irish HNPCC pedigrees, the hMSH2 and hMLHl
mismatch repair genes were screened in 18 Irish HNPCC families. Using SSCP analysis
followed by DNA sequencing, five mutations were identified, four novel and a previously
reported mutation. In families where a mutation was detected, younger asyptomatic
members were screened for the presence of the predisposing mutation (where possible).
Detection of mutations is particularly important for the identification of at risk
individuals as the early diagnosis of cancer can vastly improve the prognosis.
The sensitive and efficient detection of multiple different mutations and
polymorphisms in DNA is of prime importance for genetic diagnosis and the
identification of disease genes. A llOvel mutation detection technique hu recently been
developed in our laboratory. In order to assess the efficacy and application of the
methodology in the analysis of cancer associated genes, a protocol for the analysis of the
K-ns gene was developed and optimised. Matched llOnnal and tumour DNA from
twenty sporadic colon cancer patients was analysed for K-ns mutations using the
Glycosylase Mediated Polymorphism Detection technique. Five mutations of the K-ns
gene were detected using this technology. Sequencing analysis verified the presence of
the mutations and SSCP analysis of the same samples did not identify any additional
VB
mutations. The GMPD technology proved to be highly sensitive, accurate and efficient
in the identification ofK-ras gene mutations.
In order to investigate the role of the replication error phenomenon in Irish colon
cancer, 3 polyA tract repeat loci were analysed. The repeat loci included a 10 bp
intragenic repeat of the TGF-P-RII gene. TGF-P-RII is involved in the TGF-P epithelial
cell growth pathway and mutation of the gene is thought to play a role in cell
proliferation and tumorigenesis. Due to the presence of a repeat sequence within the
gene, TGFB-RII defects are associated with tumours that display the replication error
phenomenon. Analysis of the TGF-P-RII 10 bp repeat failed to identify mutations in any
colon cancer patients. Analysis of the Bat 26 and Bat 40 polyA repeat sequences in the
sporadic and HNPCC families revealed that instability is associated with HNPCC
tumours harbouring mismatch repair defects and with 200At of sporadic colon cancer
tumours. No correlation between K-ras gene mutations and the RER+ phenotype was
detected in sporadic colon cancer tumours. '.
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GENERAL INTRODUcnON '
THE GENES INVOLVED IN COWRECfAL CANCER
:;. ;'
I
(I) GENETICS OF COLORECfAL CANCER: GENERAL INTRODUCTION
Colorectal cancer is • common malignancy responsible for approximately 12010 of
all cancer deaths in Ireland each year (National Cancer Registry). Traditional diagnostic
IIld therapeutic approaches have made little impact on survival over the last 30 years.
Advances in molecular biology however, have greatly improved our understanding of the
disease, and have had a major impact OIl early detection, treatment and prevention of
colon cancer.
In recent yean the cloning, identification and mutation analysis of a number of
genes involved in colorectal cancer susceptibility and development hu resulted in an
unprecedented expansion in the knowledge of the fundamental genetic aspects of 1umour
biology. This general introduction briefly discusses the background of some of the most
important colorectal cancer genes and their roles in both hereditary and sporadic colon
cancer. A more detailed discussion of the topics of this thesis- HNPCC and the mismatch
repair genes (chapter 1), K-ru (chapter 2), TGF-P and the replication error phenotype
(chapter 3) is given in the subsequent chapters.
FAMILIAL ADENOMATOUS POLYPOSIS
Familial adenomatous polyposis (FAP) is 8ft autosomal dominantly inherited
cancer predisposition syndrome with reported incidence ranges from 1:17,000 to 1:5,000
(Utsonomiya and Lynch, 1990). Germline mutations in the APe gene are responsible for
the disease and data suggest that somatic mutations in APC are ubiquitous in colorectal
2
adenomu and carcinomu (Miyoshi et at., 1992; Powell et al., 1992). The disease is
characterised by the development of hundreds to thousands of adenomatous polyps in the
colon and rectum with the inevitable development of malignancy ill the absence of
prophylactic colectomy (Bussey, 1975).
Initial localisation of the APe gene wu suggested by cytogenic studies and
further mapping by genetic linkage analysis, localised the gene to a region on the long
arm of chromosome 5 (Bodmer It al., 1987). The APe gene was identified. the
causative gene when mutations in this gene were shown to segregate with FAP in affected
families (Nishisho et al., 1991). APe is a large gene consisting of 15 exons encoding a
2843 amino acid polypeptide, exons 1-14 are small whereas exon 15 accounts for 77010 of
the coding region (Kinzler et at., 1991). APe was classified IS a tumour suppressor gene
based on the frequently observed loll of heterozygosity It Sq21 in colon tumOUR
(Miyoshi et al., 1992). To date more than 300 mutations in the APC gene have been
described (Beroud et at., 1996), with 60% of all reported mutationa occurring in the 10-
called mutation cluster region encompassing codons 1000 to 1600 at the 5' part of exon
15 (Miyoshi et al., 1992). More than 95% of mutations result in a premature stop codon
with the result that a truncated protein is produced (Miyoshi et at., 1992). Within the
mutation cluster region, 10010 of mutations occur at coelons 1061 and 1309 (Nagase et al.,
1993). In the Irish population these mutations account for 6% and 11% of reported
germ.line APe mutations, rapectively (O'Sullivan et 81., 1998).
<, The APe gene encodes a 310kD protein with cytoplumic localisation. Insight
into the function of the protein '*lie when the a. and Jkatenjns were shown to co-purify
with the APe protein (Su et al., 1993). The catenins are a group of cytoplumic proteins
J
that were identified primarily due to their association with the cell adhesion molecule E-
cadherin. The association of these proteins with APe, suggests that the protein may play
a role in cell adhesion. Analysis of the role of C8tenjns in Drosophila suggest that the
APe complex may regulate transmission of the contact inhibition signal into the cell
(peifer et al., 1993). This hypothesis is consistent with the observation that APe
mutations are associated with the development of hyperplasia • III early event in
tumorigedesis. The APe protein has also been shown to associate with microtubules and
cell adhesion molecules to modify transcriptional activation and to alter cell cycle
regulation (Baeg et aI., 1995).
HEREDITARY NON-POLYPOSIS COLORECTAL CANCER.
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominantly
inherited cancer predisposition syndrome cbaracterised by the lack of any phenotype
other than the development of cancer at 1ft early age. The disease bas • high penetrance
and accounts for approximately l00At of cases of colorecta1 cancer (Bodmer et aI., 1994).
Adenomatous polyps are found in HNPCC but the numbers are much smaller than in
FAP (usually less than 10) whim is comparable to the frequency of adenomas in the
general population. There is • propensity for au-cinomas to develop in the proximal
colon and the age of onset is earlier thaD in the general population (Lynm et a1., 1993).
HNPCC can be inherited u a site specific colorectal cane« (Lynch Type I) or lISOCiated
with extraoolonic tumours sudl • stomach OVmlaa, uteriDe and other malignancies
(Lynch Type II) (Watson and Lynch, 1994). Gennline mutations in the human mismatch .
repair genes (bMSH2, hMLH1, hPMSl and hPMS2) have been causally linked to the
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disease (Leach et al., 1993; Papadopolous et al., 1994; Nicolaides et al., 1994). Genetic
analysis of these genes in affected pedigrees has greatly improved the understanding of
the disease and has facilitated in the detection of at risk individuals and in the early
detection and prevention of tumour development in these families. The genetic analysis
of HNPCC in the Irish population has been limited and the mutation spectrum in
mismatch repair genes in Irish pedigrees has not been previously investigated. A more
detailed discussion ofHNPCC is given in section 1.1.
THE p53 GENE IN COLORECfAL CARCINOGENESIS.
Abnormalities of the p53 gene are the commonest genetic events associated with
human cancers (Hollstein et al., 1991). p53 is a phosphoprotein which enters the nucleus
of the cell during DNA synthesis, exerting control over the transcription of other genes
and regulating the onset of DNA replication at the G1-8 boundary of the cell cycle.
(Vogelstein et al., 1992). Under conditions of DNA damage in the cell, p53 appears to
block cell growth allowing DNA repair prior 10 cell division. In the absence of DNA
repair apoptosis may be induced, thereby preventing the further growth and replication of
a mutant cell (Yonish et al., 1991).
The pS3 mutation spectrum exhibits tissue specificity. Most mutations in
colorectal cancer are found in codons 175, 248, 278 and 282, these are most commonly
single bue transitions in CpO nucleotidea causing missense mutations (Prives et
11.,1993). These mutations result in the production of full length protein with abnormal
conformation and function. pS3 mutation is rare in colorectal adenoma, indicating that it .
s
occurs late in the process of tumorigenesis (Carder et aI., 1993) and is more likely
involved in tumour progression rather than development
DELETED IN COLON CANCER (DCC).
Deleted in colon cancer (DCC) has been associated with the cumulative mutation
pathway in the development of colon cancer (Fearon and Vogelstein, 1990). Mutations
in OCC are usociated with more than 7()OAt of colorecta1 carcinomas (Vogelstein et aI.,
1988). The gene encodes a receptor for netrin-l a molecule involved ill axon guidance
(Keino-Masu et aI., 1989). Recent investigations have shown that DCC induces apoptosis
in the absence of ligand binding, but blocks apoptosis when engaged by netrin-l (Mehlen
et aI., 1998). Mutation analysis of OCC suggests that the protein may function IS a
tumour sUpPreSSOr gene by inducing apoptosis in cells that are not exposed to the ligand •
u in metastatic or invuive cells. Mutations in OCC result in lou of function and
enhances cell survival of cells OU1Side the region of ligand availability. This is consistent
with reports that DCC mutation is a late event in the tumorigenic pathway of colon
cancer (Cho and Fearon, 1995).
THE K-RAS GENE.
The involvement of K-I'IS ia colorecta1 tumorigenesis has been widely
investigated. Mutations in K-ras have been identified in 500At ofcolon cancers (Bas et aI.,
1987; Forresster et aL, 1987). K-ras is • member of the l'8S gene family of cellu'"
oncogenes. These proetins play a role in signal transduction from G-protein coupled
receptors. A signal from the receptor triggers the binding of GTP to the ru protein and
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GTP-ras transmiu the signal onwards to the cell. The GTPase activity of the ras proteins
resulu in the rapid breakdown of the active GTP-ras to inactive GDP-ras (Barbacid et al.,
1987). Mutations in the TIS gene lead to reduced GTPase activity with the result that the
signal remains active longer, leading to excessive response to the signal from the receptor
and thus cellular proliferation (Barbacid et al., 1987). Mutations in K-ras have been
detected in carcinomas, adenomas and also in the earliest detectable cancer lesions
(aberrant crypt foci) of cancer patients (Shivapurkar et al., 1997~ Forrester et al., 1987~
Vogelstein et al., 1988). These findings suggest that K-ras mutations are an early event
in the tumorigenic pathway in colon cancer.
TRANSFORMING GROWTH FACfOR PRECEPTOR n
The transforming growth factor Pprotein (TGF-P) is a member of the supergene
family of facton that regulate cellular growth. TGF-P inhibits epithelial cell growth and
as such it is believed that alteration of the normal activity of this protein may have a role
in tumorigenesis (Roberts et al., 1990).
TGF-P forms a complex with two receptors; type I and type n, in the cell (Chea
et al., 1993). Mutation analysis of both recepton identified mutations in • intragenic
repeat region of the RII gene. These mutations were confmed 10 tumours displaying
miaosatellite instability (Markowitz et aI., 1995). The cumulative evidence from TGF-
pm studies reveal that 7o-900!e of RER+ tumoun (sporadic or HNPCC) barbour
mutatioDl in this gene. It bas been proposed that due to the nature of the intragenic
repeat sequences of TGFJi-RII- the gene is • target for mutations, which escape'
correction due to mismatch repair defects. The loss of tumour suppressor activity of
1
TGF~ (through the inactivation of RII) provides a selective growth advantage to the cells
thus advancing the tumorigenic pathway (Markowitz et al., 1995; Akiyama et al., 1996).
THE MULTISTEP PATHWAY OF COLORECTAL TUMORIGENESIS.
The molecular basis by which cancers arise has been investigated abundantly.
Due to the availability and relative ease of obtaining tumours at early, late and
intermediate stages of cancer development, colon cancer has become one of the most
widely investigated human cancers.
Tumorigenesis is believed to be a multistep process in which malignant colorectal
tumours arise from pre-existing benign adenomas. Histopathological and clinical
assessment of cancer development suggest that most tumours arise from early adenomas,
these progress in size, become dysplastic and eventually form an invasive tumour. This
concept is known as the theory of clonal expansion (Nowell et al., 1976; Loeb et al.,
1991). Various models have been proposed to explain the sequential development of
colon cancer. The most widely accepted genetic model for colorectal tumorigenesis
proposes that colorectal tumours arise IS a result of mutational inactivation of tumour
suppressor genes coupled to the mutational activation of cellular oncogenes. The model
proposes that at least four genes are required for the formatiOD of a tumour and that it is
the overall accumulation of mutations in specific genes such as DCC, APe, K-ru, p53
and the human mismatch repair genes that give rise to a tumour. (Fearon et al., 1990).
The increased understanding of the molecular mechanisms underlying the·
development of colorectal tumourigenesis will greatly improve advances in predictive
•
testing, diagnosis, gene therapy, chemoprevention and quality of life of those affected
with the disease. An understanding of the genetic mechanisms associated with colorecta1
cancer in the Irish population will have major implications for clinical practice, early
diagnosis of at risk individuals and may playa role in reducing the death rate due to
colon cancer in this country.
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CHAPTER 1
MUTATION SCREENING OF THE hMSIU AND hMLHl GENES
IN IRISH HNPCC FAMILIES
;' .'
1.1 INTRODUCTION
1.1.(1) HEREDITARY NON-POLYPOSIS COLORECTAL CANCER.··
HNPCC is an autosomal dominantly inherited colorectal cancel' predisposition
syndrome characterised by early onset «4S years), colorectal tumours located
predominantly in the proximal colon (70% of cases) and with an excess of synchronous
and metaebronous colonic cancers (Lynch et al., 1993). HNPCC tumours display an
unfavourable histology in that they are poorly differentiated, however prognosis tends
to be better than in sporadic colon carcinomas. Prolonged survival in HNPCC Patients
is associated with the diploid status of tumour cells (Frei, 1992).
The HNPCC syndrome (originally canca- family syndrome) was first
mcognised by Warthin in 189S, when an aggregation of cancer of the colon, stomach
and endometrium in a large pedigree known as family G was noted (Warthin, 1913).
However, the hereditary significance of 1he disease was not elucidated lUltil 35 yean
laa, when Lynch and colleagues defined the clinical features and inheritance profile of
the disease (Lynch et al., 1993). HNPCC, also known as Lynch syndromes I and II,
does not display the classical FAP like pre-malignant polyps (see 'General Introduction'
for a more detailed account of FAP), rather there is what appears clinically to be a
progression from normal non neoplastic mucosa to adenoma (pre-cancerous growth)
and ultimately to tumour (Lanspa et al., 1990). As there are no pre-neoplastic
indicators of tumour development early diagnosis of HNPCC has proved difficult
The disease is sub-classified as LYnch syndrome lorn based on the presence
or absence ofextra-eolonic tumOUlS. Lynch type I pedigrees display the charactrzistica
outlined above, with the lack of extra-eolonic tumours. Lynch n syndrome pedigrees
display all the Lynch I type clinical features in addition to a significantly elevated
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frequency of endometrial tumours and an associated modest increase in the frequency of
uterine, ovarian, stomach, pancreas and small bowel tumours (Watson and Lynch,
1994). Recent investigations of tumour type and frequency in Lynch I and n cases
suggest that there is discordance among researchers on the necessity of this
subdivision. Analysis of the occurrence of non-colorecta1 tumours in 40 Finnish
HNPCC pedigrees with and without endometrial tumours showed equal frequencies of
extra-colonic tumours. The only significant difference between endometrial and oon-
endometrial tumour families was that there were more affected members and specifically
more affected female members within the endometrial canca" families (Mecklin and
Jarvinen, 1991).
INCIDENCE
The issue of incidence of HNPCC is actively debated with values varying
greatly from 1 in 200 to as low as 1 in 15,000 in the Western population (Bodmer d
al., 1994). Epidemiological studies have demonstrated that 1-5% of all colorectal
cancers fully satisfy the criteria for HNPCC (Mecklin, 1987; Ponz De Leon, 1989; Ieee
,tal., 1991(a». The variation in incidence rates is most likely due to lack of objective
diagnostic criteria and lack of KCUl'8te clinical data on family history of the disease.
However, with the rapid advancement ill HNPCC research and the ongoing
establishment of national database networks, mOte a:curate incidence values may soon
be available.
HNPCC PEDIGREES: CRITERIA FOR SELECTION.
The minimum criteria for the selection of a HNPCC pedigree were agreed upon
at the second meeting of The International Collaboratiw Group on HNPCC in
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Amsterdam in 1990 (Vasen • al., 1991). The minimum criteria known as 'The
Amsterdam Criteria' are :
I)There should be at least three family members with a histologically verified
colorectal cancer, one a first degree relative of the other two.
2)There must be at least two successive generations affected.
3)At least one individual must be less than SO years of age at the time of
diagnosis.
4)Familial adenomatous Polyposis Coli (pAP) must be ruled out.
1bese criteria serve to eliminate most cases of chance clustering. There is however,
disagreement among researchers as to the selectivity of this criteria. Many believe it is
too stringent as it does not take into account family members with endometrial and other
extra-colonic tumours. Furthermore due to the small sizes of western families there is a
limited probability of three cases of colorectal cancer occurring in these Pedigrees and it
excludes~ of reduced pene1l'allre and de Novo gennline mutations. This may lead
to under-diagnosis of HNPCC and some research groups are now using less strict
criteria for the selection of their families (Beck et al., 1997). The Amsterdam criteria
however, remain the standard criteria for Pedigree selection in genetic based screening
studies. A recent publication by the ICG-HNPCC analyses the mutations spectta of
202 HNPCC Pedigrees of diverse ethnic and geographical backgrounds (peltomaki,
1997). 1be majority of these Pedigrees (82%) sttictly satisfy the Amsterdam criteria
and results from mutation screening in these families show that 85% of all identified
mutations have been confined to hMSH2 and hMLHl. Although many mutations ill
hMSH2 and hMLHl have been identified in HNPCC Pedigrees which satisfy tbe
Amsterdam criteria, Iitt1e is known about the involvement of these genes in Pedigrees
which do not satisfy all the criteria. It has been suggested that the Amsterdam criteria
confer a selection bias towards pedigrees barboming bMSH2 and hMLHl mutations
and that smaller Pedigrees with less affected members and later age of onset may
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harbour mutations in other mismatch repair genes such as hPMS1, hPMS2 or in ceJl
growth regulators such as TGF~RII and others (Wijnen et al., 1997).
CLINICAL ASPECTS OF HNPCC
Double contrast barium enema is the standard method used to clinically diagnose
colorectal carcinoma. Patients usually present with a change in bowel habit and in
many cases, abdominal bleeding. A typical carcinoma appears as an obstruction of the
colon and bas a characteristic apple core-like appearance. In many cases this visual
characteristic is not obvious and confirmation requires colonoscopy, biopsy and
histological verification. Treatment is usually by colonic resection. Histological
assessment of the carcinoma and mesenteric lymph nodes is used to stage the tumour
and define prognosis. Dukes staging of colonic tumours is the most commonly used
scheme. Dukes A tumours are confined to the bowel wall. Tumours that have
inftlttated the bowel wall in the absence of lymph node metastases are classified as
Dukes stage B. Once the regional lymph nodes become involved and liver metastases
are observed the carcinoma is classed as Dukes C. Dukes A carcinomas carry a mean
five year survival rate of 85%, Dukes B is associated with a decreased value of 65%
after colonic resection while the prognosis of Dukes stage C with liver metastases is
less than 1% (pounder et al., 1989).
GENETIC ASPECTS OF HNPCC
The HNPCC syndrome was first recognised by Warthin in 1895 when an
aggregation of colon, endometrium and stomach cancer was noted in a large pedigree.
Since its initial documentation, the clinical aspects of HNPCC have been well
elucidated, predominantly through the work of Lynch and colleagues as early as 1966
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(Lynch et al., 1966). However, the first clue to the genetics of the disease was not
discovered Wltil as late as 1993, 80 years after Wartbin described the first HNPCC
pedigree. '
Mutations in four human DNA mismatch repair genes have been shown to
segregate with predisposition to colorectal carcinoma in HNPCC pedigrees. The first
HNPCC susceptibility locus was mapped to chromosome 2p16 via linkage analysis in
two large colon cancer pedigrees, a maximum lodscore for linkage of the disease to tbe
microsatellite marker D2S123 of 6.39 at a recombination fraction of 8=0.00 was
obtained (peltomaki et al., 1993(a». Initial investigations into the putative tumour
suppressor role of the geoe product, combined with attempts to clone and characterise
the gene resulted in the observation that DNA from tumours of HNPCC patients
displayed widespread alterations in short repetitive DNA sequences (microsatellites)
when compared with DNA from nonnal, non-neoplastic tissues in the same Patient
(Aaltonen et al., 1993; Aaltonen et al., 1994; Ionov , 1993).
Simultaneously, researchers involved in yeast and bacterial genetics noticed that
the microsatellite instability observed in HNPCC tumours was similar to tbe
characteristic instability exhibited by yeast and bacterial cells known to be defective in
their DNA mismatch repair process (Fishel et al., 1993; Strand et al., 1993; Thibodeau
et al., 1993). Positional cloning identified the first human homologue of bacterial MutS
and the yeast MSH2 gene - known as hMSH2 (human MotS homologue) (Fishel et al.,
1993; Leach et al., 1993). The involvement of the geoe in HNPCC susceptibility was
elucidated based on the identification of inherited germline mutations which segregated
with the disease within HNPCC kindreds (Leach et al., 1993).
The identification of the hMSH2 gene resulted in a rapid search for human
homologues of the other known bacterial and yeast mismatch repair genes. A
homologue of MulL was identified by linkage in HNPCC pedigrees to chromosome
3p21 (Lindblom et al., 1993). The gene was cloned based on its suspected homology
to E. coli MutL and yeast MLHI (Papadopoulos et al, 1994., Bronner et til, 1994).
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The involvement of hMLHl in HNPCC was proved as with hMSH2, based on the
identification of heritable germline mutations which segregated with the disease in
affected families (papadopoulos et al., 1994; Bronner et al., 1994). Two further MutL
homologues were identified based on analysis of expressed sequence tags
(Papadopoulous et al., 1994). The cloned genes were named hPMSl (chromosome
2q31-33) and hPMS2 (chromosome 7p22) and displayed heritable mutations in
HNPCC pedigrees (Nicolaides et al., 1994). Table 1.1 details the characteristics of the
hwnan mismatch repair genes associated with HNPCC.
Other human homologues of the mismatch repair proteins have been identified,
in addition to hMSH2 there are three other human MutS homologues. Due 1 (hMSH3)
is the product of a divergent transcript from the dihydrofolate reductase promoter and
fonns a complex with hMSH2 known as hMutS P (Fujii and Shimada, 1989) while
hMSH4 is similar in sequence to E. coli MutS (Ross-Macdonald et al., 1994). The
function of these two homologues is unknown and neithez has been implicated in the
disease. GTBP a 160 kDa protein with mutS homology has been shown to bind to
hMSH2 forming what is known as the hMutSa complex which participates in
mismatch binding (Drummond et al., 1995; Palombo et al., 1995).
1.1.(11) MISMATCH REPAIR IN YEAST AND BACTERIA
Pairing errors in which Wmon-Crick bases occur in a non-eomplementary
order within a DNA helix are known as mismatcla or mispairs. Mismatched bases
arise as a result of incolTeet recombination or DNA replication errors, and have major
consequences for protein synthesis, ceD viability and ultimately evolution. Enzyme
systems which detect and correct mismatches have been identified in prokaryotes and
eukaryotes. ~ repair systems have a major role in increasing the fidelity of
replication and of preventing drastic alterations in subsequent cellular generations. The
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GENE LOCUS NO. OF EXONS
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PROTEIN SIZE % MUTATIONS
hMSH2 2p16 16 . 934 amino acids 48/126 (38%)
hMLHl 3p21 19 ... 756 amino acids 75/126 (60%)
hPMSI 2q32 unknown 932 amino acids 1/126 (0.8%)
hPMS2 7p22 l' 862 amino acids 21126 (1.6%)
Table 1.1. Human mismatch repair gene characteristics: Chromosome position, protein size
and the number of exons in each gene are detailed. The total number of mutations was
calculated based on a combination of infonnation from the ICG-HNPCC and HGDB-Cardiff
databases.
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best studied mismatch repair process with respect to both genetics and biochemistry is
the E. coli methyl directed Mot HLS system. The pathway detects and corrects
mismatched nucleotides in nascent DNA by employing a number of enzymes, some of
which have sequence homologies to the human mismatch repair enzymes associated
with HNPCC (MutS and MutL).
MISMATCH REPAIR IN B. COU
The identification and correction of mispaired nucleotides (from single mispairs
to loops of up to 4 nucleotides) in newly replicated DNA, in E. coli, relies on a large
number of cellular factors. At least 10 proteins have been implicated in the methyl
directed repair process: Mut H, Mut S, Mot L, DNA helicase n (which plays a role in
DNA unwinding), DNA Polymerase ill(holoenzyme), DNA ligase, single stranded
binding protein (SSB) and either Exonuclease I, Exonuclease VB or Reel
(exonuclease)-dePending on the position of the mismatch from d(GATC) (Cooper d
al., 1993; Grilley et al.., 1993). Also required are the four dNTP's and the co-factors
NAD and ATP (Lahue et al., 1989; Modrich, 1991; Modrich et al., 1994).
Initiation of mismatch repair in E. coli is activated by the presence of a
mismatch in newly replicated DNA MutS, a 97kD protein binds to mismatched bases
indePendently of any other factors (Su and Modrich, 1986;Su et al., 1988). MutH has
been shown to interact at d(GATC) sites that are bemimethylated at adenine residues
and to incise the unmethylated sttand. This methylation sensitive selection process
confers strand specificity and ensmes that only the newly replicated strand is corrected
(Welsh et al., 1987). The specific activity of MutL remains to be clearly elucidated,
however, it is thought to bind the MutS:DNA mismatch complex and to facilitate the
interaction between this complex and MutH at the point of DNA incision (d(GATC)
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i~ sites). These incision sites may lie up to lKb from the mismatch position (Bruni et al.,
Ii 1988). The interaction ofMutH with MutS is 1hougbt to occurdue to the formation of
i~ an a-like DNA loop structure, which brings the two regions into proximity (Modrich,
.~
1
"&"~. 1991). The incision of the unmethylated strand is followed by the removal of the DNA
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):
j~ region between the incision and the mismatch. This activity is carried out by either a
*..~ 3'-5' or a 5'-3' exonuclease depending on the position of the incision to the mismatch.
Finally, Polymerase mholoenzyme fills in the gap in the DNA duplex inserting the
correct bases and rectifying the mismatch (Figure 1.1). Additional proteins- Helicase
n and single stranded binding protein are required for the unwinding and subsequent
stabilisation of single stranded DNA in the process (Modrich, 1989; Lahue, 1989;
Grilley et al., 1993; Cooper at al., 1993).
MISMATCH REPAIR IN YEAST.
1-:00 0: ,.... '
Although the mismatch repair processes in Eukaryotes are less well studied than
those of bacterial systems, the pathways share many similarities although a number of
differences have been elucidated. Analysis of S.cervisiae mutants has led to 1be
identification of a number of gene products which are similar in sequence and activity to
the components of the bacterial MutHLS mismatch repair system.
MSH2 of S.cervisiae is homologous to the MutS family of bacterial proteins
~ and as with E. coli mutS it is capable of binding to mispaired bases within DNA
(Reenan and Kolodner , 1992; AJani et al., 19(5). A number of other MotS
homologues including MSH3 and MSH4 have been identified in S.cervisiae however
they have not been shown to play a major role in mismatch repair (New et al., 1993;
Ross- MacDonald et al., 1994). PMSI (postmitotic segregation gene), (Kramer et al.,
1989) and MUfI (Strand et al, 19(3) in yeast are both bomologta of bacterial Mu1L
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and can form a complex that binds DNA bound MSH2 in a similar manner to mutL and
MutS in E. coU. (Prolla ~tal., 19(4). A signifteaDt difference between Eukaryolic and
Prokaryotic mismatch repair is the lack of a MutH homologue in Eukaryotic systems -
strand specificity in yeast as in humans is not governed by the methylation state of DNA
sequences as in E. coli. The precise mechanism of strand specificity in these organisms
is not well understood, however the presence of replication associated nicks in the
nascent DNA sttand are thought to substitute for d(GATC) sequences in directing
strand specificity. Differences between tbe binding specificity of yeast MutS and
MSH2 in humans have also been elucidated -the affinity of MutS for mismatched
Ducleotides decreases considerably in stretches greater thaD 4 nucleotides in length
(Parker and Marinos, 1992). Human MSH2 however has been shown to readily bind
stretches of up to 14 nucleotides in length. (known as insertion/deletion type loops
IDL's), (Fishel ~t al., 1994).
Finally, S.c~rvisiaeMSH2, PMSI and MLHI mutants exhibit increased rates of
expansion and conttaction at microsatellite repeat sequences which demonstrates the
importance of these proteins in maintaining correct transmission of genetic infonnatiOll
from cell to cell (Strand ~t al., 1993).
1.1.(111) HUMAN MISMATCH REPAIR PROTEINS
DNA from tumOlU'S of HNPCC patients display alterations in microsatellite
repeat regions compared to DNA from their normal ceUs (Aaltonen ~tal., 1993). Based
on a similar observation in S.c~rvisiae cells harbouring mutations in their mismatch
repair genes, a search for human homologues of the bac1erial and yeast MMR
(Mismatch Repair) proteins was initiated. Using a variety of methods including,
linkage analysis (Lindblom et til, 1993) cloninl -based OIl suspected sequence
homologies to becterial proteins, and the analysis of expressed sequence tags
(Papadopoulos et al., 19(4) a numbez of homologta of bacterial and yeast mismatch
repair genes were identified in humans. Four human MutS homologues have been
identified of which two (hMSH2 and hMLHl) are known to have a specific role in
MMR. hMSH2 acts similarly to E. coli MutS and yeast MSH2 by binding mismatched
nucleotides. As in yeast, binding of hMSH2 to mismatches is not directed by
methylation of d(OATC) sequences rather pre-existing replication associated nicks in
the DNA are thought to direct binding (Fang et al., 1993). hMSH6, more commonly
known as pl60 or OTBP (for orr binding protein) was identified based on its ability to
bind orr mismatches in vitro. This l60kD protein cannot however, bilxi orr
mismatches indePendently, the presence ofhMSH2 is required (palombo et al., 1995).
The hMSH2:0TBP complex known as hMutS a purifies as a l00kD:l60kD activity
which restores mismatch repair activity in LoVo cell extracts (cells deficient in hMSH2
activity), (Drummond et al.,1995). Mobility-shift experiments have demonstrated that
the hMutS a complex can bind Off or 1-2 nucleotide loops with high affmity, this
however decreases by 1I1Oth with AIr homoduplex DNA and with larger mismatch
loops (Karran et al., 1995). Figure 1.2 outlines the possible mechanism for mivnatcll
correction by MutS a. .
Cell lines deficient in OTBP activity display alterations primarily in
mononucleotide repeat tracts, which suggests that GTBP may have a role in simple
base: base correction (papadopoulos et al., 1995). hMSH2 on the other hand, can
independently bind loops of up to 14 nucleotides in length and is thought to be
responsible for correcting more dramatic mismatches.
More recently another complex comprising of hMSH2 and hMSH3 (DUC-I)
known as hMutS phas been shown to carry out mismatch correction activities similar
to the hMUTsa complex (polambo et al., 1996). h would appear that the roles of
OTBP and DUC-I in MMR are overlapping and somewhat confined to small single or
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dinucleotide loop repair, while the role of hMSH2 is more significant as it is required to
repair larger more dramatic mismatch stretches. This fact is bome out somewhat by
noting that no mutations in either GTBP or DUC-l have been identified in HNPCC
patients while nearly 38 of 126 identified mutations have been confined to hMSH2
(Peltomaki et m., 1997).
A number of MUT L homologues have been identified in humans. hMLHl was
named due to its similarity to the MUlL homologue in E. coli (Bronner et al., 1994;
Papadopoulos et aI•• 1994). The PMSI and PMS2 homologues display closes
homology to the yeast PMS genes (Nicolaides et 41., 1994). The activity of MutL in
human mismatch repair is facilitated via die formation of • hMLHl:hPMS2
heterodimer. The activity purifies as a 106:104kD complex displaying 1:1
stoichiometry (Li et 01., 1995). Complementation of cells lacking nonna! hMLHl with
this activity restores MMR function, the mode of activity is unclear, however it iI
suspected that hMLHl:PMS2 binding as ill bacteria, is dependant OIl otbez ceDw.
components (Li et al., 1995). Sixty percent of mutations identified in 202 HNPCC
pedigrees 1Wft localised to hMLHI which emphasiseA the role of hMLHI in
maintaining efficient and accurate DNA replication (Peltomaki et al., 1997).
1.1.(IV) THE HUMAN MISMATCH REPAIR GENES AND HNPCC
The identification of four human mismatch repair genes targeted these genes for
mutation screening in HNP<..'C pedigrees. Genetic analysis of the four mismatch repair
genes in many pedigrees from diverse origins has now led to the identification of more
than 120 gennline mutations. Two mutations haw been identified in hPMS2 and 1 ill
hPMS1, the low mutation rate of these genes in HNP<..'C may be due to the fact that for
the most put, researcbers ba'We limited their screening to hMSH2 and hMLHl and
confined their analysis m pedigrees which strictly satisfy the Amsterdam selection
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criteria (Peltomaki et al.,1997). Initially it was believed that mutations in hMSH2 were
responsible for the majority of HNPCC cases with values of >6()'1, for hMSH2 and
only 30% for hMLHI (Lui et al., 1994; Han et al., 1995). However, a more accurate
evaluation of mutation spectta is documented in a recent report by the ICG-HNPCC
which presents the results on the mutation analysis of 202 pedigrees of diverse ethnic
and geographical origin. The analysis of 126 mutations reveals that 38% of mutations
affect hMSH2 and 59% affect hMLHl. Further analysis of the mutation spectra of the
202 HNPCC kindreds reveals that the majority of mutations are point mutations with
59% representing single base substitutions as opposed to deletions or insertions (41%).
Most mutations identified are unique with no obvious muta1ion hotspots, however in
hMSH2 the most frequently altered exons include 12 (17% of hMSH2 mutations), 7
(15%),5 (9%), and 6 (9%). In hMLHl mutations occum:d more frequendy in exons
16 (15%), 9 and 13 (9%) and 19 (8%). The report represents the efforts of the ICO-
HNPCC to establish an international database of HNPCC mutations. The database was
established to provide infonnation to researchers to facilitate evaluation of mutation
spectra of HNPCC genes and to assess geographic and population variation in mutation
spectra (peltomaki et a!., 1997), (Table 1.2).
MUTATION SCREENING PROTOCOLS
Due to the diversity of mutations in tenDs of tyPe and position, the identification
of a causative mutatioo within • affected pedigree is a tedious process. The most
widespread protocol for pedigree analysis involves 1he initial selection of pedigrees
based on the Amstentam criteria, followed by an evaluation of RER (replication error)
phenotype via assessment of microsateDite instability. A positive RER phenotyPe
suggests that the mismatch repair pr0ce8S in these patients may be defective. A number
of screening methods have been employed in the identification of mutations in HNPCC
pedigrees world-wide. Initially, SSCP and OOGE (Orita et al., 1989a; Sheffteld et al.,
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GENE MUTATION TYPE MUTATIONS IDEN I IFIED lUfAL
.~
.(
hMSH2
hPMSl
Transitions
Transversions
Deletions
Insertions
Transition
Deletion
12
9
19
8
1
1
48
2
Table 1.1. Mutation profile of the human mismatch repair genes. Mutations have been
identified in four human mismatch repair genes. Mutation type, number of mutations and total
mutations are provided for each gene. The information used to construct this table was obtained
from ICG-HNPCC database and the HGDB at Cardiff.
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1989; Traystman et al., 1990) analyses were the most commonly used mutation
detection methods, however, when it was detennined that a large proportion (>80%) of
the mutations resulted in the generation of a stop codon and the subsequent production
of a truncated protein product, many ~hers chose to use the in vitro protein
synthesis assay (lVPS) or protein ttuncation test (PIT) as the method of analysis
(Roest et al., 1993: Powell et al., 1993). The employment of this method in HNPCC
analysis however, has proved troublesome due to the fact that there are a number of
alternatively spliced transcripts of the hMLHl gene (Charbonnier, 1995). Analysis
using the PIT results in false positive results, in that what is believed to be a defective
ttuneated protein product is merely the product of a naturally occmring alternative
transcript of the mRNA for this gene. This transcript is normally not translated in vivo,
but because the PIT is designed to selectively amplify segments of mRNA, they are
translated in the PIT. Wi1h the advancement in automated sequencing, direct
sequencing of genes bas also proved successful in identifying muta1ions within
HNPCC genes.
THE HUMAN MISMATCH REPAIR GENES • STRUCTURE AND
FUNCTION
", J
The hMSH2 gene contains approximately 73kb of genomic DNA with a 2727bp
open reading frame. The gene contains 16 exons and encodes a 934 amino acid protein
with 41% homology to the yeast MSH2 gene (Figure 1.3). The intron-exon boundaries
have also been determined (Fishel et al., 1993; Kolodnez et al., 1994b).
The hMLHl gene contains approximately 58kb of genomic DNA with an open
reading frame of 2525 nucleotides. The gene encodes a 756 amino acid protein and
11 contains 19 exons (Figure 1.4). As with hMSH2 the intron-exon boundaries have also
been determined (Kolodner et m., 1995).
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The open reading frame sequences of hPMS1 and hPMS2 have been detennined 81
2,795bp and 2,586bp respectively. The hPMS1 gene encodes a protein of 932
amino acids and shows 27% homology to yeast PMS1. hPMS2 contains 15 exons,
encodes an 862 amino acid peptide and shows 32% identity to yeast PMS1 (Nicolaides
Ital., 1994; NicobUdesetal., 1995)
1.1.(V) MICROSATELLITE INSTABILITY
Microsatellites are regions of highly repetitive DNA sequences «CA)n,(GT)o,
aDd polyA tracts) found interspersed randomly throughout die genome. 1'bere are
between 50,000-100,000 (CAn) repeats within the human genome, the majority are
located within introns or between genes. The lengths of many of these repeats vary
naturally from one individual to another and have proved very useful as a tool for
following genetic 1raDsnrission aDd in locaIisatioo of mse.e causing regions within •
gene (Weber et al., 1989).
Slipped strand mispairing (SSM) is widely believed to be the mechanism by
which alterations in the sizes of repeats occur and plays a vital role in the evolution of
repetitive DNA sequences by generating large numbers of short framesbift mutations
within these regions. The tandem nature of simple repeal sequences is thought to
render diem prone 10 slipped strand mispairing aDd hence iDsertiOll ex' deletion
mutagene&s during replication. The process of slipped strand mispairing involves
mispeiring of two strands of duplex DNA within a tandem repeM area, die mispaired
duplexes may serve IS primers for subsequent DNA synthesis, thus duplication occurs
(Kunkel, 1993).
Examination of the mutation frequency within a Poly CA sequence inserted into
.becteriopbage M13 in E. coli, showed • increase ill frameshift mutatioo. frequency of
greater than 1% in a 40 base pair tract, when compared to random non-repeat DNA
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This augmentation in frequency~ more than 13 fold in cells deficient in methyl-
directed mismatch repair (MutS', Mud.: hosts) suggesting that mismatch repair plays a
vital role in correcting frameshift mutations (Levinson and Guwan, 1987).
MICROSATELLITE INSTABILITY IN HNPCC
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MI) as a result of defects in any of the mismatch repair genes (Aaltonen et al., 1993;
Parsons et al., 1993; Loeb et al., 1994).
Evidence to support this theory stems from the observation that mutations in any
of hMSH2, hMLHl (W hPMSI lead to 100-200 fold~ in microsatellite
instability in yeast cells whereas mutations that alter the proof reading effect of DNA
polymerases have little consequence, suggesting that DNA instability arises due to an
inability to correct mutations caused by strand slippage during replication- the role of
the mismatch repair genes (Strand et al., 1993).
Furthermore, microsatellite instability has been observed at more than one locus
in the tumour cells of patients and this instability can often be observed in the pre-
tumourigenic adenoma stage (Ionov et al., 1993). A recent study shows that aberrant
crypt foci, which are microscopic colonic lesioDS, thought to be the earlie8t identifiable
precursors of colon cancer, also display microsatellite instability (Heinen et al., 1996).
This suggests that microsatellite instability occurs at an early stage during tumour
development and lends evidence to support the mutator phenotyPe hypothesis.
MICROSATELLITE INSTABILITY IN NON COLON TUMOURS IN
HNPCC
Microsatellite instability has been observed in an number of other cancer types
other than colorectal cancer. Due to the association of eodometrial eatcinomas with
HNPCC, tumours of this tyPe have been studied for microsatellite instability by a
number of different groups. Risinger et til, report that in a study of 36 sporadic
endometrial tumours 17% showed instability at microsatellite loci, whereas 75% of
endometrial tumours from HNPCC pedigrees display microsatellite instability (Risinger
et al., 1993). Katabuchi et al., analysed sporadic endometrial tmnours for instability
and those that were positive were subsequently analysed for mutations in the four
known mismatch repair ge~. Two of nine microsatellite instability positive tumours
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showed mutations in hMSH2, these mutations were somatic and not germline mutations
which would suggest that mutations in the mismatch repair genes are not responsible
for the microsatellite instability observed in sporadic endometrial tumours and further
supports the mutator phenotype hypothesis (Katabuchi et al., 1995).
1.1.(VI) ROLE OF MISMATCa REPAIR MUTATIONS IN CANCER
DEVELOPMENT.
Vogelstein et al., hypothesised that the development and progression of colon
canca" is not a single step process, rather, it is associated with the accumulation of
mutations in a Dumber of highly important genes (Fearon and Vogelstein, 1990),
(Figure 1.5). These genes include regulators such as the APe (adeDomatous polyposis
coli) gene, p53, K-ras and DCC (deleted in colon cancer). APe is a tumour supPreSSor
gene which bas been localised to chromosome ~21 and is believed to playa role in the
regulation of the contact inhibition signal of a cell and is associated with microtubules
aDd cd1 adhesion regulation (Pfiefer Gill., 1993; Baeg ., tIL, 1995). PS3, the
guardian of the genome is putatively involved in almost all cancers. Like APe it also
exerts a tumour supPreSSor role by switching off replication during repair of DNA
damage, ceDs arre8t at die GI checkpoint of the cdl cycle, if DNA damage mnains
unchecked p53 may 1riggel' cdl suicide by apoptosis thereby preventing the further
growth and replication of a mutant cdl (Yonish-Rouach et al., 1991). The K-ras
oncogene is mutated at the adenoma stage in many colon CIDCtft and is thought to be
one of the earliest mutations in this cumulati", pathway (Vogelstein et al., 1988). III
addition, the DCC locus OIl chromosome IRq, methylation status and other mutational
events are thought to playa major role in tumour progression (Silverman et al., 1989;
Fearon et al., 199Ob). In FAP, gamline mutations in the APe FIle predispose
individuals to the de"Yelopment of polyps and subsequently cancer. However, loss of
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heterozygosity at the APe locus in addition to the accumulation of mutations in other
cell cycle regulators are required for tumour development (Bodmer et al., 1987).
Similarly, an inherited mutation in one of the mismatch repair genes predisposes 1be
individual to the development of colon cancer, however, a gennliDe mutation alone is
not directly involved in cancel'development HNPCC affected patients C8lT)' a germline
mutation which inactivates one copy of one of thar mismatch repair geDt8. Analysis of
tissues in these individuals reveals that they are phenotypically normal (it has been
demonstrated that cell lines, with one mutant allele of a mismatch repair gene exhibit
normal levels of mismatch repair even under conditions of increased mutation
frequency), (Branch et til., 1993), they are however It increased risk of developing
colorectal cancer. When a second somatic mutation in the MMR gene occurs, this
inactivates both copies of the gene and mismatch repair activity becomes defective. A
hypennutable state exists in these cells with the re4U1t 1bat more and more mutations
pezsist after each round of DNA replication. This hypermutable slate is cbaracterised by
microsatellite instability, also known as an RER+ phenotype. This decreased ability 10
correct mutations is thought to result in an increased risk of accumulation of mutaboos
in critical twnour suppressor genes, oncogenes and cell regulators with the subsequent
development of a neoplastic growth and tumour developmmt (Lazar el til., 1994).
MISMATCH REPAIR GENES AND CELL CYCLE REGULATION
The development and progression of a tmnour stems from an uncontrolled cdl
cycle. A mutant cell DO longer grows, replicate8 or di~ III the same rate as ita
normal neighbouring cells, furthermore, the apototic process which facilitate3 suicide
and hence the elimination of the damaged cell may be defective or switched off, thus
facilitating uncontrolled cell growth. Examination of die expression leveJs of MMR
proteins during various stage£ of the~ cycle demoDs1raIe 1bat ill norma1 ceDs these
genes are expressed at all stages (constitutively expressed). Furthermore, the levels of
the hMLHl protein increased by 50% at Gland S phases -suggesting an upregulation
in expression level of hMLHl. Similarly the Jevd of bPMSI iDcreases It 01 and S
phases while the hMSH2 level remains constant (Myers et al., 1997). Sequence
analysis of die hMSH2 promoter region revealed a site with homology to die p53
consensus DNA binding sequence. Mobility shift assays demonstrated that purified
p53 binds to hMSH2 ill vitro suggesting that pS3 may play a role in die expression of
hMSH2. This evidence of altered expression levels supports the hypothesis that MMR
proteins may play a role in regulation of the cell cycle (Myers et al., 1997).
..: ;
HNPCC AND TOLERANCE TO ALKYLATING AGENTS
An increased resistance to a1kylating agents such as n- methyl-nitroso-urea has
been observed in cells lacking MMR activity (Branch et al., 1993; K.oi et al., 1994).
This observation suggests that cells defective in their mismatch repair activity CID
tolerate DNA adduc1s caused by these agents. Under DOI'IDa1~ conditions, these
adduets if not conected would result in c:dl atTeSt or death. The phenomenon of
tolerance bas been linked to the inactivation of hMLHl in particular. HCT16 cdllines
lacking hMLHl, display microsatelli1e instability, methylation tolerance aDd mismatch
repair deficiency. The introduction of chromosome 3 (hMLH1 Iocu) restores normal
functionality to the cell and des1roys tolerance levels (Koi et al., 1994). These findings
may have important implications in chemotoxic 1reatment of HNPCC 1WnOUl'S, however
the exact mechanism by which this tolerance occurs is still to be established.
CANCER RISK IN HNPCC PEDIGREES
A numta' of studies based on calculating the lifetime risk of developing cancer
for a carrier of a HNPCC gene defect have beea performed. The results a'e impodaDt
in 1emlS of surveillance and genetic counselling of patients. A recent study by Vasen d
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al., 1996) assessed the age specific cancer risk in a large series of patients with known
mutations in either bMSH2 or hMLHl. A total of 210 gene carriers were analysed
Risk assessment was canied out on the basis ofcarriers developing cancer from birth to
death. Data was evaluated using survival analysis methods and survival curves wete
constructed with use of Kaplan-Meier estimates. Their results show that the lifetime
risk of colorectal cancer was 80'1> aDd was the same whether die mutatKm was ill
hMSH2 or hMLHI. They also found that there was a very high relative risk of
generating cancer of the small bowel aDd carriers of hMSH2 gene mutations bad a
higher risk of developing cancer of the urinary tract, stomach and ovaries, than hMLHl
carriers.
Dunlop et al., (1997), suggested that while the Vasen study was significant to
known HNPCC pedigrees it did not take into account families carrying mismatch repair
gene mutations which were not strictly 'Amsterdam Families'. They used the RER
status of tumours from HNPCC aDd sporadic cancer patients 10 determine whether
patients carried defects in their mismatch repair genes. The calculated risk of
developing any cancer by age 70 was 91% for males and 69% for females. The risk of
colon cancer was higher in males than in females (74% versus 30%) and the risk of
uterine caDa2' exceeded that of colorectal caDCa" in femalea (42% versus 3()Cf,). 11ae
results have particular significance in terms of screening protocols, especially in terms
of uterine screening in female carriers of HNPCC pedigre.ea.
MUIR-TORRE SYNDROME
Muir-Torre syndrome (MTS) is an autosomal dominant disorder cbaracterised
by die development of sebaceous gland tumours and skin cancers such as
keratoacanthomas and basal cd1 carcinomas (Muir et al., 1967). In addition affected
individuals may develop a numbez of internal malignancies including colorectal,
endometrial, upper gastrololical and urinary 1Iact cancers (Cohen et al., 1991). As in
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HNPCC, tumours in these patients display microsatellite instability, they are usually
synchronous and metaebronous and prognosis is usually favourable. Ot the basis of
similarities between Muir-Torre syndrome and HNPCC it was suggested that there is a
common genetic link (Lynch et al., 1985). Analysis of a number of Muir-Torre
families has led to the identification of mutations in the hMSH2 gene in 6 unrelated
Muir Torre pedigrees (Kolodner ~, til, 1994b). This finding bas impor1aDt implications
at the clinical level as the presentation of sebaceous gland and skin tumours implies that
the patient may have mismatch repair gene defects and is at risk of develoPing other
HNPCC type tumours.
GENETIC DIAGNOSIS OF HNPCC
The traditional clinical procedme for the diagnosis of HNPCC was based on an
early onset colorectal cancer associated with the 1act of FAP type symptoms. Ql
presentation of such a patient a family history was obtained to detennine if there was an
associated familial component. However due to small family sizes aDd lack of accurate
knowledge pertaining to other family members, most cases of colorectal cancer were
defined as sporadic. The lack ofdefinitive diagnostic criteria bas made it difficult in the
past to accurately diagnose HNPCC in a family. The identification of four genes
associated with HNPCC has greatly improved the diagnosis and outcome in HNPCC
pedigrees. The large number and betezogeneous nature of causative mutations in
HNPCC means that genetic diagnosis is a rather tedious process, however once a
causative mutation bas been identified within a particular family, subsequent screening
of younger members has major implications for surveillance and 1reatmeDt of these
patients. .'
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1.2. MATERIALS AND METHODS
1.2.(1) DNA ISOLATION FROM PERIPHERAL BLOOD
Blood was collected in tubes containing EDTA as an anti-coagulant and stored at
-20°C. DNA Isolation was performed using one of the two methods outlined below.
Method 1is a modification of the Kunkle et al., (1978) protocol. This method is more
labour intensive and time consuming than method two, however tbe isolated DNA iJ
more robust, free &om residual proteins <average A2(IJ/A280 ratio of 1.7), with aD
average yield of SOOng of DNA from 10mls of blood and remains stable when stored II
-200 C for at least four years. Method two is less tedious, less time consuming and
does not require the use of phenol-chloroform, however the yield is lower <average
yield 300ng from 10 mIs blood) and the quality of the DNA is poorer- samples which
have been stored for more than 1 year at -20°C are poor PeR templates and residual
proteins must be removed by using DNA clean-up systems such as Wizard 'I'M DNA
Clean- Up system (Promega).
DNA ISOLATION METHOD 1:
Ten mIs of blood was combined with 90mIs of lysis buffer (0.32M sucrose, 10mM
Tris-HCI, pH 7.S, SmM MgC~, 1% Triton X-tOO) at 4°C. Lysis was spontaneous.
Nuclei were collected by cen1rifugatiOl1 at 12,000g for 10 minutes in a sorvall RC-2B
centrifuge maintained at 4°C. The nuclear pellet was re-suspended in 4.Sml of
suspension buffer (24mM FDTA pH8, 72mM NaCl) and transferred to a 30ml
centrifuge tube. To this, O.Sml of SfJ> SDS (fmal concentration O.SfJ» and Proteinase K
to final concentration of 2OOtJ.glIJl were added. Samples were iDcubated at SsoC
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overnight Following incubation, Sml of Tris saturated phenol pH8.0 was added to the
solution, mixed by inversion and centrifuged at 12,OOOg for 10 minutes at 4°C in a
Sorvall RC-2B centrifuge (the top aqueous phase contains the DNA, whereas the
protein remains at the inten~ and· in the organic phase). The aqueous 1a)U wu
retained and phenol extraction was repeated twice to ensure maximum removal of
residual PrOteins. Sml Chlorofonn: isoamylalcohol (24:1) were added to the aqueous
phase, mixed by inversion and centrifuged at 12,OOOg for 10 minutes as before. The
aqueous layer was retained and chloroform extraction repeated. The aqueous phase was
removed, added to a solution of O.Sml Sodium Acetate (3.0M) pH 4.8 and Ilml of
100% ethanol The tube was inverted until DNA PreciPitated. The DNA was transferred
to a solution of 70'1> ethanol for 30 seconds and transferred to a clean tube and allowed
to dry. The DNA was re-suspended in O.Sml TE buffer (10mM Tris-Q pH 8.0, 101M
FDTA pH 8.0) and stored at 4°C for 3 days to ensure complete ~-suspension. The
DNA concentration was estimated from the A260 readings obtained using •
spectrophotometer. The average yield of SOOng DNA was obtained from 10mls blood.
DNA ISOLATION METHOD Z:
The method outlined is for 300tJl of blood, this was proportionally increased for larger
volumes.
Cell lysis was induced by adding~ of whole blood to 900tJl Red Blood een
(RBC) Lysis solution (ISSmM Ammonium Chloride, 10mM Potassium Hydrogen
Carbonate, hnM FDTA). Tubes were inverted lID mix and incubated at room
temperature for 10 minutes. Sampl~ were centrifuged for 20 seconds at 16,OOOg in a
bench top centrifuge. The supernatant was removed to leave a visible white pdlet
(contains the white blood cells) these weze vortexed vigorously to resuspend the white
blood cells in the remaining re&idualliquid. 300tJl of cell lysis solution (2SmM EDTA,
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2% SDS) was added and pipeUed up and down to lyse the cells. Samples WeIe
incubated at room temperature for 30 minutes or until the solution was homogeneous.
Samples were incubated with IU RNase A at 37°C for IS minutes and subsequently
cooled to room temPerature. lOOJ.l1 of Protein precipitation solution (10M ammonium
Acetate) was added to the cell lysate and vortexed vigorously for 20 seconds. Samples
were centrifuged at 16,OOOg for 3 minutes as before (a tight dark Pellet of proteins
fonned). 100 supernatant containing the DNA was removed to a new tube containing
300J.l1 of 100% isopropanol. The samples were mixed by inverting gently SO times until
white threads of DNA became visible. DNA was removed by centrifugation at 16,OOOg
for I minute. The supernatant was removed and DNA was drained by inverting tube on
clean absorbent paPer. 300tJl of 70% ethanol was added to wash the DNA sample, after
centrifugation at 16.000g for I minute the ethanol was removed and DNA was allowed
to air dry. DNA was re-hydrated by adding So-lOOJ.l1 of TE buffer and stored at 4°C for
'd.'
3 days to ensure complete re-suspension.
1.2.(0) PCR AMPLIFICATION OF HNPCC SAMPLES
The hMSH2 gene contains 16 exons and the hMLHl gene contains 19 exons.
Each exon was amplified using published primer sequences (Kolodner et al., 1994a,
1995). Primer sequences are listed in table 1.3 and 1.4.of Section 1.3. (VIll).
Amplification reactions were initially Perfonned in a 2SJ1l reaction volume
containing 60ng genomic DNA, sOng of each primer, 0.2mM dNTP's, IU Taq DNA
Polymerase, Taq DNA Polymerase buffer (SOmM KCl, 10mM TrisCl pH 9.0, 0.1%
Triton X-loo, 1.SmM MgClJ. Samples were overlaid with mineral oil.
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Cycling parameters: Amplification was performed on an MJ PTe-lOO thelmal cycler.
All samples were heated to 95°C for 5 minutes (Hot-start) to ensure complete
denaturation and subjected to 30 cycles of 95°C for I min, 55°C for I min, 72°C for I
min followed by a [mal extension step of 72°C for 10 minutes. PeR optimisation was
performed on primer pairs which did not give good PeR yield under these conditions.
Optimisation involved performing the PeR reactions according to the above conditions
however, either the concentration of MA or the annealing temperature was altered.
1be optimum conditions for each primer pair are detailed in table 1.5. Section
1.3.(VII).
PCR AMPLIFICAnON FOR SSCP ANALYSIS
Gene segments for SSCP analysis were amplified essentially as described
above, however the reaction volume was reduced to lotJ.l and the dNTP mix
concentration was reduced to 0.02mM. In addition 2J.lCi of [a32P]-dCTP
(3OOOCilmmol) was included in the reaction.
1.2.(111) SSCP ANALYSIS
Following PeR amplification in the presence of [a32P]-dcrP, samples were
diluted 1:100 in formamidedye (95% formamide, 20mM EDTA, 0.05% Bromophenol
blue, 0.05% Xylene cyanol). Samples were denatmed at 95°C for 5 minu~ and
individual DNA strands were separated on a 6% polyacrylamide gel under three
conditions. (I) with 5% glycerol at room temperature (2) with 5% glycerol at 4°C and
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(3) 0% glycerol at 4°C. Constant power of 60 Watts was maintained and samples were
separated for approximately 4 hours. Gels were dried and subjected to autoradiography.
1.2.(IV) DNA SEQUENCING .
Nucleotide sequence analysis of the HNPCC samples was performed either by
the direct sequencing of PeR products or by sequencing the cloned PeR product
Cloning of PeR products:
The pTag cloning vector (R&D Systems) exploits the additional T residue that
Taq DNA polymerase adds on to the end of PeR. products. Ligation of the PeR
product with the pTag plasmid was perfonned by incubating 2J.1l of PeR product
(removed directly from a 10f..tl PeR reaction tube) with 2U T4 DNA ligase, ligase
buffer, 5mM DTT, 0.5mM ATP and 50ng ofpTag plasmid in a lotJl reaction. Samples
were incubated overnight at 16°C and subsequently transformed into competent E.coli
cells as described by Sambrook et al., 1989. Transfonnants were plated on LB-AMP-
IPTG-X-gal plates and incubated overnight at 37°C. Recombinant clones were selected
based on antibiotic resistance and insertional inactivation of the P-Galactosidase gene.
Plasmid DNA was isolated by minipreparation of the plasmid as outlined in: Molecular
Cloning a Laboratory Manual, Sambrook d al., (1989). Plasmid inserts were
sequenced in both directions using either a radiolabelled primer (see below) and the 17
DNA sequencing kit (Phannacia) or diIect cycle sequencing of the PeR. product using
[«" -P] labelled dideoxy terminators and Thennosequenase as outlined in the cycle
sequencing kit (Amersham Life Sciences).
Sequencing products were diluted with an equal volume of Formamide loading dye
(95% formamide, 20mM EDTA, 0.05% Bromophenol blue, 0.05% Xylene cyanol)
denatured and separated on a 6% denaturing OM urea) polyacrylamide gel. Analysis of
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the DNA sequence data was perfonned by comparing with the known published
sequences of the genes.
1.2.(V) OLIGONUCLEOTIDE LABELLING
Primers used in the sequencing ~0IlS were ald labelled by incubating·
6Opmol primer with IV of T4 Polynucleotide Kinase (New England Biolabs), the
appropriate buffer and SOuCi [.,.32Pl-ATP (3000cilmmol) at 37°C for 30 minutes. One
volume of 4M sodium acetate and two volumes of ethanol was added in order to
precipitate the primen and to remove unlabelled nucleotide. Primers were re-suspended
in water to the required concentration.
'. ~':'
.... 'j
1.3 RESULTS
1.3.(1) OBJECTIVES
The objective of the research included in this chapter was to collect as many
Irish HNPCC pedigrees as possible in the given period and to analyse the hMSH2 and
hMLHl genes for causative mutatioDS. It was envisaged that the results would provide
information on the Irish HNPCC mutation spectrum, facilitate comparison with other
ethnic HNPCC populations and would provide information pertaining to she
susceptibility of individuals within affected pedigrees.
Mutations in four human mismatch repair genes are known to segregate with
HNPCC (hMSH2, hMLH1, hPMSI and hPMS2), of an the mutations identified, over
80% are confined to hMSH2 and hMLHl (peltomaki et al., 1997). In an attempt to
detennine the mutation spectrum of HNPCC genes in the Irish population, eighteen
HNPCC pedigrees were ascertained, sampled and analysed for mutations in die
hMSH2 and hMLHl mismatch repair genes. Figure 1.6 displays a diagrammatic
representation of the methods employed and the ordez of analysis in this study. Briefly,
Irish HNPCC patients were selected based on presentation at Cork University Hospital,
with colorecta1 carcinoma in ODe individual in association with a soong family history
of colorecta1 cancez and in some cases extta-eolonic HNPCC associated tumours.
Genomic DNA was extracted from peripheral blood leukocytes from at least one
affected member of each family. The hMSH2 gene contains 16 exons while hMLHl
contains 19 exODS, each individual exOll of both genes was amplified via PeR,
optimisation of each PeR amplicon was performed and each fragment was
subsequently re-amplified from genomic DNA template in the presence of a
radiolabelled precursor, using the optimised PeR conditions. Radiolabelled PCR
fragments were subsequently analysed by SSCP under varying conditions. Any
regions displaYing aberrant electrophoretic patterns were sequenced to identify
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Segregation analysis of putative mutations identified -in affected
families and normal individuals
Figure 1.6. Schematic representation of the protocol for the mutation
screening of the hMSH2 and hMLHl genes in Irish HNPCC families.
mutationslpolymorphisms responsible for the altered migration pattem. In the case
where a mutation wu identified in an individual, other affected and unaffected members
of the pedigree were sequenced to determine whether the putative causative mutation
segregates with the disease in the pedigree. Finally fifty normal control samples wem
screened for the presence of the mutation to determine the likelihood that the observed
mutation could be a polymorphism.- .
Each step of the analysis required careful appraisal of available techniques to
determine which method would best suit this study. Furthermore, careful optimisation
at each stage of analysis was performed. Finally quality control checks were included
to avoid discrepancies and errors during analysis. Each stage of the research will be
discussed in detail.
1.3.(11) PATIENTS ". ii, . . - ~
Pedigrees were selected based on presentation at Cork University Hospital, with
colorectal carcinoma in ORe individual, ill associatioo with a strong family history of
colorectal and in some cases extra-colonic HNPCC associated tumours. Pedigree
identification, diagnosis, ascertainmeDt of family history and blood sampling were
performed by Drs. Cliona Murphy, Maureen 0'Sullivan and Eamonn Kavanagh under
die supervision of Prof~. Liam Kirwan of 1be Dept. of Surgery at CUH. The
selection criteria used in this study were: (1) There must be a S1rong family history with
It least two affected members in two generations. (2) Early onset « 50 years) colon
cancer in at least ODe individual (3) Localisation of tumours to the proximal colon (4)
FAP must be ruled out. These criteria are Jess stringent thaD die AmstenIam Critaia
which stale that there must be at least three affected members in two successive
FneratioDl. HoweW2" tbe Amsterdam guidelines had DOt been published at the
commencement of this project. The aiteria were chosen to compensate for the lack of
documeotatim of family bistcry in medical cbms and die fact that most of this evidence
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was provided by the patient themselves and in many~ incomplete histories were
provided. Many but not all of the pedigrees iDcluded in this study satisfy an the
Amsterdam criteria however, tumours of the proximal colon, evidence of family
history, and the absence of FAP is true for all pedigrees. It is important to note at this
stage that genetic screening was carried out blind with respect to whether the pedigrees
satisfied an the Amsterdam Criteria or nol Pedigree details were only examined after
all families were screened and mutations identified. Details of each pedigree included in
this study are detailed below, for ease of reference, determination of whether pedigrees
are 'typical' Amsterdam (satisfy all the Amsterdam criteria) or not has been included
with the family details.
DNA from forty unrelated unaffected Irish DNA samples (collected for another
umelated study), and ten unaffected "married in" individuals from the HNPCC
pedigrees were employed as the control population sample.
1.3.(111) PEDIGREE DETAILS
Figure 1.7 details symbols used in pedigree diagrams.
Pedigree Bl (Figure 1.8)
In this pedigree the proband, individual IV:I presented with canca' of the proximal
colon at SO years of age. His brother, individual IV:5 Previously diagnosed at 48 years
and his sister IV:7 diagnosed at 50 years were dereased at time of study. Three other
siblings presented with colorectal carcinoma IV:4, IV:8 and IV:9. This pedigree is a
tyPical Amsterdam HNPCC pedigree in that all the aiteria laid out by the International
Collaborative Group on HNPCC are satisfted. There is a strong family history of
cancer with 14 members affected with colorectal cancer in three generations (maternal
and paternal) and two cases of breast C8lcinoma on the ma1emal side. Individual IV:l
bas two as yet asymptomatic cbildren and one who presented with a colonic lesion
which was clear on histological analysis. (see Section 1.3.(XD) for the genetic analysis
of this individual). Samples included for analysis in this s1Udy are IV:l, IV:3, IV:4,
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Figure 1.8. HNPCC Pedigree 81
IV:8, V:3 and V: 1. In addition DNA was obtained from individual IV:I0 an unaffected
"married in" individual, and was used as a population normal control
Pedigree Cl (Figure 1.9)
The proband, individual ll:I presented with Dukes A colon cancer at S9 years of age.
His father was diagnosed at 7S years with colorectal cancer, obtained a total colostomy
and died eight years later. The probands sister (ll:2) presented with bowel obstruction
and underwent bowel resection at 60 years. Individual ll:3 is asymptomatic at 65 years
of age. Individual n:l has five children aged between 28-37 years, the youngest aged
28 (Ill:2) recently presented with colon cancer however was unavailable for inclusion in
this study. This pedigree satisfies all the Amsterdam selection criteria in that there are •
least three affected members within two generations with at least one diagnosis before
the age of SO. FAP was roled out in all cases. DNA was obtained from 2 affeaed
individuals ll:l and ll:2 and two unaffected individuals- ll:3 and 11:4. DNA from II:S
and ll:4 was included as normal "married in" population controls.
Pedigree Fl (Figure 1.10)
This large typical Amsterdam HNPCC pedigree includes five cases of colon cancer in
two generations in addition to two extta-colonic cancers. The proband, individual m:3
was diagnosed with colon cancer at 39 years of age, her sisters m:5 and m: 1 were
diagnosed at 3S and 30 years respectively. A brother (llI:9), diagnosed at 40 years is
now Hving in the USA and was unavailable for iDclusiOll in this study. Individuals
m:7 and m:8 aged 40 and 48 are asymptomatic to date. In addition two cases of breast
cancer and one case of honey metastases of the spine are evident in this pedigre;e. DNA
was obtained from individual m:s, ill:3 and one unaffected sibling m:8. DNA from
individual m:4 and m:6 were included as "married in" aormal control samples.
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Figure 1.10 HNPCC Pedigree F1
Pedigree HI (Figure 1.11)
There are six affected members in two successive generations in this pedigree.
Furthennore, there is one case of uterine cancer and one nephroblastoma in an
individual of 1.5 years of age. The proband (ll:4) was diagnosed with colon cancer at
48 years, her father diagnosed at 67 years is now deceased. Her two sisters (ll:1 and
H: 12) diagnosed at SO and 54 years respectively are also deceased. DNA was also
obtained from two brothers (ll:7 and n:13) diagnosed at 52 years and 47 years. There
are 5 asymptomatic siblings. DNA was obtained from 8:4, ll:7, ll:13 and one
unaffected sibling aged 59 years n:ll.
Pedigree OS 1 (Figure 1.12)
The proband m:3 was diagnosed with colon cancer at 44 years of age. His father (ll:1)
died aged 80 of colon cancer and two uncles (aged 50 and 70) an aunt (aged 59) and his
grandfather 9Ie1"e aD affected. The brother of the proband (m:4) and his sister (m:5)
were diagnosed with colon cancer at 30 years and 59 years respectively. There are four
asymptomatic siblings. A nephew, the son of an asymptomatic sister died aged 34 of
colon cancer. This is a typical HNPCC pedigree which satisfies all the Ams1etdam
criteria- 9 affected, four within two successive generatioDS, three individuals diagnosed
before the age of 50 and FAP was ruled out in all cases. Affected individuals ill:3, ll:4
and m:5 were included in the analyses in addition to 1 unaffected sibling: ill:7.
Individual m:8 was included as a nonnal population control
Pedigree M3 (Figure 1.13)·
The proband in this pedigree (ll:2) was diagnosed at 47 years, his brother ll:1 was
diagnosed at 35 years and both parents died of the disease. There is one asymptomatic
sibling; H:3- all three samples were included in the analysea. This is a true Amsterdam
pedigree, there are 4 affected in two generations, two diagnosed before the age of 50
and FAP was ruled out.
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Figure 1.11 HNPCC Pedigree H1
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Figure 1.12 HNPCC Pedigree OS1
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Pedigree W3 (Figure 1.14)
The proband (ll:1) presented with colorectal cancer at 62 years of age, her brother (ll:3)
diagnosed at 42 years of age is deceased. The proband has seven children, two have
been diagnosed with colon cancer m:4 at 26 years and m:7 at 31 years of age. The
remaining five siblings are asymptomatic to date. This pedigree is a typical Amstentam
pedigree. DNA was only available from individual ll:l.
Pedigree McS 1 (Figure 1.15) ,
The proband (ll:1) in this pedigree presented with colorectal cancer at 69 years of age.
His father was diagnosed at 49 years of age. There are two affected sibs, diagnosed at
60 and 40 years respectively. There is one asymptomatic sibling. This pedigree
satisfies an the Amsterdam selection criteria. The proband and one affected sibling
(ll:2) were included in the analyses.
Pedigree C2 (Figure 1.16)
The proband (ll:2) in this pedigree presented with colon~r at SO years of age. Her
brother was similarly diagnosed at 60 years of age. There is one asymptomatic sibling
and both parents are deceased, die cause of death was unknown. This pedigree is an
atypical HNPCC pedigree as there are only two affected siblings, furthermore DO
diagnoses were made before the age of SO. DNA was obtained from individuals ll:2
and ll:3.
Pedigree Ml (Figure 1.17)
The proband D:2 presented with colon canal' at 54 years of age. One affected sibling
was diagnosed at 48 years (ll:1). There is one asymptomatic sibling and a single case
of gastric cancer. This pedigree fails to satisfy all the Amsta"dam aiteria in Ibat there
are only two affected members in two generatioDS, there is however a strong family
history of the disease, a diagnosis before SO years of age , evidence ofextra-eolonic
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tumours and FAP was mled out in all cases.
Pedigree WI (Figure 1.18)
The proband D:2 presented with colon cancer at 31 years. Her father died of pancreatic
cancer at 47 years. There is one affected sibling (D:4), diagnosed at the age of 30 but
unavailable for inclusion in this study. There are two asymptomatic siblings. This
family fails to satisfy the Amsterdam criteria in that there are only two affected members
in two successive generations. DNA was obtained from individualsnn:2 (affected,
D:3 (unaffected), furthermore, individual D:5 was included as a "married in" normal
conttol sample.
Pedigree W4 (Figure 1.19) ..
.'
The proband individual D:2 presented with colorectal cancez at 27 years. One affected
sibling died at 58 years of age of colon cancer. This pedigree fails to satisfy the
AmstenJam criteria but was included in the study due to 1be history of the disease and
the very early age of onset in the proband. Samples inculded in the analyses were D:1
and D:2.
Pedigree DI (Figure 1.20)
Individual n:3, was diagnosed with colon cancer at the age of 61, her sister (ll:2) now
deceased, was similarly diagnosed at the age of 51 years. Her brother (ll:1) also had a
positive diagnosis of colon cancer however 1he age of diagnosis was unknown. 'Ibe
father of the proband presented with cancez of the bowel at 62 years of age. This
pedigree does not satisfy the AmstenJam aiteria as there was DO proof of diagnosis
before the age of 50 in any affected member. However as there are three affected
memben in two generations the pedigree was included in the analyses. DNA was
obtained from individuals D:3 and D: 1.
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Pedigree D3 (Figure 1.21)
In this pedigree there are three affected members in two successive generations,
individual ll:1 had a positive diagnosis of colon cancer at the age of 55. His sister now
deceased, was diagnosed at 57 years of age. Individual I:1 the affected mother died at
60 years of age as a result of colon cancer. This is an atypical HNPCC pedigree as
there is no diagnosis before the age of 50 in any individual. 1bere is however, a strong
family history of the disease, FAP was ruled out and there are three affected members
within two generations. DNA was obtained from peripheral blood of individual n;l
and from parraffm embedded tissue from individual ll:2.
Pedigree MG1 (Figure 1.22)
The proband in this pedigree presented with Dukes stage C colon cancer at the age of
37. Her brother individual ll:3 presented for biopsy at the age of 34. The mother (1:1)
died of suspected colon cancer, however this bas not been verified. There is evidence
of colon cancer in the maternal &randmother and two cases of non-colonic tumours in
two paternal uncles. This pedigree fails to satisfy the Amsterdam criteria in 1hat 1bere
are only two verified cases ofcolon cancer in two successive generations. This family
was included in this study due to the strong family history and the early age of onset in
affected individuals. DNA was obtained from ll:2 and ll:3 (affected) and from one
unaffected individual ll:4.
Pedigree D5 (Figure 1.23)
The proband in this atypical HNPCC pedigree presented with colon caDCa' at 3S years
of age. Her brother individual ill:3 was diagnosed at 34 years of age. 1be father of
these siblings is reported to have died aged 42 of colon cancer however this has not
been clinically verified. There is evidence of colon cancer in a paternal aunt and her
son. DNA was available from individuals m:2, m:3 and m:l. DNA from individual
D:2 and ll:4 was included as nonnal conttol samples.
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Pedigree D6 (Figure 1.24)
The proband in this pedigree presented with Duke8 stage B colon cancer at the age of
40. His sister now deceased was similarly diagnosed at 50 years of age. There is
evidence of colon cancer on the maternal side however this had not been verified. DNA
was obtained from samples ll:1 and IT:2.
Pedigree WS (Figure 1.25)
There are two affected siblings in this atypical HNPCC pedigree. Individual IT: 1 was
diagnosed with Dukes stage C colon cancer at 45 years of age, his brother individual
ll:2 was diagnosed at 50 years of age. There is evidence of colorectal canca' on the
paternal side, however this was not clinically verified. DNA was obtained from
individuals IT: 1 and ll:2.
1.3.(IV) SAMPLE COLLECTION
Three, five ml volumes of blood were collected from an affected individual
(proband) in each family. Where available, blood was obtained from other affected and
an unaffected members. DNA was extracted from 1 x 5ml blood as outlined in Material
and Methods Section 1.2.(1), a second S ml blood sample was stored at -7crc as a
back-up sample and the third 5ml sample was used for lymphocyte preparation. It is
essential 1bat lymphocyte preparation is Performed as soon as possible after blood
sampling (within a maximum of 24 hours), however as this was not compatible with
our sampling procedure (many samples bad to be posted or sampling involved
travelling long distances) blood was sent by courier to the ECACC facility at Porton
Down in the UK. Lymph~were transformed on site and stored lDltil required.
This step was taken as a precautionary measure to ensure tbat a constant supply of
DNAIRNAIceDs were available should the need arise.
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1.3.(V) DNA EXTRACTION
Genomic DNA was extracted from peripheral blood leukocytes using two
different methods (see Section 1.2.(1). The first method, a rather laborious and lime
consuming (2-3 days) method is based on cell lysis and ex1raction using the standard
phenol-chloroform method (Kunkle ., al., 1978). This method provided, high yield
(average SOOnglul), good quality DNA with an average A2f1J1A28{) ratio of 1.7. An
A2f1J1A28JJ reading of 1.8 is indicative of a pure preparation of DNA (Sambrook et
al., 1989). DNA extrae1ed by this method is robust free from residual. proteins and
remains stable when stored at -2()OC for at least 4 years. 1be second method is based
on the Puregene method by gentra systems, USA, it is a less tedious procedure, which
can be Performed on large and very small quantities of blood «10001). Furthermore
the process does not require the use of phenol-chloroform and can be completed within
1 day. However the Yield is lower than that of the standard method (average 300nglul),
more importantly the quality of DNA is poorer, PeR efficiency decreases as DNA
sample ages, samples' stored for more than one year at -200C are poor PCR templates.
Re-extraetion of DNA using DNA clean-up columns greatly improved the efficiency of
PCR suggesting interference from protein residues in the sample. The second method
is suitable for situations where once off analysis of a sample is required, however for
long tenn use and storage, the more 1ime consuming phenol chloroform method
provides highest quality DNA
1.3.(VI) MUTATION DETECTION METHODS
HNPCC is usually caused by mutations in one of four mismatch repair genes-
hMSH2, hMLHl, hPMSI and hPMS2 (Leach et al., 1993; Papadopoulos et al., 1994,;
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Nicolaides etal., 1994). More than 90% of reported mutations have been confined to
hMSH2 and hMLHl. The aim of this study was to saeeD both these genes for
causative mutations in the 18 Irish HNPCC families collected.
There are many methods currently employed to screen for mutations in genes.
The most common of these being, Denatming gmdient gel electrophoresis (Sheffield eI
Q/.., 1989), Chemical cleavage, RNase A protection analysis (Myers et al., 1985), single
stIand conformation polymorphism analysis (SSCP) (Orita et al., 1989b), ProteiD
truncation test (PTIj or IVPS (in vitro protein synthesis), (powell et al.,1993 Roost et
m., 1993) and direct sequencing.
The RNase A protection assay (Myers ., al., 1985) involves the PCR
amplification of the region of interest from the affected individual. A radiolabelled wild
tyPe probe is hybridised to the PeR amplified DNA If the PCR amplified DNA
fragment contains amutation, a mismatch occurs between the DNA:RNA duplexes and
complementary annealing does DOt occur at this position. The resulting beteroduplex
are subjected to cleavage by RNase~ which digests only unbound RNA, hence it wiD
only cleave RNA at a mismatch position. The resulting fragments are analysed by
polyacrylamide gel electrophoresis, the size of the fragment indicates the position of the
mismatch. One drawback of this technique ia the fact that some DNA:RNA
heteroduplexes are resistant to cleavage by RNase A, hence mutations may be missed in
die analysis. Secondly the use of RNA C8Il often prove troublesome as it requires •
RNaseAfreeenvironment.
Denaturing Gradient FJ electrophoresis (DOGE) (Sheffield et til., 1989;
Traystman et al., 1990) exploits the smaD differences in melting temperatures (Tm) of
two DNA moJecules differing by a single base. The technique involves 1be
electrophoresis of DNA fragments through a gel containing increasing amounts of
denaturant (usually a cbemical gradient, however tempenture gradients may also be
used). As the DNA migrates in the gel, it encounters iDctasing concentraboas of
denaturant aud at some point, it becoD8 partially or totally single stranded. 1be
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position in the gel where the DNA becomes denatured is determined by its nucleotide
sequence and composition. A single base pair difference between a normal and a
mutant DNA duplex is sufficient to cause them to migrate to different positions in the
gel. The technique is potentially highly sensitive and reproducible however it requires
the attachment of OC-sequences (clamps) to the S' ends of all primers to provide this
sensitivity which makes it an expensive procedure when large numbers of fragments are
being analysed. This method is more suitable to diagnostic work where the mutation is
already known, rather than for screening large samples for unknown mutations.
Direct sequencing of genes is effective, however it is tedious and exPenSive,
furthennore a high pen:a1tage of spurious bands JR observed on sequencing Ialce
necessitating replication of sequencing for verification. This method is essential in
identifying mutations in regions containing putative alterations, however it is not
efficient for broad scale screening of large regions or sample numbers.
The protein truncation ~t (YI'1) or in vitro protein synthesis assay (IVPS) is
based on the use of RT-PeR in combination with 1raDSCrip1ion and translation of
genomic PeR products in vitto (Roest et al., 1993; Powell et al., 1993). The ~t.ing
radiolabelled peptides are separated by polyacrylamide gel electrophoresis and
compared to a wild-type full length peptide to identify any ttunealed producta. DNA
from patients displaYing 1rUDCated products are further analysed to detemrine 1be exact
molecular nature of the ttuneation. This method is highly successful in the
identification of translation taminating mutations or large deletions, and it has been
iDsttumentai ill the identification of hundreds of mutatioos ia genes w~ early
terminations are common, such as in the APe gene in Familial Adenomatous polyposis
coli. (O'Sullivan et al., 1998). Despite its effectiveness, we chose not to use this
lechnique in our analysis as it relies OIl the use of RNA as a template. RNA preparation
is~ requires an RNase free environment and RNA is Jess robust than DNA, ill
addition the identification of a Dumber of alremative RNA transcripts of the hMLHl
genem~ it difficult to detemrine whether observed truncated~ lie the result
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of alternative transcripts or true mutations.
SSCP analysis (Orita et al., 1989a; 1989b) involves electrophoresis undez non-
denaturing conditions, of single stranded DNA fragments. The single stranded DNA
adopts a folded conformation which is stabilised by intrasttand interactions, so that the
conformation and therefore the mobility is dependent on the sequence. Therefore 1be
allelic variants ofDNA segments which differ by a single base substitution, deletion or
insertion exhibit a mobility shift upon denaturation and electrophoresis in a neutral
polyacrylamide gel. Initial screening of the hMSH2 and hMLHl genes in this study
was carried out using SSCP as it is a simple, raPid and efficient method and has been
used routinely for mutation screening in our laboratory. A more comprehensive
description of SSCP is given in "SSCP analysis" Section 1.3.(VIH).
1.3.(Vll) PCR AMPLIFICATION OF bMSH2 and bMLHl
The hMLHl and hMSH2 genes contain 19 and 16 exoDS respectively with an
average sim of ISO base pairs (Kolodner et al.,1994, 1995). DNA oligonucleotide
primers previously published by Kolodner et al., (1994, 1995) were used to amplify
each of these exons for subsequent SSCP analysis. The primers were designed to flank
each individual exon of the genes and to include the intton-exon boundaries (Table 1.3
and 1.4).
PCR is sensitive to changes in reaction conditions-the ramping rate of 1be
thennal cycler, reagents used, the 1bermostable DNA Polymerase used, magnesium
concentration and annealing temperature mayan effect the efficiency of the reaction. In
Older to test the compatibility of the published PeR amplificauon conditions with our
reagents and equipment, PeR was initially performed OIl a at sample (three HNPCC
DNA sample8, and a negative control (no DNA). Inefficient amplifica1ion in addition to
non-specific spurious amplicons were observed for most primer pairs, undez die
published conditions (results not shown). In Older to ensure efficient accurate and
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EXON SEQUENCE S'-3' EXON SEQUENCE ~'-3'
1 F tegcgcattttetteaacc 2 F gfCtttaeccattatttatagg
R gtccctceceagcacgc R gtatagacaaaagaattattcc
~ F gaagtecagetaataeagtgc .lllF ggtagtaggtatttatggaatae
R ctteaeatttttatttttetaete R catgttagagcatttaggg
3 F gcttataaaattttaaagtatgttc liF cacattgcttctagtacac
R gccttteetaggcctggaatetee R ccaggtgacatteagaac
~ F tteatttttgcttttettattee UF atteagtattcctgtgtac
R atatgacagaaatateette R cgttacccccacaaagc
~ F ccagtggtatagaaatcttcg .uF cgcgattaatcateagtg
R ccaateaacatttttaaccc R ggacagagacatacatttctatc
6 F gtttteaetaatgagcttgcc .1jF taeeacattttatgtgatgg
R gtggtataateatgtggg R ggggtagtaagtttccc
2 F gacttaegtgcttagttg UF etettetcatgctgtccc
R gtatatattgtatgagttgaagg R atagagaagctaagttaaac
.a F gatttgtattctgtaaaatgagate lnF taattaetcatgggacatte
R ggcctttgctttUaaaaataae R taeetteatteeattactgg
Table 1.3. Primer sequences used to amplify each exon of the hMSH2 gene.
Sequences are written 5'-3'. F denotes forward primer, R denotes reverse primer.
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EXON SEQUENCE S'-3' EXON SEQUENCE S'-3'
1 F aagcaetgaggtgattggc llF gggctttttctccccct
R tegtagcccttaagtgagc R aaaatetgggcteteacg
.2 F aatatgtacattagagtagttg llF aattataeetcatactagc
R cagagaaaggtcctgacte R gttttattacagaataaaggagg
J F agagatttggaaaatgagtaac UF tgcaacccacaaaatttggc
R acaatgtcatcacaggagg R etttcteeatttccaaaacc
,
j F aacettteeetttggtgagg ~F tggtgtctctagttctgg
R gattaetetgagacctaggc R eattgttgtagtagctetgc
~ F gattttetettttcccettggg llF cccatttgteccaactgg
R caaacaaagcttcaacaatttae R cggteagttgaaatgtcag
.,,'':'" .. ; " J;' ~
~ F gggttttatttteaagtacttct .16F eatttggatgcteegttaaagc
R gcteagcaactgtteaatgtatgagc R cacccggctggaaattttatttg
1 F etagtgtgtgtttttgc llF ggaaaggcaetggagaaatggg
R eataar£ttateteeaee R ccetecagcacacatgcatgtaccg
1 F eteagccatgagacaataaatee .1!F taagtagtctgtgatctecg
R ggttcccaaataatgtgatgg R atgtatgaggtectgtec
i F caaaagcttcagaatete .12F gacaccagttgatgttgg
R etgtgggtgwectgtgagtgg R gagaaagaagaacaeatca:
lDF eatgaetttgtgtgaatgtacacc
R gaggagagcctgatagaacatetg
Table 1.4. Primer sequences used to amplify each exon of the hMLHl gene.
Sequences are written 5'-3' F denotes forward primer, R denotes reverse primer.
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specific PeR products, optimisation assays were perfonned for each primel'set (table
1.5 outlines the optimised PeR conditions ).
peR OPTIMISAnON
Hot- Sta"
In Older to ensure complete denaturation of double sttanded template, and to
avoid the risk of introducing non-specific amplicons • III early stage, an initial '1Iot-
start" was performed for all PCR. reactions. The 'Hot Start ' technique involves the
deliberate exclusion of at least ODe essential reagent from the reaction mixture. The
missing component (in this case Taq DNA polymerase) is added only after the reaction
mixture bas reached a temperature of at least 7rfC. In the optimisation of samples, Taq
DNA polymerase was only added after the PeR. reaction mixture had undergone an
initial beating step to 940C for Sminutes. The effect of "hot- start" is that it prevents the
synthesis of extraneous productl arising from Don-specific primerhemplate
hybridisation at temperatures between 3(1C aud 6<rC, a range at which Taq polymerase
retains partial activity. (Ruano et al., 1991). These non-specific products could be
synthesised during the first cycle of the PeR. if the entire reaction was prepared at room
temperature and ramped to 94OC. In subsequent cycles, spurious products could serve
IS templates resulting in a beterogeoeous populatim of amplified producta.
Changes ill the PeR reaction buffer will usually effect the outcome of die
reacUOD. ID particular changes ill magnesium coocentratioDs profoundly effect the
dIiciency and specificity of the reaction. Exce4S magnesium usually results in 1be
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accumulation of non-specific amplification products while insufficient magnesium will
reduce the yield. Furthermore, deoxynucleotide triphosphates quantitatively bind
magnesium therefore the concentration of dNTPs in the reaction will have bearing on
the amount of free magnesium available.
In order to ensure the most efficient reaction conditions for this study, a
magnesium titration curve was performed for ea:h primer set. In the magnesium
optimisation procedure, five samples were amplified (three HNPCC DNA samples, a
standard lab control DNA sample, and a negative control (no DNA». 1be reactions
were performed at a range of magnesium concentrations, all other components remained
constanL Figure 1.26 demonstrates the effect magnesium titration may have on a
particular amplification reaction. Table 1.5 outlines the optimum PeR reaction
conditions obtained for each primer seL
Temperatur.
A temperature optimisation reaction was performed on any primer sets where
residual non-specific products were observed or inefficient amplification occurred post-
magnesium optimisation. The annealing temperature at which a PCR is performed
dePends on the length and base content of the primers. Generally, primers with high
GC content require higher annealing temperatures than those with high AT sequence
however a close approximation to the exact annealing temperature can be calcuJated
based on the sequence content of the primers. An annealing temperature penniUing
binding of primer to a matched 1eDlplate results in a highly specific amplification and
reduction of non-specific amplifications. An annealing temperature above the optimum
often results in the partial or complete loss of the amplification product as the primers
can no longer anneal to the DNA. Conversely, an annealing temperature which is much
lower than the optimum, results in die amplification of non-specific fragments, as die
primers randomly anneal to the DNA at points of incomplete complimentarity. A range
hMSH2
MUnesium concentration Annealin& temperahJ'fj
EXONI l.SmM S8°e
EXON2 2.SmM ssoe
EXON3 2.SmM ssoe
EXON4 I.SmM ssoe
EXON5 2.SmM 5soe
EXON6 I.SmM 56°e
EXON7 3.SmM 5soe
EXON8
\ ~-}.
2.SmM 5soe
EXON9 2.OmM 5soe
EXON 10 3.OmM 56°e
EXON 11 2.SmM 54°e
EXON 12 3.OmM 5soe
EXON 13 2.OmM 56°e
EXON 14 l.SmM 5soe
EXON 15 2.SmM 55°e
EXON 16 2.SmM 57°C
-------------------------------------------------------------------------------------------------------Table 1.5(a). Optimised PeR conditions for the amplification of the 16 exons of the
hMSH2 gene.
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hMLHl
EXONI 2.SmM ssOC
EXON2 2.OmM SSoC
EXON3 2.SmM SSoC
EXON4 2.SmM ssOC
EXONS 3.OmM SSoC
EXON6 3.OmM SSoC
EXON7 2.SmM 55°C
EXON8 I.SmM SSoC
EXON9 l.SmM sSOC
EXON 10 2.OmM ssOC
EXON 11 2.SmM SSoC
EXON 12 I.SmM SSoC
EXON 13 3.OmM SSoC
EXON 14 3.OmM SSoC
EXON IS 3.OmM SSOC
EXON 16 2.SmM SSoC
EXON 17 2.SmM ssOC
EXON 18 2.OmM ssOC
EXON 19 I.SmM SSoC
Table 1.S(b).Optimised PeR conditions for the amplification of the 19 exons of the
hMLHl gene.
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of annealing temperatures close to the calculated annealing temperature were employed
in optimising the amplifications in this study. The optimum annealjng temperatures am
shown in Table 1.5, Figure 1.27 demonstrates the effect that a change in annealing
temperature may have 011 a PeR reaction.
1.3.(VIII) SSCP ANALYSIS
AMPLIFICATION OF SAMPLES FOR SSCP ANALYSIS
Once the optimum PCR conditions had been determined for each primes set, an
DNA samples to be analysed by SSCP were amplified in the presence of [a'2P]-dCTP,
using original genomic DNA as the template. The radiolabelled nucleotide precursor
was incorporated into the amplified PCR product at C positions thus providing a tag to
facilitate the detection of the fragment in SSCP gels by autoradiography.
The detection of mutations by SSCP is dependent on the confonnational
changes of a single stranded DNA molecule (caused by a change in base sequence),
within a polyacrylamide gel, hence the method is sensitive to changes in the physical
environment of the gel. This includes, temperature, ionic concentration, presence of
solvents such as glycerol (Orita et al., 1989a) and the extent of cross-linking in the gel
(Hayashi et al., 1991). Furthermore, the mobility of single stranded DNA and the
mobility shift caused by a mutation can be dramatically altered in response to changes in
the temperature of elecu-ophoresis, for example 4°C versus room temperature (Orita et
al., 1989b). Changes in the concentration of the running buffer are also reported to
affect the mobility shift (Orita et al., 1989b). Reports indicate that running the gels in
O.S X lBE (45mMTris-Borate., ImM FDTA) rather than IX lBE (9OmM Tris-
borate,lmM EDTA) may result in sharper bands (Spinardi et al., 1991) whereas other .
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reports indicate no significant change in band separation (Iizuka et al., 1992). The
presence of low concenttations (5-10%) of solvents, such as glycerol in the gel can
improve separation of mutated sequences (Orita et al., 1989a). The weak denaturant
action of glycerol on nucleic acids is thought to partially open the folded structure of
" single stranded DNA and increase the probability of altering the mobility of the strand
with locally confined sttuetural differences caused by the mutation (Hayashi et al.,
1991). Raising the glycerol content above 10% does not result in improved separation
(Spinardi et al., 1991) - a concenttation of 5% glycerol in the gel results in the detection
of the majority of mutations (Hayashi et al., 1991). Increasing the polyacrylamide
concentration above 6% does not significantly improve detection of the mobility shift
(Spinardi et al., 1991) It has been reported that the extent of cross-linking (ratio of
acrylamide to N,N'- methylenebisacrylamide) within the gel may have an effect on
detection efficiency. In one report, electtophoresis was perfonned in either 5%
polyacrylamide gels with an acrylamide:bisacrylamide ratio of 29:1 or in 6.,
polyacrylamide gels with a ratio of acryalmide:bisacrylamide of 19:1 with similar results
(Michaud et al., 1992). Hayashi et al, (1991), ft'CODlDleod a ratio of 99:1 since die
increased pore size of the gel seems to be more sensitive with respect to detection of
conformational changes in DNA.
On analysis of all the reported SSCP conditions, SSCP in this project was
perfonned using 6., polyacrylamide gels with an acrylamide:N,N'-
methylenebisacrylamide ratio of 99:1. The electtophoresis buffer used was O.5X TBE.
Constant temperature was maintained during electrophoresis using thin gels (O.4mm), a
gel apparatus with an aluminium plate to maintain an even temperature distribution and a
fan was used to cool die gel. Electrophoresis was performed under three different
conditions (1) with 5., glycerol at room temperature (2) with 5., glycerol at 4°C (3)
without glycerol at«. This was to ensure that ifa mobility shift was mjssed under
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one of the conditions, it was unlikely to be missed under all three conditions. Figure
1.28 demonstrates the principle of SSCP analysis.
SSCP ANALYSIS RESULTS.
Sixteen exons of the hMSH2 gene and 19 exons of hMLHl were amplified in
the presence of [a32P]-dCI'P and subjected to SSCP analysis. Fifty genomic DNA
samples were analysed by SSCP, these included the proband and an unaffected
individual from each family and where available any additional affected individuals
detailed in Section 1.3.(nI). Furthennore 50 control genomic DNA samples were
similarly analysed. Aberrant SSCP fragments were observed in 14 samples. These
SSCP changes were confIDed to 7 different exons. In hMSH2 SSCPs were observed
in exoDS 7 and 5, while in hMLHl SSCPs were observed in exoDS 8, 12, 15 and 17.
Table 6 details the gel conditions, observed SSCPs and positions in the gene. Analysis
of this table reveals that the most successful condition for detecting mobility shifts is
using 5% glycerol at 4°C. Running fragments in gels without glycerol at room
temperalUre was the least successful at detecting mobility shifts and could perhaps be
eliminated from SSCP detection protocols.
Figures 1.29-1.33 show the autoradiographs of the DNA subjected to SSCP analysis.
As 100 genomic DNA samples were analysed by SSCP for 35 exoDS it was not feasible
to show a gel image for each sample, therefore, only protions of the gels where an
SSCP is visible are shown.
SSCP analysis of exon 5 of the hMSH2 gene identified altered SSCP mobility
in five fragments. Figure 1.29 shows the autoradiograph of the SSCP analysis of
Exon 5 of the hMSH2 gene under conditions of 5% glycerol at 4OC. Altered migration
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patterns are visible in individual IV:I of pedigree BI (lane 2), individual ll:2 of
pedigree MCSI (lane 3), Individual ill:7 of pedigree OSI (lane 6), individual ll:D of
pedigree HI (lane 7) and individual ill:3 of pedigree FI(lane 10). Alterations were
observed under all three e1ecttophoretic conditions (0% glycerol at 4OC, S% glycerol at
room temperature and 5% glycerol at 4OC) however, using the latta' conditions,
alterations were more pronounced.
Individual IV:I of BI and ill:3 of pedigree FI are affected HNPCC patients,
individuals ill:7 (OSI), ll:D (HI) and D:2 (MCSI) are unaffected individuals from
HNPCC pedigrees.
Figure 1.30 shows the SSCP banding pattern of exon 7 of tile hMLHl gene in 2
affected HNPCC probands under the most stringent electrophoretic conditions of S%
glycerol at 4OC. Of the SO genomic DNA samples analysed a single altered SSCP
fragment was observed in individual D: I of pedigree D3 (lane 2). This SSCP is not
highly obvious and was not observed under the two other electrophoretic conditions.
However as the SSCP was not detected in the 50 nonnal controls analysed, the sample
was sequenced to determine if it is a rare polymorphism or a disease causing mutation
in this pedigree.
Figure 1.31 shows tile SSCP analysis of exon 12 of hMSH2. Exon 12 of the
hMSH2 gene was amplified from SO genomic DNA samples from the Irish HNPCC
families. Alterations in the SSCP migration pattern was observed in two sample8-
individual IV:I of pedigree B1 (lane 5) and individual D:3 of pedigree C2 (lane 6). This
SSCP is likely to be an innocuous polymorphism as 1he sequence change does DOt
segregate with the disease in these families. Individual IV:I of pedigree Bl is affected
and displays the SSCP pattern, however an affected sibling IV:4 does not exhibit the
same SSCP alteration in this exon (lane 8). Furthennore, individual D:3 of pedigree C2
is an unaffected membez of a HNPC'C pedigree. Analysis of the nonnaI control
population identified a corresponding SSCP of exon 12 in 3/SO control samples (not
shown). These results are consistent with the SSCP representing a polymorphism
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rather than a disease causing mutation.
Exon 8 of the hMLHl gene was amplifIed from SO genomic DNA samples from
the HNPCC families and analysed by SSCP. The SSCP analysis of exon 8 of the
hMLHl gene in 8 samples is shown in Figure 1.3%. An altered SSCP migration
pattern was observed in three samples- individual 8:2 of pedigree Cl (lane 20),
individual 8:1 of pedigree W3 (lane 22) and individual 8:1 of pedigree Cl (lane 23).
This altered SSCP pattern is likely to represent a mutation in pedigree CI as it was
identified in two affected members of this family (ll:1 and 8:2) however the
corresponding SSCP was not detected in two unaffected members of this pedigree, or
in the SO normal control samples.
SSCP analysis of exon 17 of the hMLHl gene was perfonned on 50 genomic
DNA samples from the 18 Irish HNPCC pedigrees. Altered SSCP eJec1rophoresis
fragments were observed in three affected individuals from pedigree HI -individual 11:4
(lane 4), individual 8:7 (Jane S) and individual 11:13 (lane 6). No alteration in SSCP
Pattern was observed in an unaffected individual of the same pedigree (11:11, lane 7).
The SSCPs are likely to represent mutations in this exon in this HNPCC pedigree as the
SSCP segregates with the disease in the family and is absent from an unaffected
member. (Figure 1.33).
Table 1.6. details the results of the SSCP analysis of the Irish HNPCC population.
1.3.(IX) SEQUENCE ANALYSIS
In order to determine the nature of the DNA sequence changes responsible for
the mobility shift observed during SSCP analysis, any fragments displaying an altered
migration Pattern were subsequently sequenced. Sequencing was carried out using two
different methods.
Method 1 involved the PCR ampHfication of the product, and the subsequent
cloning of the PeR fragment into the TA cloning vector. The vector was subsequently
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2021 22 23
I 2 4 6 7 9 10
Electrophoretic
conditions
RT, 5% G
4°C, 5% G
4°C, 0% G
Gene Exon SSCP
observed
5 5 samples
hMSH2 5 5 samples
S 5 samples
RT, 5% G 7 osample
4°C, 5% G hMSH2 7 1 sample
4°C, 0% G 7 osample
RT, 5% G
;... .::>'l f 12 2 samples
4°C, 5% G hMSH2 12 2 samples
4°C, 0% G 12 osample
RT, 5% G 8 2 samples
4°C, 5% G hMLHl 8 2 samples
4°C, 0% G 8 osample
RT, 5% G
4°C, 5% G
4°C, 0% G
17 *3 samples
hMLHl 17 3 samples
17 0 sample
Table 1.6. Results of the SSCP analysis of hMSH2 and hMLH1 in 18 Irish
HNPCC pedigrees. The conditions of analysis and observed SSCPs are detailed.
*; A similar SSCP was observed in 3 affected patients within the same family,
RT; room temperature, G; glycerol
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transformed into E. coli and colonies putatively bearing the PeR insert were selected
based on an insertional-inactivation, chromogenic assay. Plasmids were subsequently
isolated and sequenced using 17 DNA Polymerase with dideoxy terminator
incorporation and ['f'"P] labelled primers.
The second method of analysis employs the "cycle sequencing" protocol which
employs the thermostable enzyme 'thermosequenase' and facilitate& PCR coupled
sequencing with the incorporation of [a33-P] labelled dideoxy terminators.
Controls
To tuJe out the possibility that the identified mutations may be common
polymorphisms fifty unrelated, unaffected population 'normals' were analysed. The
normal population included 40 unaffected Irish samples (collected for another unrelated
study) and 10 'married in' members of the HNPCC pedigrees. The 'married in'
samples were obtained from individuals with no family history of the colon cancer and
who were over SO years of ale. The COITeSponding SSCPs were not identified in any
of the conttols.
SEQUENCING RESULTS:
An fragments bearing altezed migration patterns under SSCP conditions were
sequenced to identify any mutatiooslpolymorpbisms presenl Sequencing identified
five mutatioDS, three splice site and two point mutations. Of these five mutatioDS, four
~ DOvel and one is a previously reported common HNPCC mutation. In addition a
number of polymorphisms were identified.
Ca"satipe M"tatio"s:
Mutations were identified in five pedigrees, exon S of hMSH2 was mutated in
two pedigrees and hMLHl was mutated in three families- two mutations in exon 8 and
one in exon 17.
1IMSH2 ",,,tatio,,.:
Altered SSCP mobili~ of exon S of the bMSH2 gene were detected in S
samples from 5 independent families- individual IV: I of pedigree B1, individual D:3 of
pedigree Fl, individual ll:2 of pedigree MCS1, individual m:7 of pedigree OSI and
individual D:ll of pedigree HI. DNA sequence analysis was performed on each
sample-two different splice site mutations of exon S in hMSH2 were identified in
pedigrees Bland Fl. The SSCPs detected in the other samples were identified as
sequence polymorphisms in these patients.
Pedigree Bl, Ron 5 bMSH2 mutation:
Sequence analysis of the proband IV:1of pedigree B1 (FtgUre 1.34) revealed an
A to T transversion at the +3 position of the splice donor site consensus sequence. This
mutation has been previously reported in 14 other pedigrees and appeMS to be one of
the more common hMSH2 mutations (Lui et al., 1994) first identified this mutation in
three US pedigrees, analysis of RNA 1raDsCripts from these patients revealed that the
mutation results in the alteration of the splice site, with the result that exOll five is
skipped and a defective, truncated protein product is produced (Lui et al., 1994).
Sequence analysis of two other affected members in this pedigree (IV:4 (fig.1.35a) and
IV:8) identified the presence of a similar mutation. Subsequent to the identification of
this mutation two undiagnosed children of the proband were screened for the mutation.
Individual V:1 proved not to harbour the mutation, however the mutation was identified
in individual V:3 (see Section 1.3.(Xll) for a more detailed discussion). The mutation
was identified in four affected members of this pedigree but was not identified in 2
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unaffected members (V:1 and IV:3), this is consistent with the base change being a
causative mutation within the pedigree.
Pedigree Fl exon 5 hMSH2 mutation:
SSCP analysis of individual m:3 of pedigree Fl revealed an altered migration
pattern similar to that observed in pedigree B however sequence analysis revealed an A
to G ttansition at the +6 position of the splice donor site in pedigree Fl (Figure 1.3Sb).
This base change occurs within the region associated with 1he consensus sequence of
the intton. Therefore, it is likely that the mutation could result in the production of an
altered protein product due to aberrant splicing at this position. However RNA analysis
or the protein truncation test analysis of this gene is required to definitively prove that
this is a disease causing mutation within this pedigree (not performed). The
corresponding SSCP segregates with the disease in this pedigree- it was present in
another affected member of the pedigree-individual m:s but was not detected in an
unaffected member of this pedigree (llI:8) furthennore the corresponding SSCP was
not detected in the SO normal control samples therefore it is consistent with it being a
causative mutation within this pedign:e. This putative mutation is to date, specific to the
Irish population and has not been reported elsewhere.
"MLHI M,,'atio.,:
Three novel mutations were identified in hMLHl in three unrelated famjJjeA.
Pedigree Cl and W3, aon 8 mutatioDS:
SSCP analysis of exon 8 identified altered migration patterns in 2 affected
individuals ll:1 and n:2 of pedigree Cl and the proband (ll:1) of pedigree W3.
Sequence analysis of individuals ll:l and ll:2 of pedigree Cl revealed a OCC-ecc
change at codon 210 (Figure 1.36). This heterozygous point mutation results in 1be
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substitution of a proline residue for an alanine. Alanine is one of the mo~ simple
amino acids with a single methyl side chain, proline on the other hand, an imino acid
has a cyclical structure, usually found at the bends of folded proteins, it is not averse 10
water and matkedly influences protein architecture. Thus this amino acid change is
likely to have a significant effect on the protein structure and hence affect it's activity.
This sequence change was~t in two affected members of this pedigree however,
no cotTeSponding SSCPs were observed in 2 unaffected individuals from this pedigree
(ll:3 and m:4) or in the SO normal control individuals. The segregation of the mutation
with the disease in this family is consistent with it being a mutation. This mutation is a
novel previously unreported mutation.
Figure 1.37 shows the nucleotide sequence of exon 8 of the hMLHl gene in
individual II:1 of pedigree W3. The loss of a T at codon 224 was identified, this is a
frameshift mutation that replaces a valine residue with a serine at the 3' end of the exon.
This represents a non~nservative change in amino acid as serine contains an amino
group in its side chain whereas valine does not, this is likely to effect the function of the
resulting protein. No other affected member of this pedigree was available for analysis
however the corresPODding SSCP was not identified in SO normal conttol samples.
This mutation has not been previously reported.
Pedigree HI, eXOD 17, hMLHl:
Figure 1.38 shows the nucleotide sequence of exon 17 of the hMLHI gene in
individuals II:4, II:7, II:13 and II:II of pedigree HI. Three affected individuals (ll:4,
II:7 and 11:13) displayed altered SSCP patterns, whereas individualll:ll (sample A) an
unaffected sibling, did not show any changes in migration pattern. Sequence analysis
revealed the presence of a CCC-erc change at codon 648 in the three affected siblings. .
A normal sequmce pattern is cJearly seal in individual ll:11. This previously
100
(B))
G
T
G
G~
G( )
T G
(B)
T G
( )
T G
unreported mutation substitutes a proline residue with a leucine. This represents a
significant amino acid change as proline an imino acid has a cyclical S1rUcture, is
hydrophyllic in nature and is usually found at the folds of proteins. Leucine on the
other hand, has a basic hydrophobic side chain therefore the alteration is likely to affect
the protein function. The corresponding SSCP was not observed in the SO normal
control samples.
Polymorphi,m,
In addition to the mutations identified, a large number of polymorphisms were
detected, most of these corresponding to alterations within intronic regions. The
common hMSH2 exon S polymorphisms were identified in four samples as shown
(Figure 1.39). This highly polymorphic polyA 1l'aCt is altered ill individual ll:2
(MCSI)-sequence A, individual ill:7 (OSI) sequence B, D:ll (HI) sequence C, and
individual D:3 (WI) sequence D. Sequence analysis revealed altemtions in the number
of A residues in the poIyA tracts of each sample, however it proved difficult to count
the exact number of As spanning this tract. 1be base changes are unlikely to be
causative mutations as they were identified in unaffected individuals of the HNPCC
pedigrees. Furthermore this region is reported to be highly polymorphic in the general
population and is a repeat sequence frequently employed in the analysis of replication
error phenotype (at the BAT 2S locus) Figun 1.39 displays the differences in this
region in sequences A, B, C and D. Individual D:2 (MCSI) displays an extta GAG in
the polyA tract in addition to an increase in the number of A's (sequence A).
Figure 1.40 shows the sequence analysis of exon 7 (hMSH2) from
individual D:l in pedigree D3. A T-C alteration was observed at the downstteam -7
position, however this base change lies outside the splice site consensus sequence range
and is unlikely to affect splicing. Furthermore the corresponding SSCP was not
observed in ODe other affected membez within this family; D:2, (this individual was .
deceased at the time of the study, however paraffin embedded arehival tissue was
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available and was used to obtain genomic DNA for analysis). RNA or protein analysis
is required to prove the presence or absence of a splice site mutation iD this individual
(not perfonned).
Alterations in SCCP migration paaems weft' also observed in exOD 12 of
hMSH2 in two samples. An SSCP of exon 12 of hMSH2 was detected in individual
IV:4 of pedigree B1. This is an affected membeJ' of a HNPCC family and this sample
was previously shown to contain a mutation of cxon S of the same gene.. The exon S
mutation segregates with the disease in this pedigree however the SSCP ofexOD 12 was
not present in three other affected members of this pedigree (IV:8, IV:l and V:3).
Furthermore, the COITeSponding exOll 12 SSCP was identified iD 3160 normal control
samples which is consistent with a polymorphism rather than a causative mutation. An
SSCP ofexon 12 was also seen in individual 11:3 of pedigft'e C2. This individual iI an
lDlaffected member of this pedigree and although this individual may develop colon
cancer later in life, the presence of the SSCP in the normal population suggests that it is
most likely a polymorphism. As these SSCPs were believed to be polymorphisms
sequence analysis was not performed on these samples.
1.3.(X) TYPICAL VERSUS ATYPICAL AMSTERDAM PEDIGREES
As previously stated, genetic screening was carried out blind as to whe1her 1be
pedigreea satisfied all the Amsterdam Criteria or not. Pedigtl'e details wtft only
examined after all famities were screened and mutations identifted. Details of eAICh
pedigree included in this study are provided iB Sectdl 1.3.(1D) aod for ease of
reference, determination of whether pedigreea~ 'typical Amsterdam' (satisfy an die
Amstenlam criteria) or 'atypical' (BOt satisfying all the criteria) bas been included with
the family details. Correlation of pedigrees with mutations idmtified and 'AmstatIam'
status reveals that aD die identified mutations are confined to typical Amsterdam .
pedigreea. SSCP analysis can fail to detect up to Stf, of mutations and our mutation
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screening did not include promoter regions which are potential mutation sites, however
this does not adequately explain the lack of mutations in the Non-Amsterdam pedigrees.
Low frequencies of hMSH2 and hMLHl mutations in atypical HNPCC pedi~ was
recently reported by Wijnen et al., (1991), in their analysis hMSH2 and hMLHl gene
mutations were identified in 50% of families fully complying with the Amsterdam
selection aiteria, whereas, disease causing mutations were only identified in 8% of
families which did not satisfy the criteria. The screening protocol in the Irish pedigrees
focused on hMSH2 and hMLHl only, mutations were detected in S of 8 Amsterdam
pedigrees (62%). This is in keeping with reported detection rates for typical HNPCC
pedigrees (Peltomaki et al., 1997 ), however, the lack of mutations in these genes in the
atypical-Amsterdam pedi~ suggests 1hat perhaps some other genes are responsible
for colon cancer in these families. Table 1.1 details the mutation profile of the Irish
HNPCC pedigrees screened in this study.
1.3.(XI) SEGREGATION ANALYSIS OF IDENTIFIED MUTATIONS
IN THE HNPCC PEDIGREES.
Mutations in the mismatch repair genes were identified in five Irish HNPCC
pedigrees. Following the identification of the mutation in the proband, other available
affected and unaffected members of the pedigree were screened for the corresponding
mutation or SSCP. This analysis was performed in older to determine if the mutation
segregates with the disease in the family.
Segregation analysis was possible in four of the five families ill which a
mutation was identifted. No other members of pedigree W3 were available for analysis
therefore it cannot be definitively concluded that this is the disease causing mutation in
the pedigree. However, as the COITeSponding SSCP was not detected in the 50 normal
control samples and because the~ mutation results in the DOD-CODSeI'Vative
alteration <X an amino acid residue of the protein, which is likely to affect
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FAMILY
Bl
FI
CI
HI
MUTATION
hMSH2-Exon S
A-T @ 3' SD site
hMSH2-Exon S
A-G @ 3' SD site
hMLHI-Exon 8
GCc-ccc @
codon 210
hMLHI-Exon 17
CCC-CfC @
codon 648
CHANGE
+3 Splice
donor site
+6 Splice
donor site
Ala- Pro
Pro-Leu
NOVEL?
Previously reported
in 14 pedigrees
Novel
Novel
Novel
AMSTERDAM
STATUS
Typical
Typical
Typical
Typical
W3 hMLHI-Exon 8 Val-Ser Novel Typical
T deletion @
____~c~QdQn224 _
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FAMILY MUTATION CHANGE NOVEL? AMSTERDAM
STATUS
..------------------------------------.----~----------- -------------------------._.--------------------------- ..------_._.---------
OSI None detected N/A N/A Typical
M3 None detected : N/A N/A Typical
MCSI None detected N/A N/A Typical
C2 None detected N/A N/A Atypical .
Ml None detected
\
N/A N/A Atypical
W2 None detected N/A N/A Atypical
W3 None detected ; N/A N/A Atypical
01 None detected N/A N/A Atypical
02 None detected N/A N/A Atypical
MG None detected N/A N/A Atypical
05 None detected N/A N/A Atypical
D6 None detected N/A N/A Atypical
W5 None detected N/A N/A Atypical
Table 1.7. Mutation proftle of the Irish HNPCC pedigrees analysed in this study.
lO~
the protein function, it is likely that this is the dis~ causing mutation within this
individual (Figure 1.41).
1.3.(XII) MUTATION SCREENING· FAMILY SIGNIFICANCE:
As previously stated, a A-T transversion at the +3 splice donor site was
identified in exon 5 ofhMSH2 in pedigree Bl. This mutation results in the alteration of
the splice donor site consensus sequence and results in the subsequent production of a
. non-functional, ttuneated protein product (Lui et al., 1994). At the time of analysis
four members of this pedigree were available for screening, IV:l, IV:4 and IV:8 (aD
affected) and IV:3 (unaffected). The mutation was identified only in the affected
individuals and was not present in individual IV:3. Subsequent to the identification of
the mutation within this pedigree, individual V:3 (daughter of IV:l) presented for
colonoscopy at the age of 31yrs. A small colonic lesion was identified, however
histological analysis was clear. Analysis of genomic DNA revealed the pre3ence of the
predisposing mutation in this individual Her brother, individual V:l volunteered for
analysis and proved clear of any predisposing mutation. Identification of predisposing
mutations prior to tumour development is imPOrtant to assist at clinical level in terms of
surveillance, diagnosis and follow-up.
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1.4 DISCUSSION
Colorectal cancez accounted for 12.1'IJ of an caDCa' deaths in Ireland in 1994
(National Cancer Registry). The incidence of HNPCC in Ireland is DOt recorded
however, it may be inferred that since HNPCC is thought to account for 10% of all
colon cancer then 1.2~ of an cancer deaths in 1994 were due to HNPCC (personal
communication D Delaney, Cancer Research Board).
Sequence analysis of fragments bearing altered migration patterns under SSCP
conditioDS identified 5 mutations in 18 Irish HNPCC pedigrees. Of the 5 mutatioDS,
four are novel and one is a previously reported common HNPCC mutation. In addition
a number of polymorphisms were detected.
1.4.(1) IRISH HNPCC MUTATIONS
... :' The mutations identified in the Irish population include two splice site mutatioDl
(both in exon 5 of hMSH2), two point mutations including a C-T transition and a G-C
transversion and a single base ddetioD which .aults iD the frameshift aIteraIioo of the
downstream sequence.
ItMSHZ .uttltio••:
Two diffemlt splice site mutations of exOD 5 of hMSH2 were identified in two
famjlies. The A-T transversion at +3, splice donor site is a previously reported frequent
HNPCC mutation. An A-G transition was identified at die +6 positiOll of the splKz
donor site ill another pedigree. This mutation bas not been previously reported,
however • with the A-T mutaliOll, the hue change may resu1t in the alteratioD of the
splice site, with the resu1t that exon 5 is skipped and a defective truncated protein iI
produced.
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ItMLHl ."ttUiou:
Three novel mutations were identified in hMLHl in three unrelated pedigrees.
A CCC-eTC change was identified at codon 648 in exOll 17 in one pedigree. This
mutation substitutes a proline residue with a leucine. This is a significant change II
proline, an imino acid has a cyclical str1letu1e usually found at the bends of folded
proteins, it is not averse to wata' and markedly influences protein aJdUtecture.. Leucine
on the other hand bas a basic hydrophobic hydrocarbon side chain. The mutation waa
identified in three affected members of this pedigree and was not present in one
unaffected individual. Two novel mutations were identified in exon 8. A GCC-CCC
change was detected at codon 210 in a single pedigree, this point mutation results iD die
substitution of a proline residue for an alanine. Alanine is one of the IIlOIe simple
amino acids with a single methyl group side chain. The loss of a T at codon 224 ill
another pedigree was also observed. This frameshift mutation substitutes a valine
residue with a seriDe. This~ts a Don-conservative cbange in amino acid II
serine contains an amino group in its side chain whemas valine does Dot, this is likely to
effect the function of the resulting protein. The mutations in hMLHl are to date, unique
to the Irish population and have Dot been previously reported.
III ordes for a change ia DNA~ to be considered a disease causilll
mutation, a Dumber of criteria must be met The mutation must (1) alla'the amino acid
sequence in the resulting profein. This may be at the exact site of the DNA alteration or
may occur elsewhere in the protein IS a result of a sequence change (splice-site
alterati<m, iDsertionIddetiOD) (ii) The mutation must be absent from the IO'IDa1
unaffected population (rii) it must segregate with die disease in the family. Additional
evidence ofa disease causing mutation is provided by (iv) the conservation of the amino
acid acroa species and (v) the presence of tbe mutation in more than one affected
family. ',,'.
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The five mutations identified in this study satisfy all of the first three criteria, in
aD cases the resulting protein is altered, 1be mutation segregates with the disease and
none of the mutations were identified in the nonna! population. Analysis of amino
acids across a number of species performed using a BLAST search reveals that in the
case of mutations that cause a specific amino acid change the mutations were identified
in residues which are conserved across different species (Figure 1.42). The splice site
mutations result in the skipping of exon S of the hMSH2 gene, this entire exon is highly
conserved across species therefore deletion of the exon would have major implications
for protein function (Figure.1.43).
1be mutation at codon 648 ofexon 17 ofhMLHl causes a proline residue to be
replaced by a leucine. Peptide sequence analysis demonstrates that this residue is
conserved in R norvegicus (Rat) and S. cervisiae. The importance of this residue is
reiterated by noting that the sequence immediately preceeding the proline is not
conserved between human and S. cervisiae, however the proline is conserved Perhaps
because it is essential for the f1UlCtionality of the protein (Figure 1.43).
1he mutation at codon 210 of exon 8 in hMLHl results in the substitution of an
alanine with a proline. The alanine residue is conserved across species including
(mutL) R. IIOrvegiclU. The two exOD S mutations in hMSH2 result in the loss of the
entire exon. Comparison of the exon sequence across species reveals the high level of
conservation between mouse (M. musculus), rat (R. norvegicus) and homo sapiens.
Only 1 of SO amino acids in this peptide vary between the species (Figure 1.43).
.. ~ Oftbe mutations identified only the +3, splice donor site of exon S in hMSH2
was identified in other Pedigrees. The exon S hMSH2 splice site mutation in pedigree
B bas been previously identified in 14 other pedigrees of diverse aeographical
background (Lui et al., 1994; Peltomaki et al., 1997). The mutation has not been
detected in any other Irish HNPCC pedigrees however future analysis of more Irish
families may identify it
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Exon8hMUl1
Mutant human sequence:
Wild type human sequence:
R.NorvegicllS sequence:
Exon8hMUl1
Mutant human sequence:
Wild type human sequence:
R. IIOrvegicllS sequence:
Exon 17 hMUl1
Mutant human sequence:
Wild type human sequence:
R. IIOrvegicus sequence:
S. cervisilu sequence:
RTLNPSTVDNIRSIF
•
RTLNASTVDNIRSIF
•
RTLN ATTVDNIRSIF
f
Codon 210
SIFGNASSREL
•
SIFGNAVSREL
SIFGN A V SREL
t
Codon 224
PLLIDNYVLPLEGLPI
PLLIDNYVPPLEGLPI
•
PLLID S YVPPLEG LPI
••• • • •• *
PLLLKGYIPSLVKLPF
f
Codon 648
Figure 1.42. Blast amino acid sequence alignments between the wild type
human MLHI gene, mutant hMLHI gene sequences identified in Irish HNPCC
pedigrees and the R. norvegicus and S. cervisiae (exoD 17 only) protein. *
denotes amino acid differences between sequences.
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&on 5 hMSH2
WT- human sequence:
S.cervisiae sequeuce:
M.muscularis:
R.norvegicus:
QVAVSSLSAVIKfl EJ I SDDSNFGQFEL'ITFDFQYMKLDIAAVRALNLFQGSVEDTG
QVAVSSLSAVIKFLELLSDDSNFGQFELITFDFQYMKLDIAAVRALNLFQGSVEDTG
QVAVSSLSAVIKFLELLSDDSNFGQFELTIFDFQYMKLDMAAVRALNLFQGSVEDTG
QVAVSSLSAVIKFLELLSDDSNFGQFELITFDFQYMKLDMAAVRALNLFQGSVEDTG
Figure 1.43. Blast amino acid sequence alignment exon S of the human MSH2 gene and the equivalent sequence in
S. cervisitU, M. muscularis and R. norvegicus.
as a common HNPCC mutation in this population. The mutation has been identified ill
three other pedigrees in the USA (Lui et al., 19(4) and is responsible for the disease ill
12% of affected UK kindreds (peltomaki et al., 1997). Haplotype analysis of aD
pedigrees harbouring this mutation may allow us to trace the origins oftbis mutation.
1.4.(11) FOUNDER MUTATIONS.
The 'founder effect' refers to mutations which have arisen once and
subsequently have been passed through successive generations to present day carriers
and patients. Some founder mutations are extremely widespread and account for a large
proportion of some of today's major diseases such as the delta F508 mutation of the
CTFR gene in cystic fibrosis (Morral et al., 19(4).
The majority of mutations identified in HNPCC are unique except for a hMLHl
mutation identified in 2S Finnish famiJjes, the exOll S hMSH2 splice site mutation (14
families) and a hMLHl codon 616 mutation (9 families). These may represent founder
mutations. The exon 16 mutation of hMLHl was detected initially in five Fmnisb
families, geograpbical analysis of these famila showed that they have a common
geographical origin and share a common ancestor born in lSOS (Nystrom-Lahti et al.,
1994). Further analysis of other families which have tbis mutation showed 1bat fbm, ia
acommon shared haplotype ofalleb around hMLHl in these famifies
The cxon S splice site mutation detected in Irish pedigree B1 has been identified
in 14% mUK pedigrees (Peltomaki et al., 1997) aDd in three NoI1h-American famiJiea
The AmeriaUl families sluR DO obvious recent ancestry however, they may sluR
Nortbem Europe-. origin (Lui et al., 1994). This mutatioD may~ a founder
mutatioo originating from an individual of UK or Irish origin, haplotype analysia
arouad the hMSH2 region in families which have this mutaIioB may aDow die mlllati~
to be 1raced bact to a single individual
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1.4.(111) MISMATCH REPAIR MUTATIONS AND COLON CANCER
DEVELOPMENT
HNPCC affected patients carry a germline mutation which inactivates one copy
of one of their mismatch repair genes. Analysis of tissues in these individuals reveals
that they are phenotypically nonnal (it has been demonstrated that cell lines, with one
mutant allele of a mismatch repair gene exhibit nonnalleveJs of mismatch repair even
under conditions of increased mutation frequency), (Branch et al., 1993), they are
however at increased risk of developing colorectal cancer. When a second somatic
mutation in the MMR gene occurs, this inactivates both copies of the gene and
mismatch repair activity becomes defective. A hypennutable state exists in these cells
with the result that more and more mutations persist after each round of DNA
replication. This hypennutable state is characterised by microsatellite instability, or the
RER+ phenotype. This decreased ability to cotreCt mutations is thought to result in an
increased risk of accumulation of mutations in critical tumour suppressor genes,
oncogenes and cell regulators with the subsequent development of a neoplastic growth
and tumour development (Lazar et al., 1994), (Figure 1.5)
1.4.(IV) IRISH MUTATION SPECTRUM VERSUS INTERNATIONAL
SPECTRA
In .. effort to establish an international database of HNPCC mutations, die
in1emational collaborative group on HNPCC (lCG-HNPCC) colleaed information OIl
126 predisPOSing mutations occurring in 202 kindreds of varied geographical and ethnic
origin (Peltomaki et al., 1997). The aim of this endeavour was to provide information
to researchen, to facilitate evaluation of mutation spectra of HNPCC genes and to
assess geographic and population variation in mutation specbL Analysis of the
mutation spectra of the 202 tindreds revealed that 48 mutations were identifIed in
lIS
hMSH2 (38CfJ), 75 mutations affected the hMLHl gene (59%), one mutation was
identified in PMS1 and two were identified in PMS2. TbeJe are DO obvious mutation
'hot-spots' however in hMSH2 the most frequendy altered exons include exon 12
(17%) of hMSH2 mutatioDS, 7 (15%), 5 (9%) and 6 (9CfJ). In hMLHl mutations
occurred more frequently in exons 16 (15%), 9 and 13 (9%) and 19 (8CfJ). All but two
mutations were point mutatioDS, usually single base substitutions (59%) however •
large number of deletionfmsertions were also identified (41%). The majority of
mutations identified are unique except for a hMLHl mutation identified in 2S Finnish
families, the exon 5 hMSH2 splice site mutation (14 families) and a hMLHl codon 616
mutation (9 families) which may represent founder mutations, (see previous Section).
Comparison of the mutations identified in the Irish HNPCC population reveal
that mutation frequencies (although small sample size) are consistent with thoae of the
ICG-HNPCC report, with ']J5 of Irish mutations confined to hMSH2 (versus 38%) and
3/S confiDed to hMLHl (versus 59f1J). All mutations identified in the Irish populaliOll
lie point mutations, two affecting splice sites, one single base deletion, ODe ttansitiOll
and one transversion. No mutation hotspots were identified and there is an absence of
mutations in pedigrees which do not satisfy the all the Amsterdam Criteria (table 1.7).
The results of this study will be added to the ICG-HNPCC database so 1bat the
Irish population may be included in aD future analyses of HNPCC mutation 1rends.
The results of Ibis study provide some information OIl the mutation spectrum in Irisb
HNPCC pedigrees, may facilitate in the analyses of mutation spectra across different
edmic backgrounds and may assist in the development of efficient saeeninS sttategies
for mutation detection in affected families.
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1.4.(V) THE AMSTERDAM SELECTION CRITERIA:
TYPICAL VERSUS ATYPICAL IRISH HNPCC PEDIGREES.
Due to the absence of presymptomatic signs and a definitive clinical test 10
detenniDe HNPCC susceptibility, 1be minimum cri1eria for the identification of •
HNPCC pedigree was agreed upon at the second meeting of The International
Collaborative Group on HNPCC in Amsterdam in 1990 (Vasen d al., 1991). The
minimum criteria known as 'The Amstenlam Criteria' are :
I)There should be at least three family members with a histologically verified
colorectal cancer, one a first degree relative of the other two.
2)There must be at least two successive generations affected.
3)At least one individual must be less than SOyrs of age at the time of diagnosis.
4)FarniliaJ adenomatous Polyposis Coli must be ruled out
. . " The critaia used to select families for inclusion in this study are less stringent
than die Amsterdam critaia however StroDe family history of the disease is evident ill
aD pedigrees (see 'Pedigree details' Section 1.3.(Ill). Analysis of hMSH2 and
hMLHl in all pedigrees was carried out blind to affection status of each individual and
to whether pedigrees satisfied all the Amstadam criteria. Pedigree details were only
examined post genetic screeuinI and mutatim identification. Analysis of the 18 Irisb
HNPCC pedigrees included in this study identified two distinct groups- those pedigrees
which strictly satisfied all the Amsterdam criteria aud atypical HNPCC pedigrees which
do not satisfy an die Amsterdam aiteria but do have a strong family history of die
disease Eight pedigrees were classed • Typical Amsterdam pedigrees while 10
pedigrees failed to satisfy the criteria based OIl either (1) that there were less than 3
affected individuals within two~\'e generations or (Ii) none of the affected were
diagnosed before the qe of 50. However, all the atpyical pedigrees did have at least 2
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affected members in two generations, a strong family history of the disease and FAP
was ruled out in all cases.
Correlation of mutation identification widt Amsterdam s1atUs revealed that die
fi~ mutations identified WtK confined to 'Typical' pedigrees and DO mutaaions weft
detected in the 'atypical' Amsterdam families. SSCP as a method of analysis can fail to
detect up to SCf, of mutations aDd can be affected by chan~ in a Dumber of
experimental conditions (Hayashi et al., 1991; Sheffield et al., 1993). Comparison of
mutation detection rate in other studies with this study suggests a high detection failUle
rate when an pedigrees are taken into account, howeY« if only true Amsterdam
pedigrees are looted at the rate of mutation detection using SSCP (63~) is in bepiDa
with repor1ed detection rates of 7()'1, (Lui et al., 1996; Peltomaki et al., 1997). The
complete lack of mutations in hMSH2 and bMLHl in atypical pedigrees cannot be
explained by shortfalls in mutation deteaion rate alone. k is possible that the mutation
spec1I'UID in atypical HNPCC pedigrees diffen from 1bat of Typical AmSIeIdam
pedigrees aDd that by using the Amsterdam criteria as _ inclusion procesa theIe ia •
bias towmls selection of hMSH2 and bMLHl mutation bearing pedigrees. Mutations
in other genes including hPMS1, hPMS2 have been detected in HNPCC pedigrees (Lui
., al., 1995), furthermore a Dumba' of recent~ suggest did wbeD atypical
HNPCC pedigrees ~ analysed for hMSH2 and bMLHl mutations, the mutation
identification rates in these pedigrees are much lower dian in 'typical Amsterdam'
famities (Wijnen et aL, 1997). Perhaps mutations in other~ are responsible for
predispositicm to 1umOUr ~lopmeut in these kindreds. TIle Amsterdam aitaia Me
very stringeDt IIld were cboseD to diminatie die likelihood of dIance mutatiOll
chJsterinI. Itmay be tbat mutations in hMSH2 aad bMLHl have a mOle "aggressi~
phenotype within a pedigree and that mutations ill other lea "aggressi~ IeneI may
result ia a predisposition to coIoo caJlCa' with HNPCC symptoms but wi1b a later age m
0DSet and lower penettanee rate, as in atypical HNPCC pedigrees.
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The majority of mutations identified in HNPCC pedigrees are in hMSH2 and
hMUll, however families included in these mutations studies are for the most part
typically HNPCC in nature. Screening protocols are frequendy set up based on
analysis of published literature. 1bree important factors established from the literature
have major implications for protocol plan (i) analysis of the literature suggests that of aD
mutations identified in HNPCC pedigret8 more than 9O'f, were detected in hMSH2 and
hMUll. (ii) The Amsterdam criteria is the preferred selection criteria and (iii) There is
always a certain element of bias towards choosing genes which have the most potential
for providing results.. Taking these points into account most studies of HNPCC
pedigrees focus on bMSH2 and hMl.HI alone, this reduces the likelihood of dPtedi"l
mutations in otha' POtentially predisposing genes and increases the mutation spectrum
of the most commonly analysed genes.
The lack of mutations in atypical bish HNPCC pedigrees suggests tbat perhaps
some other~ such as hPMSI, hPMS2 (mismatcll repair ~) or TGF-BRD
(involved in epithelial ceB growth reBUlatioo) (see chapter 3) may be involved ill
predisposing to colon cancu in these pedigret8.
1.4.(VI) THE SIGNIFICANCE OF MUTATION SCREENING ·A
FAMILY FOLLOW-UP:
The identification of a HNPCC gene mutation within III affected pedigree makea
presymptomatic diagnosis of at-risk reJatiw.s possible. The early identification of
predispositioo to the development of colon cancer ill .. asymptomatic individual is
puticuIarly rdevant at the clinical~ in lenDS ofdiagnosisand~. With die
advancement of risk assessment and genetic eotnelling facilities, individuals within •
family may be made aware of ..... risk and helped to UDderstaDd the genetics of tbeir
disease this may aDow them to make informed judgements OIl their own situations.
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This has significant implications on decision making, choice of prophylactic therapy
and ultimately OIl the quality of life for the individual.
The impact of mutation identification within a HNPCC pedigree was elucidated
in the analysis of individuals in the Irish HNPCC pedigtee B. A mutation at the +3
splice donor site of exon S of the hMSH2 gene was identified in three affected first
degree relatives in this pedigree. The mutation results in the skipping of elton 5 and 1be
production of a truncated protein product Subsequent to the identification of 1be
mutation in this pedigree, individual IV:3 presented for routine colonoscopy at the age
of 31. A small lesion was detected, however histological examination did not provide
evideAce of dysplasia. Analysis of genomic DNA from this individual identified 1be
predisposing mutation canied by her father and two other affected members of die
family. An asymptomatic brother of this patient wu also analysed but DO~ of
the predisposing mutation was found. This information was passed on to the clinician
involwd in the case, for patient management
The identification of a tmnour at an early stage greatly increases the survival rate
of the patient, thus identification of an increased risk of developing a tumour facilitaa
careful monitoring of the patient and increase the chance of detecting the tumour at an
early stage. In terms ofcolon cancer, there is a greater chance that the patient will lead a
nonnallife on prophylactic removal of a tumour at an early stage. Genetic screening of
individuals in an at risk family has major implications at clinical level in tams of
surveillance, diagnosis and prophylactic 1reabneDt and has the POtential to increase the
proposis and quality of life for the patients 1bemse1ve8.
In conclusion, 18 pedigrees were analysed in this study, S mutations were
identified in S Irish HNPCC pedigrees. These tmdts are significant on a number of
levels (i) This is the fll'St analysis of the Irish HNPCC population where a large number
of pedigrees ba~ been analysed (li) Four DOvd mutations were identified. The
mutations will be added to the international HNPCC mutalioo database so that the Irish
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population may be included in all future analy~ of HNPCC mutation trends. (iii) The
exon S splice site mutation identified in the Irish population provides further evidence to
suggest that this is a HNPCC mutation hotspot (iv) The Jack of identification of
mutations in atypical HNPCC pedigrees lends support to 1he suggestion Chat HNPCC
pedigrees with • strong family history but which do not satisfy an the Ams1erdam
criteria should be analysed for mutations in a wider range of genes to detennine the true
mutation specttum in a broader HNPCC selection category. Futhermore, die
identification of a mutation within a HNPCC pedigree facilitates the ~g of
asymptomatic members in order to facilitate risk assessment and to assist at the clinical
level in terms of surveiJlance, diagnosis and prophylactic therapy. Fmally, these results
suggest that perhaps there is a case for the setting up of a national HNPCC screening
programme, the results of which can be added to a national HNPCC database, this may
serve to increase our knowledge of the disease, the mutation spectrum and the true
incidence in the Irish population and most importantly it may assist in reducing the
death rate due to colon cancer in Irish HNPCC families.
~'''f
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CHAPTER TWO
APPLICAnON OF GMPD FOR THE ANALYSIS OF I{·RAS IN
SPORADIC COLON CANCER
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2.1. INTRODUCTION
2.1.(1) SPORADIC COLORECTAL CANCER
Colorectal cancer is the most common cause ofdeath due to malignancy in nOD-
smokers in the western world. A recent report by the National Cancer Registry states
that in 1995 there were 1,757 cases of colorectal carcinoma in Ireland (Nat Cancer.
Reg., 1995 D. Delaney, personal communication). Ninety percent of aD colon cancer
cases occur in individuals where there is DO obvious family predisposition to the disease
(Lynch et al., 1993).
CLINICAL ASPECTS OF COLORECTAL CANCER
t .,....
Patients usually present with a change ill bowel habit and in many cases, reaal
bleeding. Double contrast barium enema is the standard method used to c1inically
diagnose colorectal carcinoma. A typical carcinoma appears as • obstruction of the
colon and bas a cbaracteristic apple CD'er1ite appearance. In many cases this visual
cbaracterislic is DOt obvious and confinnation requires colonoscopy, biopsy and
histological vaificatiOD. Treatment is usually by colonic teseCtion. Histological
assessment of the carcinoma and mesenteric lymph nodes is used to stage the tumour
and define prognosis. Dukes staging of colonic tumours is the most commonly used
scheme. Dukes A tumours ate confined to the bowel wall. Tumours that haw
infiltrated the bowel waD in the absence of lymph node metastasea Ire classified u
Dukes stage B. Once die regionallympb nodes become involved the aucinoma iI
classed as Dukes C. Tumours with associated liver metasfeSeS are classed u Dukes D.
Dukes A carcinomas cany a mean five year survival rate of 85%, Dukes B is associated
with a decreased value of 65% after colonic taeetion while die prognosis of Dukes
stage C with liver metastases is less than 1% (pounder et al., 1989).
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Sporadic colon cancer differs from HNPCC and FAP in that the age of onset is
greater (over 60 years) compared to hereditary colon cancer (40-45 years). Localisation
of tumours in the colon is varied with only one third being confined to the proximal
colon (compared to two thirds in HNPCC). Deviation from diploidy is higher in
sporadic cancer tumours, indicating a loss or addition of chromosomes. Prognosis in
sporadic cancers is poorer than in hereditary cancers. FAP-like polyposis is not
observed in sporadic cancers and there is no association with cancers of multiple organs
IS in HNPCC (de la Chapelle, 1995)..
GENETIC ASPECTS OF COLORECTAL CANCER.
The molecular basis by which cancers arise has been investigated abundantly.
Due to tile availability and relative ease of obtaining tumours at early intermediate and
advanced Stages of cancer development, colon cancer bas become one of the most
widely investigated human cancers.
. r
Tumorigenesis is believed to be a multistep process in which malignant
colorecta1 tumours arise from pre-existing benign adenomas. Histopathological and
clinical assessment of cancer development suggest that most tumours arise from early
adenomas, these progress in size, become dysplastic and eventually form an invasive
tumour. This concept is widely known as the theory of clonal expansion (Nowell et al.,
1976; Loeb et al., 19(1). Various models have been proposed to explain the sequential
development of colon cancer. The most widely accepted genetic model for colorectal
tumorigenesis proposes that colorecta1 tumours arise as a resuh of mutational
inactivation of tumour suppressor genes coupled to the mutational activation of cellular
oncogenes. 1be model proposes that at least fom genes are required for the formation
of a tumour and that it is the overall accumulation of mutations in specific genes rather
than the mutation order which is more important (Fearon et al., 1990).
..... ,
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1.1.(11) GENES INVOLVED IN COLORECTAL CANCER.
. "~' '. . .
TUMOUR SUPPRESSOR GENES
Tumour suppressor genes encode proteins which regulate cellular growth and
differentiation. They exert their role by down-regulating cellular proliferation when
required and thus ha\'e a vital role in preventing neoplastic progression. Loss of
heterozygosity at a specific locus in tumour DNA is interpreted as evidence that this
locus codes for a tumour suppressor protein and is based OIl Knudsons "two bit
hypothesis" which~ that the inactivation of both alleles of a gene is required to
affect the tumour suppressor role of a protein. (Knudson, 1985)
A number of tumour suppressor genes have been linked to colorectal cancer.
The APe gene on chromosome Sq plays a role in the regulation of transmission of the
contact inhibition signal in cells and is associated with a and P catenin, microtubules
and other cell adhesion molecules (Pfeifer et al., 1993; Baeg et al., 1995). Genn1ine
mutations in the APe gene are associated with a predisposition to familial adenomatous
polyposis colon cancer (FAP) (Bodmer et al, 1987; O'Sullivan et al., 1997). FAP, a
subset of the hereditary colon cancers is characterised by the development of hundreds
of colonic polyps at an early age. Progression to carcinoma is inevitable unless polyps
are surgically removed. In FAP, gennline mutations in the APe gene predispose
individuals to the development of polyposis, however loss of heterozygosity (a somatic
mutation) at the APe locus in addition to the accumulation of mutations in other cDl
regulators are required for tumour development (Bodmer et al., 1987).
The 'Guardian of the genome' p53, is putatively involved in almost aD cancers
and mutations in this gene have been detected in more than 75% of colorectal
carcinomas (Vogelstein et al., 1988). It has been demonstrated that allelic loss of the
p53 locus on 17p is associated with the progression of tumours from adenoma to
carcinoma (Fearon et al., 1987; Vogelstein et al., 1988). p53 exerts its tumour
suppressor effect by switching off replication during repair of DNA damage, cells arrest
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at the 01 checkpoint of the cell cycle, if the DNA remains un-repaired p53 may trigger
cdl suicide by apoptosis, thereby preventing further' growth and replication of the
mutant cell (Yonish- Rouach etaI, 1991).
The DCC (Deleted in Colon Cancer) tumour suppressor gene was identified by
observations of allelic loss on chromosome 18q and is associated with more than 10%
of colorectal carcinomas (Vogelstein et al., 1988). The gene encodes a receptor for
oetrin-l a molecuJe involved in axon guidance (Keino-Masu et al., 1996). Recent
studies indicate that DCC may function as a tumour suppressor by inducing apoptosis in
settings where ligand is unavailable - for example during metastasis or tumour growth
outside the region of local blood supply (Mehlen et al., 1998).
'.•.. \
ONCOGENES
Proto-oDcogenes ate geDe8 whose action promotes cellular proliferation in a
regulated manner in a normal cell. The mutant version - the activated oncogene is
ovemcti~and leads to the disrupted regulation of proIiftntion and ultimately to tumour
development Analysis of cancer related ollCOge~ demonstrates that these genes am
involved in cellular processes which if not accurately regulated would lead to cellular
proliferation. Five oncogenic classes have been defined including secreted growth
flCtOrS, ce1l surface receptors (e.g. ERR), components of the intracellular signal .
transduction pathways (e.l. Ras and ABL), DNA binding nuclear proteins (e.g. Myc
aod JUD) and components of the eycliDs netwott including eyclin dependant kioases and
inhibitors (Kamb 1995; Mullez, 1995).
Of particular importance in colorecta1 C8DCa" are the ras oncogera. Mutations in
ns genes ba~ been detected in more than SO'f, of colorectal cllcinomas (Bos ., al.,
1987; Forrester et al., 1981). Due to the presence fA mutations ill early adenomas it iI
believed that ras gene mutation may be ODe of the initiating eventI in the sporadic
colorectal cancel' pathway.
A number of models tinking the mutation of cancer genes with the stages of
colorecta1 tumorigenesis ha..e been proposed. The most widely accepted hypothesis
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suggests that a mutation in the APe gene leads to 1he generation of hyper-proliferative
epithelium, K-ras activation and possibly hypomethylation reault in the generation of an
adenoma, this coupled to the accumulation of mutations in genes such as DCC and p53
result in 1he subsequent progression from adenoma to careinoma and ultimately to
metastases (Fearon et al., 1990; Spandidos, 1995).
2.1.(111) THE RAS GENE FAMILY
The ras family constitutes a group of closely related genes which encode 21KD
(P21) proteins, which are localised to the inner plasma membrane of the cell. The ras
proteins playa functional role in signal ttansduetion from G-protein coupled receptors.
A signal from the receptor triggers the binding of GTP to the ras protein and GTP os
transmits the signal onwards to the cell. Ras proteins have GTPase activity and GTP-
ras is rapidly converted to the inactive GDP-ras form. Point mutations in ras genes
cause amino acid substitutioos which decrease the GTPase activity of the os protein.
As a result the GTPase ras signal is inactivated more slowly leading to excessive cellular
response to the signal from the receptor and thus, cellular proliferation (Barbacid,
1987).
RAS GENES AND TUMORIGENESIS
TIle involvement of K-ras ill tumorigenesis bas been widely investigated. It baa
been demons1rated using cultured cell Jines that the substitution of a single amino acid 81
particular positions in any of the ras genes results in the activation of oocogenic activity
in tbeae proteins (Forrester et al.,1987). Analysis of K-ras genes at various stages of
eolorectal tumorigeaesia suggests that K-ras mutatioos are most likely aD early event ill
the progression pathway. Mutations in K-ru have been identified in S()tI, of colorectal
can:inomas (Boa ., al., 1987; Forrester et al., 1987) and a similar percentage of
adenomas (Vogelstein etal., 1988). Furthermore, K-ras mutations have been detected
in aberrant crypt foci (ACF) of cancer patients. ACF.-e miaoscopic lesions which am
detectable (by histological staining) in 'bormal" looking mucosa of cancer patients.
137
ACF are believed to be the initial lesions which progress to carcinoma. The presence of
K-ras mutations in ACF of cancel' patients corroborates the belief that K-ras gene
mutations are an early event in colorectal tumorigenesis (Shivapurkar et al., 1997).
The identification of K-ras mutations at various stages of tumour development
stimulated the analysis of mutation type and position correlated with stage and tumour
grade. Mutations in the K-ras gene have been confined to codons 12 and 13 of exOD 1
and codon 61. The most common mutations are G-T and G-A mutations at the first and
second G positions in both codons (Cooper et al., 1982; Land et al., 1983;) with codon
12 mutations predominating (Bos et al., 1987), (Figure 2.2). Analysis of K-ras
mutations at the various stages of tumour progression reveals a correlation between
mutation position and tumour stage. Moerketk et al., 1994, have demonstrated that
Dukes B stage tumours harbour predominantly G-A (first position) codon 12 mutations,
and a smaller number of G-T mutations, whereas, Dukes C stage tumours harbour
predominandy G-T mutations with a matted absence of G-A mutations. These results
suggest that metastatic potential is related to the nature of genetic alterations in codon 12
and that cells with G-A mutations may have reduced metastatic potential Further
analysis of twnour stage and associated mutation is required in onler to determine the
true involvement of mutation type with metastatic potential.
The ability to detect K-ras mutations in a rapid and sensitive manner and 10
correlate mutation type with stage and aggressiveness of tumours may have important
implications for diagnosis and prognosis in cancer patients. More than 9()CI, of patients
with adenomas or eatcinomas confined to the mucosa can be~ with surgical
methods, whereas less than 10% of patients with distant metastases can be treated
successfuI1y (Rich et al., 1983). This highlights the significant importance that early
identification ofmetastatic potential may have on diagnosis, treatment and prognosis of
colon caDCeI' patients.
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K-RAS2
Codon 12 13
GGA acrlGGT GGC1GTA GGC
Possible Mutations: 1
TGTTGC)
Most frequent
GTIGTC
GATGAC
·AGTAGC
CGTCGC)
Least frequent
GCTGCC
Fipre 2.1. Mutations of codon 12 and 13 of the K-ras 2 gene. G to T
mutations~ the most frequently observed muaaaioDl whereas G to C
are observed at a much lower fR:queocy.
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2.1.(IV) MUTATION DETECTION
The identification of K-ras mutations may provide useful biol1l81kers for
identifying individuals at risk ofdeveloping colon cancer, particularly in tile analysis of
early pre-malignant tissues. Furthermore, the ability to identify mutations in stool
samples and colonic washings may facilitate non-invasive analysis and assist at clinical
level in the early diagnosis, treabnent and cancer prevention.
The ability to detect K-ras mutations with sensitivity and accuracy relies on the
mutation detection technique employed. A nwnber of methods have been applied to the
analysis ofK-ras mutations iDcluding SSCP, (Orita Sf al.,I989 (a and b); Moerkert, .,
al., 1994), restriction fragment length polymorphism (RFLP), RNase mismatch
cleavage assay (Forrester et al., 1987) mutant allele enrichment (MAE) and denaturing
gradient lei electrophoresis (OOGE) (Zhu et al., 1997). These techniques have proved
successful ill defeding mutations, however an require a number of manipulatioDa, are
time consuming and often require nucleotide sequence analysis in order to identify the
exact position of the mutatiOlL ~.
A new method of analysis RJCeDtly developed at the laboratory in uee
(Vaughan et al., 1998) known IS the Glycosylase Mediated Polymorphism Detectim
assay (GMPD) provi~ a highly sensitive accuraIe and reproducible method for die
aoaiysis of mutatiODl. FW1hermore the technique offen die specificity of direct
sequencing but is a much simpler process than thOle mentioned above u almost •
mutatiaos may be detected using • lingle enzyme. ID addition the process iI DDt
aequenc:e dependant, does not rely OIl the formation of beteroduplex DNA IDd il
facilitaa die detecIioD of mutations in homozygous and heterozygous samples with
equal eflicicocy. Simple manipulation of components at the mICtion allows ita use ill
the scamrinS ofmutations ill ...wlMft mutation sita are unknown (GMPD-scan),
or it may be used to detennine the presence or absence ofa mutation in a aequenc:e with
• known mutation site (GMPD-dIect).
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2.1.(V) THE GMPD ASSAY
The GMPD process employs the use of a bigbly specific DNA glycosylue
enzyme- in this case uracil DNA glycosylase. UDG is a bigbly specific DNA repair
enzyme which removes uracil from DNA Uracil is generated ift vivo by either the
misincorporation of dUTP by DNA Polymerase or by the cbmjoation of cytosine
residues (I jodahl et al., 1977). UDG clea~ the N-glycosidic bond between a uracil
base and the deoxyribose sugar iD • DNA molecule, .. apyrimidiDic (AP) site is
produced and this is usually cleaved in vivo by an associated AP endonuclease. In vi1ro
cleavage of the AP site may be induced by the addition of NaOH or specific enzymes.
(I.indabl et al., 1972; Price et al., 1991), (Figure 2.3).
GMPD-CHECK
The principle of the GMPD assay is based 011 die ability of UDG to detect die
presence or absence of • uracil residue in • specific ItJqUeDCe wi1bin a DNA molecule.
A target region ofDNA is amplified usinI primen «biped to -.plify OIIIy the region
of interest. PeR is carried out in the presence of dUI'P, dGTP, dCTP aud dATP. TbiI
eDIlft£ tbat. every T posiIioD a U residue is iDcorporated. The Oppel' or lower primer
may be IaIdIed depending 011 the Ib'aDd of interat (known • the diagnostic primer).
The primm are designed to ensure that durinI PeR ampIifica1ioa" the lint U residue is
iDcorponded • die JDUtadoD site if die mutation is present, or diJta1 to the site if die
mutation is abIeDt. Cleava,e of the JaU1bng DNA molecule with UDG JeDelIta AP
sitea wbich may be cawd emymaaicaIIy or dIemicaIIy. The mmlri"l dige8ioa
tDlfllCl.~ IeI**d by polyacrylamide IddtctI~and • specific pMtaB~
fiagmeIu is~ If tbe mutation is pIaeat tbe JabeDaI strand is cawd • die
...... positioD JeDelating a trapnmt ~ specific Jeasdl (X, lee iii 2.4) However ..
die absence ofdie IIlUta1ioD UDG &tot. DOt RrCOIDiIe die • and dravaF ocan • die
-=u U rratae 3' to die JDUWion,~ a fraImt-~ IarJer~en AaaIysis of
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the electrophoretic separation profile of the digestion fragments identifies the presence
or absence of the mutation, the pre&mee of fragment of size X indicates the presence of
the mutation, whereas the presence of fragment of size Y indieatm the absence of the
mutation at this position. As the diagnostic primer is labelled this may also be
observed, however addition of exonuclease I causes the digestion of all single stranded
DNA thus the primer may be removed if it interf~ with the analysis of the gel. This
method is particularly suitable for the routine screening for known mutatioDS.
GMPD-SCAN
The GMPD-cbeck method outlined abo~ may be modified to facilitate the
analysis of a large segment of DNA in which the presmce or abseDce of a mutation it
unknown and the investigator has no knowledge of the mutation position. This
extension of the GMPD method GMPD-scan is based on a similar principle as that of
GMPD-chect, in that UDG cleaves the sample DNA at U residues and the resulting
fragments Ie separated generating a specific DNA banding pattem which may be
analysed to identify the presence or absence of a mutation. This technique however,
does not require prior knowledge of the mutation site and hence primer design is less
stringent. It is not necessary that the primers specifically f1ank the mutation u ill
GMPD- check, rather the pimen are designed to flank a larger regiOD of i.nteRst with
either the upper or lower primer labelled. The PCR ~on is perfonned in the
presence of dOlP, dC1F, dATP and a ratio of dUTP: dTI'P. The ratio of U:T depends
on the frequency ofT residues in the DNA fragment The ratio of U:T ensures that in
CW2')' amplificatioD a proportiOll of fragments wiD have a U residue at the first T
position only, some fragments at the second T position only and so on 10 that the
resulting tr8t sample wiD provide a heterogeneous mix of DNA fragments with U
residues at an possible T positions. The resulting fragments are cleaved by UDG to
genen1e AP sites which are digested cbemicaIly or emymatically. The resulting
fragments are analysed by PAGE. Analysis of the resulting banding pattern allows the
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identification and localisation of a mutation. For example, analysis of a normal DNA
fragment containing 10 T residues with GMPD-scan will yield a PAGE ladda' of 10
labelled fragments. Analysis of a similar fragment with a T-e mutation at the third T
residue will result in the generation of a PAGE ladder of 9 fragments with the absence
of a labelled fragment at the position of the third T residue. Uracil is not incorporated at
the mutation site, cleavage does not occur so a DNA fragment of this p811icular size is
not generated. Alternatively, if the sequence contains a mutation which results in an
extra T residue, an extra labelled fragment will be observed in the PAGE ladder.
In order to screen the entire sequence for mutations, the process must be canied
out in two reactions one with the forward (F) prima' labelled aDd the other with the
reverse (R) primer labelled. The technique facilitates the identification and localisation
of a mutation without the need for multiple manipulations and DNA sequencing (Figure
2.5).
2.1.(VI) APPLICATION OF GMPD·SCAN AND GMPD·CHECK TO
MUTAnON ANALYSIS OF THE K·RAS GENE IN IRISH SPORADIC
COLORECTAL CANCER PATIENTS.
In an attempt to assess the suitability of the GMPD technology for the analysis
of K-ras mutations in tumours of cancer patients, protocols specific for the GMPD
analysis of codon 12 and 13 and the GMPD scanning of exon one of the gene were
designed.
Previous analyses of DNA from tumour cells shows that cells are very often
mixed with populations of non-mutated cells (Moerkerk et al., 1994). The specificity of
the GMPD technology (particularly GMPD-cbeck) should facilitate the detection of
mutant DNA even in a heterogeneous cell population.
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This cbapta' ptaeDts the protocols established for both methods and die results
of the appIicatioD of these techniques to die detection of K-ns mutatioos ill human
co1oreJctal cancer samples. Briefly 20 matched normal and tumour samples were
analysed using the GMID-scan aDd GMPD-cbeck methodology. Samples displaym,
scan profiles indicating the preIeIlCC of mutations wae cloned and re-analysed to W2ify
die initial results.. MUIaIioDI were w:rified by DNA sequeaciDI aDd SSCP wu
perlonned OIl samples which did not display mutations, to~ die acancy of die
GMID technology.
The K-ras gene is particularly suited to die use of GMID tecbnology - GMPD-
cbeck in particular, as most mutations are confiDed to codon 12 and 13 of the first exOD.
1'1Ir2 are six possible documented mutations within tbese codou, dms by cudul
design of appropriate oligonucleotide primers and optimisation of analysis conditions, a
protocol for die analysis of K-ras mutalions using GMPD tceImoJogy could be
estabIisbed. 11Ie dcNeIopment m• simple, sensitive and JqJIoducibIe medIod for die
identification of K-ras mutations bas major impIicatioDs for die diagnosis, progDOlia
and choice of therapy in the treatment ofcolorectal cancer patienls.
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2.2 MATERIALS AND METHODS
j ,
2.2. (I) DNA ISOLATION
DNA used in the GMPD analysis of the K-ras gene was isolated from blood,
tumour tissue, nonnal mucosa and paraffin embedded archival tissues. DNA isolation
from blood was performed as oudined in chapter 1 (Section 1.2.(I). TISSue samples
were supplied in liquid nitrogen and immediately stored at -70°C. For DNA isolation
10-20 mg of tissue was maintained in liquid nitrogen and crushed to a fine powder
using a sterile mortar and PeStle. The tissue powder was added to 6OOtJ1 of eeB lysis
solution (25mM EDTA, 2% SDS) at 4°C. 3 J1l of Proteinase K (2Omglml) was added
and samples were incubated at 55°C overnight RNase A (IU) was added to the lysate
and samples were mixed by inverting 25 times and incubated at 37°C for 60 minutes.
Tubes were cooled to room temperature. Proteins were precipitated by adding 200tJl
protein precipitation solution (10M Ammonium Acetate). Samples were vortexed
vigorously by centtifuging at 16,OOOg for 3 minutes. A tight protein pellet fonDS - (the
DNA remains in the supernatant) The supernatant was transferred to a clean tube
containing 6OOtJ1100% Isopropanol Samples were invened at least 50 times until
DNA strands became visible. Aftel' DNA precipitation the sample was centrifuged at
16,000g for 1 minute, the supernatant was removed and DNA was drained by inverting
on clean absorbent paper. 6OOtJ1 70% ethanol was added to wash the DNA pellet. The
sample was again centrifuged at 16,000g for 1 minute ethanol was removed and DNA
allowed to air-dry. DNA samples were re-hydrated by adding SO-IOOJ.tl1E butTer
(TrisHClIOmM pH 8.0, ImM EDTA) and stored at 4°C for 4 days until dissolved.
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DNA ISOLATION FROM PARAFFIN EMBEDDED TISSUES (PET):
DNA exttaction from paraffin sections was perfonned using the Nucleon HT
DNA Isolation kit from Amersham Life Science. 20-30 micron sections were sliced
from PET tumour sHdes at the histology laboratory at CUH.
TISSue sections were placed in a 1.5ml tube (one section per tube) covered with
Xylene and incubated at 370C for 20 minutes (Xylene dissolves the paraffin). Samples
were centrifuged at 1300g for 5 minutes and xylene was removed. Samples were again
incubated in xylene for 2 minua at room temperature, cmtrifuged and the xyleoe was
removed. The samples were re-hydrated by washing consecutively in 100% ethanol,
7S'J, ethanol, SO% ethanol and 25'J, ethanol and finally sterile water. Samples were
centrifuged at maximum speed for 3 minute3 between each wash. The water was
removed from the pellet after the final wash and 0.35ml of reagmt B (supplied in die
Nucleon HT kit) was added. 18J1l of Proteinase K (2OnglJ1l) was added and samples
were incubated overnight at 55°C. Proteins were removed by adding lOOJ1l of SM
sodium perchlorate solution and inverting. 6()()J1l of chlorofonn was added and tubes
were inverted again. 1501J.l of Nucleon resin (supplied) was added to the tubes and
samples were centrifuged for 1 minute at 350g. The upper aqueous phase (containing
the DNA) was removed to a clean tube, two volumes of 100% ethanol were added tubes
were mixed by inversion and incubated at -200C for 1-2 hours to allow DNA
precipitation to occur. Tubes were centrifuged at top speed for 15 minutes and the
supernatant discarded. The remaining DNA pellet was washed by adding 1m! cold 70%
ethanol, inverting, centtifuging and removing the supematanL The DNA was air dried
and re-suspeoded in 5OIJ1 ofTE (TrisHCI IOmM pH 8.0, ImM EDTA) and incubated al
40C until dissolved.
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2.2.(11) GLYCOSYLASE MEDIATED POLYMORPHISM DETECTION
ANALYSIS.
Oligo"ucleotide IAbelli"g:
Nucleotide sequences of an the primers employed in the GMPD analysis of the K-ras
gene are listed in table 2.1.
Primm (6Opmol) were end labelled by incubation with 1U of T4 Polynucleotide Kinase
(New England Biolabs), the appropriate buffer and SOuCi [-,.32p]_ATP (3<XXlCilmmol)
at 37°C for 30 minutes. One volume of 4M sodium acetate and two volumes of ethanol
were added in order to precipitate the primers and to remove unlabelled nucleotide.
Primers were incubated overnight at -200C, centrifuged for 20 minutes at high speed to
precipitate, the supematent was removed and primers were allowed to air dry. Primm
were re-suspended in water to the required concen1ration.
PCR AMPLIFICAnON OF SAMPLES FOR GMPD·SCAN ANALYSIS.
Sekcti.e ."'Pli.fictltio. 01 tit. K-,a 2 I."ctio,," ,e••:
In order to selectively amplify the functional K-ras 2 gene and not the pseudogene, an
initial PCR was performed using primer pair U+2. PeR amplification was performed
in a 101J.1 reaction volume containing 40ng genomic DNA, 40ng each primer, 0.2mM
dNTPs, lU Taq DNA polymerase and Taq DNA polymerase buffer (SOmM KCI,
10mM TrisCl pH 9.0, 0.1" Triton X-l00 and I.SmM MgC1J.
Cycling conditions: Reactions were performed on an MJ PTe-tOO tberma1 cycler.
Samples were initially denatured by heating to 9SOC for S minutes (hot-start) before the
addition of the Taq DNA polymerase. Reactions were subjected to 3S cyca of 9SoC
lSI
for 1 minute, 55°C for 1 minute and 72°C for 1 minute. To ensure complete extension
a final 10 minute incubation at 72°C was perfonned.
Prepartltio" 01 ,amp"' lor GMPD-,call:
Exon 1 of the K-ras 2 gene was amplified for GMPD analysis using primer pair
F+R. PeR amplification was perfonned in a 10J.tl reaction volume containing 2J.ll of
1/100 dilution of the U+2 amplified template, 20ng of each primer (with either the F or
R primer labelled), 1U Taq DNA polymerase, Taq DNA polymerase buffer (as before)
and O.2mM dNTP mix containing O.2mM dGTP, dCTP, dATP and O.2mM
dC'1F:dTIP at a ralio of 1: 10. Cycling parameters: Samples were subjected to a hot
start denaturation step of 95°C for 5 minutes followed by 30 cycles of 95°C for 1
minute, 55°C for 1 minute and 72°C for 1 minute, a final incubation step of 72°C for
10 minutes was also included.
PeR AMPLIFICATION OF SAMPLES FOR GMPD-CHECK
ANALYSIS.
The primers used to detect mutations at CodODS 12 and 13 of the k-ras 2 gene
included combinations of primers A, B and C. The primer sequences are listed in table
2.1 and the primer pair combinations and target mutations are outlined in Figure 2.12.
One labelled primer was included with an unlabelled primer in eAdl reaction u
appropriate.
PCR amplification using primer pair A+C was performed in a 10J,ll reaction volume
containing 2IJl of 11100 dilution of the U+2 amplified template, 20ng of each primer,
lU Taq DNA polymerase and buffer (as before) and O.2mM dNTP mix including
152
dATP, dGTP, dCTP and dUTP. No d1TP was added, this ensures that an the PeR
products are digested with UOO at the first U residue
Cycling Parameters: Amplification was performed on an MJ PTe-lOO thermal cycler.
Samples were subjected to a hot start denatmation step followed by 3S cycles of 9SoC
for 1 minute, 62°C for 1 minute, 72°C for 1 minute and a final extension step of 72°C
for 10 minutes.
PeR amplification using primer set B + C was performed as above, however an
annealing temperature of 65°C was required to ensure optimum amplification.
GLYCOSYLASE MEDIATED CLEAVAGE OF DNA:
The radiolabelled PeR products, containing U residues were treated with
Exonuclease I (Exol) (Amersham Life Sciences), to digest any primers unused in the
amplification reaction. SJ1l of PeR product was incubated with 1U of Exol at 370C for
30 minutes. Samples were subsequently~ to SOOC for IS minutes in order to heal
inactivate the exonuclease. IU of Uracil DNA Glycosylase (UDG), (E. coil) was then
added and the incubation was continued at 37°C for 30 minutes. The UDG cuts the
DNA at the U teSidues, the resulting apyrimidinic sites in the DNA sample. were
cleaved to completion by adding NaOH to a final concentration of O.OSM and ~ting to
95°C for IS minutes (cleavage occurs at the S' side of each AP site). The reaction was
neuttalised by adding Tris base to a final concenttation of 3OmM. The dilution buffer
for UDG and Exol contains 70mM HEPES-KOH, pH 8.0, ImM FDTA, ImM DIT
and 50% Glycerol
~ .'
IS3
PREPARATION OF SAMPLES FOR GEL ANALYSIS.
Samples were diluted with an equal volume of fonnamide loading dye (95%
fonnamide, 0.025% bromophenol blue, 0.025% xylene cyanol) and denatured by
heating at 85°C for S minutes. Samples were subsequently loaded onto a 20%
denaturing (1M urea) polyacrylamide gel and electtophoresis was canied out for 3-4
hours at 60 Watts. Following eJec1rophoresis autoradiography was performed by
exposing gels to X-ray ftlm for 2-12 hours (depending on the signal intensity) at -70°C.
2.2. (DI) SEQUENCE ANALYSIS OF I{·RAS GENE PRODUCTS
Samples which appeared to harbour mutations in the GMPD analysis were cloned, re-
analysed by GMPD-check: and sequenced.
CWNING OF PCR PRODUCTS
The pTag cloning vector (R&D systems) exploits the A residue that Taq DNA
polymerase adds on to the end of PCR products. Ligation of the PeR product with the
pTag plasmid was performed by incubating 2J1l of PeR product (removed directly from
a lotJ.l PeR reaction tube) with 2U T4 DNA ligase, ligase buffer, 5mM DIT, 0.5mM
ATP and 50ng of pTag plasmid in a 10J1l reaction. Samples were incubated overnight
at 16°C and subsequently transformed into competent E. coli cells as described by
Sambrook et al., 1989. Transformants were plated on LB-AMP-IP1U-X-gal plates and
incubated overnight at 37°C. Recombinant clones were selected based on antibiotic
resistance and insertional inactivation of the p..Galactosidase gene.
Sixty colonies from each plate were re-analysed by GMPD-check in order 10
determine the presence or absence of the mutant fragment Analysis was performed on
1S4
products amplified directly from colonies (colony PeR). Samples which proved
positive for mutations on GMPD-chect re-analysis were sequenced either by cycle
sequencing incOrPOrating an-P labelled dideoxy terminators and the Thermosequenase
Cycle Sequencing Kit (Amersham Life Sciences) or by fluorescent analysis using Cys
labelled primers in a cycle sequencing reaction incorporating unlabelled dideoxy
tenninators.
DNA sequencing was performed either directly on the colony PeR product
(PeR was performed using the U+2 primer pair- sequencing was performed using the
GMPD check primers A, B or C), or on plasmid DNA isolated using the
minipreparation protocol as outlined in Sambrook et al., 1989. PeR products for
sequencing were prepared by incubating sJ1l PeR product with O.IU ExoI, 0.2U
Shrimp albHne phosphatase at 37°C for 30 minutes followed by 85°C for 15 minutes.
This removes uninCOrPOrated dNWs and primers.
Analysis of the radioactively labelled sequencing products was performed by
electrophoresis in a 6% denaturing polyacrylamide gel whereas the fluorescent analysis
was performed on an ALP -express automated DNA sequencer (Pharmacia).
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( Primer name: Primer Hquenee Size I
u 5' TAO TCA CAT TIT CAT TAT TIT TAT TAT AA 3' 29mer
..
~
2
F
R
A
B
5' OCATATTAAAACAACTAAATOGAGA 3'
5' TAA GGC erG erG AAA ATG AC 3'
5' AITGITOGA TCATATTCGTC 3'
5' AACITGTTGTAGITGGAGcr 3'
5' AAACITGTGOTAGITOOAGCTOOT 3'
24mer
20mer
20mer
20mer
24mer
C 5' TAG erG TATCGTCAAGGC AcrcrrOCC TA 3' 29mer
Table 2.1. Nucleotide sequence analysis of oligonucleotide primers used in the GMPD
analysis of the K-ras 2 gene.
2.3 RESULTS
2.3.(1) PATIENTS and SAMPLES
Tumour samples and matched normal colonic mucosa were obtained from
twenty sporadic colon cancer patients who presented at Cork University Hospital.
Sporadic colon cancer cases where chosen based on the absence of FAP symptoms
(polyposis), HNPCC characteristics (exttaeolonic tumours and early onset) and
evidence for a family history of the disease. The samples set included thirteen females
and seven males an over SO years of age who had been diagnosed with cancer of the
colon. Matched normal and tumour DNA from these patients were analysed for K-ras
mutations using the GMPD-scan followed by the more specific GMPD-eheck method.
2.3.(11) GMPD·SCAN
Primer selection andprotocol design:
Hybridisation analysis using genomic DNA coupled to the characterisation of
molecular cl~ has identified two strueturally distinct human K-ras genes known as
K-ras 1 and K-ras 2 (Chang et al., 1982). Sequence analysis of these genes suggests
that the K-ras 2 gene is more complex than K-ras 1 which shares homology with the
viral ras gene. Sequence comparisons identified K-ras 1 as a pseudogene which
Jesembles a processed mRNA molecule rather than an intact gene and as such is a
functionless genetic entity (McGrath etal., 1983).
In order to specifically target the K-ras 2 functional gene, primers were designed
10 selec1ively anneal to and amplify regions unique to the K-ras 2 gene. Figure 2.6
details DNAseq~ unique to K-ras 2 and indi~ the position of the specific PeR
primer. In order to provide good quality, high quantity, clean DNA for analysis, a
Jated PeR amplification reaction was performed. The initial amplification
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product of the K-ras 2 target sequence (selection primers designated U and 2 see Figure
2.7) was subsequently used as a template in a second round PCR reaction using primers
designed to amplify exon 1 of the K-ras 2 gene (designated F and R primers see fig 2.7)
Figure 2.8 outlines the PCR strategy for GMPD scan analysis.
OPTIMISATION OF U:T RATIO.
In order to ensure a strong DNA signal and the optimum digestion at all possible
U positions in the target sequence, PCR amplification was initially perfonned using
various ratios of U:T. The optimum ratio varies for the upper and lower strands as they
have different AT content
Optimisation of the U:T ratio was performed by carrying out a GMPD analysis
with the F (forward) primer labelled at ratios 1:5 U:T, 1:10 U:T, 1:15 U:T and 1:20 U:T
on four individual samples. The resulting autoradiograph is shown in Figure 2.9. The
optimum signal was obtained at a ratio of 1:10 U:T for these samples. A similar
optimisation reaction was performed for a reaction using the R (reverse) labelled primer
with a similar optimum ratio ofU:T obtained.
Figure 2.10 represents the autoradiograph of GMPD-scan analysis on IS
matched normal and twnour DNA samples obtained from colorectal C8DCa' patients.
The reaction was camed out with the F primer labelled. A clear banding pattern
cOtreSponding to the cleavage at the T residues in the normal sample is observed. No
differences in the DNA fragment banding pattern were observed between matched
normal and tumour samples. This suggests that GOT to roT or GOT to G1T
mutations of codon 12 or GGC to roc or GGC to GTe mutations of codon 13 were
not present in the analysed samples.
Figure 2.11 shows the autoradiograph of GMPD-scan analysis on the same
sample set as above however in this reaction the R (reverse) primer was labelled. As in
the previous assay, a clear banding pattern corresponding to the number of U
incorporation sites in the sample DNA is observed. However in this case a number of
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igure 2.9. Optimi ation 0 th U:T ratio for G PD- can analy i . Exon 1 0
th -ra 2 g n wa amplified from 4 D A ample in aPR rea ti n
containing y32P labelled primer F and unlabelled primer R. Th reaction wa
p rformed with U:T ratio of 1:5, 1:10, 1:15, 1:20 indicated. Following
amplification, GMPD analy i w performed on each ample, dige tion
pr duc were parated in a 10% denaturing p lya rylamide gel and vi uali eel
by aut radiography.
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igure 2.1 . Aut radiograph h wing th G PD- can analy i of rna hed n rmal
and tumour D from 15 p radi c I n cancer pati n . E n of the K-r 2 gen
w amplifi d from 2 mat h d normal and tumour D A ampl (n t all hown) in a
re ti n containing unla lIed prim r R and l2 la 11 d prim r F. Following
amplification, G PD analy i a p rf nned on all ampl and dige ti n pr uc
were parated in a 1 ~ d naturing polyacrylamid g 1. ormal ( ) and tumour (T)
D ample were 1 ad d indi ated.
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igure 2.11. Autoradiograph showing the GMPD-scan analysis of matched normal (N) and tumour (T) DNA from 14 sporadic
colon cancer patients. PCR amplification of exon 1 of the K-ras 2 gene was performed in a reaction containing unlabelled F primer
and 12 labelled primer R. Following amplification samples were UDG digested~ NaOH treated and separated in a 10% denaturing
polyacrylamide gel. The corresponding normal DNA sequence is shown and codon 12 and 13 are indicated, additional digestion
products are present in tumour DNA from patients 2, 10, 14,40 and 44 (indicated by arrow).
1
very faint additional bands are present in sampl~ 2, 10, 14, 40 and 44. The ex1ra
bands wete observed in tumours from S sporadic colon cancer patients and are not
visible in the DNA samples obtained from the corresponding normal mucosa. This
indicates that the additional fragments are most likely due to a mutation in~
samples. The mutations which may be detected when the reverse primer is labelled are
Grr to GAT or AGT at codon 12 and OOC to GAC or AGe at codon 13.
On analysis of the results obtained using the GMPD-scan method, it was
detamined that the absence of mutations in the reaction with the F primer labelled and
the low signal obtained for additional bands observed when the R primer was labelled
was due to 1be fact that the tumour DNA may have been contaminated with normal
DNA Contamination may have occurred at the DNA extraction stage as it is likely that
surgical removal of tumour from the patient may have also included normal tissue. Tbis
may have been inadvertently extracted from the sample OD DNA isolation. It was not
possible to estimate the amount ofcontamination IS this is dependant on the accuracy of
tissue dissection.
In order to determine if the additional bands observed represent true mutations,
and to re-assess the remaining samples for mutatioDS, the GMPD-check method was
employed. The GMPD-check method is more sensitive as it specifically targets the
region of interest directly, furthermore no d'rIF residues are included in the PeR,
lIence the resulting signal is stronger as all the labelled DNA is digested at the site of the
first U residue.
2.3.(111) GMPD· CHECK ANALYSIS OF THE J{·RAS GENE
Selection of primers for use in GMPD-check analysis requires careful design
and positioning. The pre-requisite for analysis of a particular mutatioo using the GMPD
check method is that the labelled priJna' must lie close to the target base so that the first
uracil incorporated will be It the target base site if a mutation is present or at the next
dlymine residue if a mutation is absent. Due to the numerous mutations which are
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possible at codons 12 and 13 of K-ras, three primers were designed so that depending
on the primer combinations and labelling options, all mutations could be detected.
Figure 2.12 details the target sequence, primer annealing sites, possible mutations and
the primer combinations which may detect them. It should be noted that the template
DNA in an cases was the PeR product of a PeR reaction performed with primers U
and 2. These primers ensure that only the K-ras 2 gene sequence is analysed.
GMPD analysis was performed on the twenty matched normal and tumour
samples using primer combinations of (1) primer A and C with the A primer labelled,
(2) primer B and C with B labelled and (3 ) prime&' A and C with C labelled. (see fig
2.12). Analysis of the assay design revealed 1bat in the case of detecting mutation
number 3 and 7 (fig. 2.12) in codons 12 and 13 (GOT to TOT and GGC to TOe), the
resulting products are similar in size to the labelled primer. Therefore, in onier to avoid
masking the mutation by the presence of 1he primer, exonuclease I was added to the
reaction. Exonuclease I digests an single stranded DNA, thus digesting the labelled
primer and leaving the target DNA intact
PCR amplification of the K-ras gene for GMPD-cbeck analysis was performed
using the primer combination of A and C with the A (upper) primer labelled. Twenty
matched normal and tmnour DNA samples from colorectal cancer affected patients were
amplified in an AC PeR reaction, in the presence of dUTP in place of dlTP, resulting
products were digested with UDG and DNA cleavage was induced by the addition of
NaOH. Digestion products were separated by e1ecttophoresis in a 10% polyacrylamide
gel. Figure 2.13 shows the GMPD-check analysis of 10 sporadic colon cancer patients.
Lanes 20-40 represent normal and tumour samples respectively from the ten patients.
Lane 41 contains labelled primer A only which was treated with exonuclease I (Exo I).
The absence of a band in this lane demonstrates that labelled primer is removed in aD
&01 treated samples. Lane 42 contains undigested labelled primer A only (20bp
product). Normal samples which do not contain a mutation yield products of 22bp after
digestion. Full length uncut PeR product of S4bp is visible in all samples, indicating
that digestion of amplified products by UDG glycosylase was incomplete. A band of
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22bp corresponding to normal digestion product is however, present in all samples
(normal and tumour), this indicates that GOT to roT or GOT to G1T codon 12
mutations were not detected in these samples.
GMPD-check analysis was performed on the 20 matched normal and tumour
samples using primer set B and C in order to select for codon 13 mutations. PeR was
performed with the primers B and C with the B primer labelled. Twenty Normal and
tumour DNA samples were analysed as above. The possible mutations which may be
detected using this primer combination include GGC to TOe and GGC to GTe of
codon 13 (see fig 2.12) As is cleM from the autoradiograph (fig 2.14) only labelled
primer (24bp), normal digested product (28bp) and full length uncut DNA (55bp) is
present in all samples (nonnal and tumour). No additional bands or loss of fragments
were observed indicating the absence of G-T codon 13 mutations in these samples.
GMPD-check analysis of 20 matched normal and tumour samples from sporadic
colon C8DCa' samples was performed using the primer combination of A and C in the
PCR amplification. In this case the lower C primer was labelled which facilitates the
analysis of the complementary DNA strand. PeR products were digested with uno
glycosylase and cleaved with NaOH. The resulting fragments were analysed on a 10%
denaturing polyacrylamide gel The possible mutations which could be detected in this
analysis include codon 12 GOT to AGT and GOT to GAT and codon 13 GGC to AGe
and GGC to GAC. The3e mutations produce digestion products of 33bp, 32bp, 30bp
and 29bp respectively. Figure 2.15 shows the autoradiograph of GMPD-check analysis
in these samples, labelled primer C (27bp) and full length UDCUt product (54bp) are
clearly visible in lanes 43 and 41 respectively. Lanes 20-40 contain nonnal and tumour
DNA samples from the ten patients. All samples clearly display a 37 bp fragment which
corresponds to the normal digestion product, additional bands are seen in samples 2,
10, 14, 40 and 44, the additional bands in samples 2 and 44 are not cleady visible in
tile autoradiograph image (fig 2.15) but are visible in the original autoradiogmph.
Samples 2 and 40 display bands of similar size, whereas samples 10, 14 and 44 exhibit
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lanes
igure 2.14. Autoradiograph of the GMPD-check analysis of a 55bp PCR product of the K-ras 2 gene. PCR amplification
was perfonned on matched normal (N) and tumour (T) DNA samples from 20 sporadic colon cancer patients (not all shown).
The 55bp product was amplified in a PCR reaction containing unlabelled primer C and end labelled primer B. Following
amplitication samples were UDG digested, NaOH treated and separated by electrophoresis in a 100/0 denaturing
polyacrylamide gel. Lanes 10-29 contain digestion products from 10 patients. Normal digestion product is visible in all
samples (28bp). Lane 1 contains labelled primer B only (24bp) and lane 3 contains undigested full length product (55bp).
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igure 2.15. Autoradiograph of the GMPD-check analysis of a 54bp PCR product of the K-ras 2 gene. PCR
amplification was performed on matched normal (N) and tumour (T) DNA samples from 20 sporadic colon cancer
patients (not all shown). The 55bp product was amplified in a PCR reaction containing unlabelled primer A and end-
labelled primer C. Following amplification samples were UDG digested, NaOH treated and separated by electrophoresis
in a 10% denaturing polyacrylamide gel. Lanes 12-45 contain digestion products from 17 patients. Normal digestion
product is visible in all samples (37bp). Lane 48 contains labelled primer Conly (27bp) and lane 46 contains undigested
'ulllength product (54bp). Additional digestion products are visible in the tumour DNA from patients 2, 10, 14, 40 and
(indicated by arrows). The additional bands are not present in the matched normal DNA from these patients.
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larger additional fragments. The presence of the additional fragments in these samples
indicates the presence of K-ras mutations in these patientl. FunhermoJe the fragmenta
are only present in the tumour DNA from the patients and not in the DNA exttacted
from the DOrmal mucosa. The presence of the normal digestion product in all samples
including those bearing mutations suggests the presence of some normal cells in the
tumour tissue.
2.3.(IV) BACTERIAL CLONING OF mE I{·RAS GENE PCR
PRODUCTS
In order to analyse the mutant tmnour DNA without interference from the
normal DNA contaminant, PeR products were cloned and subsequendy analysed using
GMPD. PeR amplification was Performed using the original nested primer set U and
2. These primers ensure that exon 1 is amplified from the K-ras 2 gene only and not the
pseudogene. PeR products were ligated into the pTag cloning vector (R&D systems),
which exploits the T overhangs produced by Taq DNA polymcnse during
amplification. pTag ttansformed colonies were selected based on chromogenic assay.
Colonies were further analysed using the GMPD technology for the presence or absence
of mutations. Cloning of the initial PeR products ensures that only one copy of the
DNA is analysed- either a PCR product bearing the mutation or a normal product AD
samples in which an additional mutant fragment was observed during GMPD analysis
were cloned and re-analysed
RE·ANALYSIS OF CLONED "Clt PRODUCTS
Sixty colonies were selected from each of the five patient samples which
displayed a mutation on previous analysis. Colony PeR was performed using the A
and C primer combination with the latter primer labelled. Products were uno digested,
NaOH treated and separated on a 10'1> denaturing polyacrylamide gel.
Figures 2.16-2.20 display the autoradiograpbs of GMPD analysis ofcloned fragments.
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Additional (mutant) K-ras fragments were detected in 11/60 (18.3%) of colonies from
sample 40, 2/60 (3.3%) of colonies from sample 44, 4160 (6.6%) of colonies from
sample 10,2/60 (3.3%) from sample 2 and 7/60 (11.6%) of colonies from sample 14.
These values provide a basic indication of the amount ofcontamination by normal DNA
in the tumour samples. The number of colonies containing mutant samples is
~tative of the 1rUe tumour DNA and OIl average 14% of colonies analysed
contained tumour DNA Furthermore it should be noted that samples 2 and 44
exhibited mutant fragments in only 3.3% of colonies, this correlates with the intensity
of the additional fragments observed on tmeloned GMPD analyses of these samples (fig
2.1S) In the previous GMPD scan analysis samples 2 aDd 44 display additional bands,
however the signal intensity is relatively lower than that in samples 10, 14 and 40.
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lanes 1 5

3 5 728
ure :l.:lU. Autoradiograph of the GMPD-check analysis of a 54 bp segment of the K-ras 2 gene. PCR amplification of this fragment
was petformed on 60 E.coli colonies transformed with the pTag vector containing exon 1 of the K-ras 2 gene amplified from tumour
A frmn patient 44. Colony PCR was performed in a reaction containing unlabelled primer A and end labelled primer C. Following
amplification samples were UDG digested, NaOH treated and separated by electrophoresis in a 10% denaturing polyacrylamide gel. Th
normal GMPD-check profile was observed in 58 of 60 colonies analysed (not all shown). Additional bands were present in 2 samples
(lanes 16 and 22) however normal digestion product was absent from these samples, indicating that a pure colony containing only mutant
tumour samples was analysed. Lane 39 contains labelled primer C only and undigested full length product (54bp).
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2.3.(V) SEQUENCING OF MUTATION BEARING COLONIES
In order to verify that the presence of an additional fragment in the GMPD
analysis profile of a sample is due to a mutation, nucleotide sequencing was performed.
Cycle sequencing analysis was performed on tumour DNA from sample 10 and sample
2. Analysis perfonned on an ALF-express semi-automated DNA sequencer identified
the presence of a GOT to GAT codon 12 mutation in sample 10 (Fig 2.21a) and cycle
sequencing performed with the incorporation of a 33p-dCfP identified a GGC to GAC
codon 13 mutation in sample 2 (fig 2.21b). Two other samples (14 and 44) displayed
additional mutant bands of similar~ in their GMPD profiles as sample 10 and the
additional band observed in sample 40 is of similar am to that of sample 2. The
cloning and sequencing results verify that GMPD analysis of tumour DNA from
sporadic colorectal cancer patients identified the presence of three GOT to GAT codon
12 mutations and two GGC to GAC codon 13 mutations in the twenty sporadic colon
samples analysed (Figure 2.21).
2.3.(VI) SSCP ANALYSIS
The GMPD method of analysis did not identify mutations in fifteen out of the
twenty sporadic tumour samples analysed. SSCP analysis was performed in order to
determine if the technique had failed to detect any mutations which may be present in the
samples. Fifteen samples which did not display additional bands in their GMPD profile
were analysed by SSCP. Nested PCR amplified products were separated in a 6.,
polyacrylamide gel containing 5'11 glycerol Figure 2.22 shows the autoradiograph of
the SSCP analysis of K-ras exon I in 15 normal and tumour samples. SSCP analysis
under these conditions failed to identify any aberrant banding patterns, this is consistent
with the GMPD findings and suggests that the technique is accurate in its ability to
detect mutations.
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2.4. DISCUSSION:
1be ability to detect mutations in colorectal cancer associated genes has major
implications for diagnosis, prognosis and treatment of colorecta1 cancer patients. MOle
than 90% of patients with carcinomas confined to the mucosa can be successfully
treated with surgical intervention, whereas less than 1(}CJ, of patients with distant
metastases are successfully treated (Rich, ., al., 1983). Mutations of K-ras are
associated with early stages of development in colon carcinogenesis, with more than
50% of adenomas displaying K-ras defects (Vogelstein et al., 1988). 1be ability to
detect K-ras mutations ill asymptomatic patients may have significant impact OIl
widescale screening programmes and may help to significantly reduce death due to the
disease. ,. ,
In the routine identification of genetic mutations associated with disease it is
important that the technique employed is efficient, easy to implement, sensitive and
reproducible. Many different mutation detection techniques are employed in genetic
diagnosis of diseases however many are laborious, time-consuming aDd require •
combination of multiple steps (usually a mutation scanning reaction coupled with DNA
sequencing). The glycosylase mediated mutation detection systems (GMPD acan and
check) were employed in the analysis of the K-ras 2 gene in matched normal and
tumour tissue DNA samples obtained from twenty Irish sporadic colon cancer patients.
This analysis was canied out in order to develop and validate a GMPD based mutation
detectim protocol specifically designed for K-ras mutations and to assess die efficacy
and suitability of this technique in the detection of mutation activated oncogenes ill
coloreaal cancez samples.
1.4.(11) GMPD·SCAN
1be initial mutation screening ofexon 1 of the K-ras gene employed die GMPD
technology 10 scan the entire exon for mutations. This method is less seIectne than die
GMPD-cbect which selects a small target sequence ofDNA GMPD scan analysis wu
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canied out using nested PCR amplification products. The primary PCR reaction
selectively amplified DNA from the fimetional gene and not for the K-ras 1 pseudogene.
The oligonucleotide primers employed in the second stage analytical PCR were
designed so that by labelling the forward (F) primer, mutations of GOT to TOT and to
orr of codon 12 could be detected and mutations of GOC to TOe and to GTe of
codon 13 could be detected. The resulting OMPD profile was consistent with normal
DNA which does not harbour mutations. It was concluded that GMPD scanning
analysis of the twenty samples did not detect any mutations in an assay where the F
primer is the labelled diagnostic primer. . ,
A OMPD scan method where the reverse primer is the labelled diagnostic primer
was designed to detect GOT to GAT and to AGT codon 12 mutations and GOC to
GAC and to AGe codon 13 mutations. The resulting GMPD scan profile identified five
samples with additional bands. These additional fragments were only identified in the
tumour DNA sampl~ and \¥e1'e not present in the DNA from normal mucosa DNA ill
the same patients. The results suggested that the additional bands observed in the
tmnour sample8 arose from mutations in these samples.
The OMPD -scan method of analysis was successful in identifying O-A codon
12 and 13 mutations in five colorectal C8DCa' tumour samplea. The method is highly
sensitive to contamination by DOrmal DNA which ~ults in a weak signal for the mU1aDl
fragment when a large population of normal DNA is present in the sample. The ability
of the technique to detect mutations in a mixed DNA population may prove useful in the
detectiOll of mutations in clinically 6'nonnal" mue<a which is at the early stage of
neoplasia. The technique is highly efficient, does not require multiple manipulations
IDd can be completed rapidly. The GMPD scanning technique is applicable to the large
lCale analysis of multiple samples where the exact region of the mutation is unknown or
where a variety ofmutations may exist in a cluster region. The technique bas a distinct
advantage over conventional scanning methods such as SSCP, DOGE or heteroduplex
analysis in 1hat it does not require subsequent sequence analysis to vaify the presence
of the mutation. The presence or absence ofa band OIl the OMPD SCID analysis profile
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indicates that either a T residue has been inserted or lost from the sequence. By
comparing the banding pattern obtained for a sample with the pattern of a normal
sequence the position of the change can be determined and the mutation identified.
2.4 (Ill) GMPD·CHECK
, The GMPD-check method was employed to determine the sensitivity of the
GMPD scan technique. The GMPD-check method, unlike the scanning technique,
targets the exact mutation position, furt.hermore only uracil residues are iDcorporated 81
the T positions during the amplification reaction, this results in a stronger signal as aD
fragments are dig~ at the rust U position. A GMPD-check assay was designed to
specifically detect mutations of codon 12 and 13 of the K-ras 2 gene. Using
combinations of primers and various labelling options the mutations outlined in Figure
2.12 could be detected. No mutations were identified in reactions with either the A or
the B primer labelled thus GIT to TOT or to GIT mutations of codon 12 and OGC 10
GTC or to TOe mutations of codon 13 were not detected. Comparison of the results
for GMPD-check with the GMPD-scan method revealed that in both methods mutations
of this type were undetected. ,:~: f " \, '
GMPD-cbeck analysis of the samples in reaction with the C (lower) primer
labelled identified five mutatioDS, two of a higher molecular weight than the other three
samples. The mutations which could be de1ected with the C diagnostic primer am
outlined in table 2.12. Comparison of the GMPD scanning technique results with those
obtained on GMPD- chect analysis revealed that mutant fragments were obsa:ved in the
GMPD profiles of the same samples using both techniques. The GMPD-cbeck medlad
provides a stronger signal than GMPD-scan as U msidues In' incorporated at all the T
positions, thus ifa mutation exists at the first T position, all fragments will be digested
by uno at this position.
In 0Idc2' to determine if the GMPD technology bad failed to identify any mutam
samples SSCP analysis wu performed. SSCP aDalysis of exon 1 was performed OIl
the fifteen samples in which a mutation bad not been previously identified by GMPD.
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No aberrant SSCP profiles were observed which is consistent with the results of the
GMPD analyses.
Sequencing of cloned PCR products from the tumour samples of the five
patients identified the higher molecular weight fragment as a GOT to GAT mutation of
codon 12. Analysis of the lower molecular weight fragment identified the mutation as a
OGC to GAC codon 13 change.
The combined GMPD technology identified 5 K-ras mutations in twenty Irish
colon cance!' Patients (40%). This result is consistent with Previous studies which
report K-ras gene mutations in about 50% of colon tumours with 84% of these confined
to codon 12 or 13 (Vogelstein et tal., 1988).
Two OGC to GAC codon 13 mutations and three GOT to GAT codon 12
mutations were identified in tumour samples only. Analysis of previously reported
mutations reveals that the G-A mutations are the most common K-ras mutations and that
codon 12 G-A mutations occur more frequendy than any other K-ras mutations
(Moerketk et al., 1994).
2.4 (IV) GMPD ANALYSIS OF HETEROGENEOUS DNA SAMPLES.
The presence of wild tyPe DNA in tumour samples poses problems for mutation
detection in~ ceDs. A large amount of wild type DNA can often mask 1be mutant
sequence with the result that the disease causing mutation may remain undetected. The
ability to detect mutant DNA in a heterogeneous DNA sample depends OIl the sensitivity
of the mutation detection technique employed. It has been demonsttated, in DNA
mixing experiments, that direct sequencing is only successful when there is at least 1<Yf,
mutant sequence in a mixed DNA sample, whereas SSCP is sensitive at detecting
mutatioos in a sample containing 5411 mutant sequence (Burmer n al., 1989). 1'be
GMPD analysis of the K-ras gene in tumour samples from Irish colon cancer patients
shows that the technique can detect mutations in samples where the mutant to normal
allele is as low as 3.3%. Exon 1 of the K-ras 2 gene was amplified from tumour
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samples and subsequently cloned and transformed into E.coli cells. Subsequent
analysis of the resulting colonies identified only two mutant inserts in 60 colonies
containing DNA from patients 44 and 2. This is representative of the proportion of
mutant sequence in the original DNA samples. GMPD analysis of tumour DNA from
these patients was successful in detecting the mutation in heterogeneous DNA obtained
from tumour biopsies. Precise DNA mixing experiments may demonstrate that the
technique is effective at mutation detection in samples containing even less than 3%
mutant sequence.
Analysis of GMPD-scan and GMPD-chect demonstrated that the latter
technique is more successful in detecting mutations ill a heterogeneous DNA sample..
The GMPD-check technique involves the incorporation of U residues It every T
position in a PeR product of a target region, thus even in mixed DNA sequences,
digestion occurs at the first U position, therefore both tumour and normal DNA
digestion products will be observed on gel analysis. The GMID-scan technique waa
successful in identifying mutations in DNA samples with a low percentage of mutaDt
sequence, however because a ratio of U:T ~dues is incorporated into the PeR
products, digestion does not occur at the first U in every PeR product, thus the signal
from the UDG digestion products is much weaer for the mutant sequence than it is
with GMPD-chect.
, The ability of GMPD to detect mutations in heterogeneous DNA samples is
particularly significant in the analysis of mutations which predispose to cancer. K-ru
mutations have beal detected in histologically nonnal mucosa in regions adjacent 10
carcinoma, suggesting the presence of a field of genetically abnonnal tissue which may
be predisposed to the formation of further neoplasms (Bunner et al., 1989). The ability
of GMPD 10 detect K-ras mutations in samples containing predominantly wild type
DNA may facilitate 1be identification of potential tmnour sites at a stage preceding
histological evidence of neoplasia.
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2.4.(V) ADVANTAGES OF GMPD-SCAN AND GMPD-CHECK OVER
EXISTING MUTATION DETECTION TECHNOLOGIES.
Current technologies for the detection of known and unknown sequence
changes are either cumbersome, difficult to optimise, poorly informative with respect 10
the location and nature of unknown mutations or inefficient 1be GMPD-scan and
GMPD check techniques offer a number of advantages over current technologies:
GMPD technology offers a high probability of detecting a mutation/polymorphism as it
can detect all deletions, insertions and 83% of point mutations. With the inclusion of a
second glycosylase specific for G-C mutations the technique will detect 100% of base
changes.
1be GMPD methodology is faster, and more cost effective than dideoxy 01'
cbemical DNA sequencing methods, the processea can be perfonned directly on
amplified genomic DNA, require significandy fewer manipulations and utilise less
hazardous reagents. Moreover the techniques are not sequence dependant and are not
dependent on heteroduplex formatioD. Most significantly in terms of cancez mutation
detection, unlike heteroduplex and mismatch cleavage methods, the technology allows
the detection of known and unknown mutations in homozygous or heterozygous
samples. Furthermore, the intensity of the digestion product signal is likely to reflect
the proportion of mutant to nonnaI DNA in the sample. The methodology is superior to
SSCP, cleavage fragment length polymorphism (CFLP) or IXJGE as it not only detects
but also determines the sequence of the mutation. It is superior to the protein tnmcation
test (Pn) since mutations including those leading to the formation of an in-frame stop
codon are detectable and the position of the mutation is determined whereas in P1T it is
DOt.
In conclusion, it has been demonstrated that the GMPD analysis protocol
established provides a practical basis for a new and rapid approach for detecting the
presence of mutated colorectal cancer cells. Furthermore, as K-ras mutations have been
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detected in both pre-malignant tissues and carcinomas it may be employed as a method
to detect surgically~le tumours in the preneoplastic stages of tumour progression
and may have a role in reducing deaths from the disease. Moreover, the type and
position of tile mutation may provide infonnation on tumour stage and prognosis, with
some reports suggesting that the metastatic potential of tumours is related to the nature
of the genetic alteration. The glycosylase mediated mutation detection method can
accurately detect all nucleotide base changes except G-C or C-G mutations. However
the inclusion of a new glycosylase will overcome this problem. This additional
glycosylase, coupled with the K-ras GMPD analysis protocols established in this
investigation may provide an accurate simple and diagnostically applicable method for
detecting K-ras gene mutations.
In addition to K-ras gene mutations other mutant genes are involved in the
tumorigenic pathway in colon cancer. 1be GMPD method could be manipulated to scan
for and detect mutations in oth« colorecta1 caocer genes involved in the tumorigenic
pathway. The method also has potential application in the detection of mutations in a
non-invasive manner via the analysis of stool samples and colonic washings.
. Further research is required to establish the exact association between K-ras
mutation type with tumour stage and potential, however if a strong link is dermed the
GMPD analyses methods may prove an important tool in the diagnosis and prognosis of
disease and may playa significant role in reducing deaths due to colorectal carcinoma.
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CHAPTER 3
ANALYSIS OF INSTABILITIES AT REPEAT DNA SEQUENCES
IN IRISH COLON CANCER PATIENTS
.,
..
, ).
3.1. INTRODUCTION
3.1.(1). MICROSATELLITE INSTABILITY AND COLON CANCER.
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directed mismatch repair (MutS-, MutL- hosts) suggesting that mismatch repair plays a
vital role in corre.cting frameshift mutations (Levinson and Gutman, 1981).
Microsatellite instability (MI) is observed as an increase or decrease in the
electrophoretic mobility of a repeat sequence of a tumour cell which is not consistent
with the similar sequence in a normal cell (Figme 3.1). This instability is believed to be
a manifestation of DNA repair defects in the cd1 and is commonly known as the
replication error phenomenon (RER) (parsons et al., 1993; Loeb, 19(4).
, < The RER phenotyPe has been detected in more than 7~ of HNPCC tumours
(Aaltonen et al., 1993) and is associated with mutations in the mismatch repair genes
hMSH2, hMLHl, hPMSI and hPMS2 (Leach d al., 1993; Bronner et al., 1994;
Papadopoulos 0 al., 1994). In HNPCC, mutations in the mismatch repair (MMR)
genes are more common in families which satisfy the strict Amsterdam selection criteria,
(true HNPCC) (Vasen et al., 1991; Wijnen, 0 al., 1997), concordantly MI is observed
more frequently in typical HNPCC pedigrees than in pedigrees which fail to satisfy an
the criteria. The analysis of 16 colorecta1 tumours identified MI in 3 of 11 atypical
HNPCC pedigrees compared to 4 of 6 HNPCC pedigrees which satisfy an the
Amsterdam criteria (Wijnen oal., 1997). ',",
The association of MI with mismatch repair gene defects in HNPCC led to the
proposal of the 'mutator phenotype , hypothesis (Loeb 0 al., 1991). This hypothesia
. suggests 1bat some cells in cancer patients undergo an early mutation event (mismatch
repair gene defect) which renders them susceptible to the accumulation of multiple
mutations throughout the genome. If these mutations occur in essential regulatory genes
such as tumour suppressor genes or oncogenes the cells may become tumorigenic. A
mechanism for microsatellite instability involves replication induced errors in repeat
DNA sequences as a result of MMR defects. Replication induced errors occur
frequently in repeat sequences however the normal mismatch repair system detects and
corrects these mismatched nucleotides (Kunkel, 1993). If these mismatched nucleotides
are not corrected (due to defective mismatch repair), they become fixed into the genome
by subsequent rounds of replication (Kolodner et al., 1994). Replication errors by
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DNA polymerase are most likely to occur at microsatellite sequences due to their repeat
nature and are the most obvious manifestation of the RER+ phenotype (Schlotterer et
al., 1992; Loeb, 1994).
Microsatellite Instability has also been detected in sporadic colorectal cancers,
however the incidence is much lower (15%) than in HNPCC tumours (70%) (Aaltonen
et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993). The RER. phenomenon in
sporadic colon cancer tumours, as in HNPCC is associated with mutations in mismatch
repair geDe8 (Lui et al., 1995; Borresen, 1995). A notable feature of RER + sporadic
colorectal tumours is that they display HNPCC like characteristics including localisation
to the proximal colon, diploid DNA content and a more favourable prognosis than RER-
tumours (Aaltonen et al., 1993; Ionov et al., 1993; Lothe et al., 1993), this suggests
that a subset of sPOradic colorecta1 tumours may develop through a tumorigenic pathway
similar to that of HNPCC tumoun. Instability in DNA bas also been observed in
moDO, tri and tetta repeat sequences (parsons et al., 1993; Loeb, 1994).
Genetic models to explain the pathological differences between RER+ and RER-
tumours have been developed. The most plausible hypothesis proposes that two
pathways for tumorigenesis exist, one based on the RER+, MMR defect route and the
other is the more classical tumour suppressor, oncogene activation pathway. The flJ'St
model proposes that mutations at repeat sequences remain unrepaired due to defects in
the mismatch repair genes, if the increased mutation rate results in mutations of
sequences in essential reJUlatory genes such as the transfonning growth factor Pgene
receptor, a selective growth advantage for the cell results in rapid tumour advancement
The second pathway is not characterised by MI as it is believed that mismatch repair
gene defects may not have a major causative role as in RER+ tumours. This model is
based on the classical K-ras, APe, p53 tumorigenic pathway in which the accwnulation
of mutations in a number of specific genes is l"eqllimi for tumour development (Fearon
et al., 1990).
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3.1.(11). ANALYSIS OF MICROSATELLITE INSTABILITY
The RER status of a tumour is established by comparing the size of repeat DNA
sequences from tumour tissues with the repeat size of DNA from nonnal tissue of the
same patient Microsatellite instabilities are observed as increases or decreases in the
size of repeat sequences in tumour DNA which are not present in corresponding normal
DNA (Figure 3.1). Analysis of heterogeneous cell populations containing nonnal and
tumour DNA exhibits both increased repeat size due to the tumour DNA and the wild
type unaffected repeat sequence due to DNA from nonnal cells. TumoW'S are
conventionally classified as RER + if at least two repeat sequences demonstrate MI (Lui
et al., 1995). Evaluation of POlyA tracts commonly analysed in RER assessment
revealed a gradual decrease in the proportion of tumours displaying MI as the length of
the tract decreases. Poly A tracts of 26 bp-40bp showed more frequent instability than
tracts of IObp or less (parsons et al., 1995). The markers most commonly employed in
RER analysis are the BAT (for adenine tract) markers BAT 40, BAT 26 and BAT 25
(Parson et al., 1995; Lui et al., 1995) (Figure 3.2). The BAT 26 nwter amplifies a 26
bp poly-A tract of the 3' intron of exOll 5 of hMSH2. The BAT 40 nwter amplifies a
40 bp repeat of aD iDtron of the 3-B-hydroxysteroid dehydrogenase Foe aod BAT 2S
amplifIeS a 25 bp poly A 1raCt of the c-kit oncogene (parsons et al., 1995).
3.1.(Un. TRANSFORMING GROWTH FACTOR BETA RECEPTOR II.
mechanism by which TGF-B exerts its tumorigenic activity Markowitz et ale (1995)
analysed RI and RII for expression levels and microsatellite instability. Mutations were
identifIed in the TGF-B-RII gene in RER+ cell lines but not in RER- samples.
Furthermore the mutations in TGF-a-RII were confined to small repeat sequences
within the gene. These mutations result in the absence of cell swface receptors, thus it
was postulated that mutations in TGF-B-RII result in the inability of the TGF-8 protein
to exert its regulatory role in epithelial cell growth and hence it plays a central role in
tumour progression.
Further evidence for this hypothesis was provided in a study which identified
100 TGF-8-Rll mutations in 111 RER+ colon tumours (Parsons et al., 1995). These
mutations were again confmed to polyAdenine tracts within the coding sequence of the
gene. The most common frameshift mutation 0CCUl'red in a IObp poly-A sequence 81
nucleotides 7(1)-718. Mutations in this repeat sequence are predicted to result in the
production of a truncated receptor protein (parsons et 01., 19(5).
In an attempt to clarify the role ofTGF-a-RII mutations in spondic colon cancer
Akiyama et ale (1996) identified 1 samples with TGF-a-Rll mutations, these mutations
were confined to RER+ tumours and an tumours were localised to the proximal colon.
1be association ofTGF-B-RII mutations with proximal localisation was corroborated in
studies by Togo et ale (1996). These results suggest 1bat RER+ sporadic tmnours
progress via a pathway similar to RER+ HNPCC tumours.
The aunulative evidence from TGF-B-Rll studies reveal tbat 70-90% of RER+
tumours (sporadic or HNPCC) harbour TGF-B-Rll mutations. TGF-8-Rll mutations
in RER- tumours are very rare and are most likely cbance somatic mutations rather than
effects of mismatch repair defects within the cell. A common feature of TGF-B-Rll
mutations is 1hat tumours are located for the most part in the proximal colon and
prognosis is more favourable in proximal sporadic tumours, .. in HNPCC (Akiyama eI
aL, 1996). It bas been proposed that due to the nature of the intragenic repeat sequencea
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of TGF-B-Rll, the gene is a target for mismatch repair defects and is therefore
associated with an RER+ phenotype. The loss oftwnour suppressor activity of TGF-B
(through the inactivation of RD) provides a selective growth advantage to the cells thus
advancing the tumorigenic pathway (Markowitz et al., 1995; Akiyama et al., 1996).
The association of TGF-B-RII mutations with MI and proximal colon location further
corroborates the hypothesis that two tumourigenesis pathways exist- the proximal
tumour pathway involves early mismatch repair gene defects which result in an RER+
phenotype and a selective growth advantage due to TGF-B-RII defects. The second is
based on the Fearon and Vogelstein model of tumorigenesis which involves the loss of
tumour suppressor activity coupled to the mutational activation of oncogenes through
APe, K-ras and p53 gene defects. The latter pathway is not associated with the RER+
phenotype and shows no increased association with the proximal colon (Togo et Ii,
1996; Akiyama et al., 1996; Tannergard et al., 1997).
3. 1. (IV). OBJECTIVES
In order to investigate the relationship betweea instability at repeat DNA
sequences and TGF-B-RII mutations in the Irish population, 38 Irish colorectal cancer
patients were analysed for alterations in the lObp polyAtract at nucleotides 708-719 of
TGF-B-Rll and for instability at two poly-A ttact repeat loci. The 38 samples included
18 Irish HNPCC patients and 20 sporadic colorectal cancer patients. Due to the fact that
the HNPCC patients had been previously screened in this study for muta1ions in the
hMSH2 and hMLHl mismatch repair genes (chapter one) and the sporadic colon
tumours bad been analysed for Ie-ras mutations (cbapta'two), it was envisaged that
correlation of the results of the various DNA analyses (MMR- HNPCC genes, Ie-raa,
MI and TGF-B-Rll) might provide better insight into the 1Wnourigeoesis pathways in
the Irish samples analysed.
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3.2 MATERIALS AND METHODS
3.2 (I). DNA ISOLATION:
DNA samples used in the analysis of the BAT-IIR, BAT-26 and BAT-40 loci had been
previously isolated for the analysis of the k-Ras gene and the HNPCC mismatch repair
genes (chapter I and 2 ) and were isolated as outlined in materials and methods sections
of chapter I and 2.
3.2.(11) PCR AMPLIFICATION AT THE BAT-IIR, BAT-26 AND BAT-
40 LOCI
Amplification reactions were initially performed in a 2SJ.1l reaction volume
containing 60ng genomic DNA, sOng of each primer, 0.2mM dNTPs, IU Taq DNA
Polymerase, Taq DNA Polymerase buffer (SOmM KCI, 10mM TrisQ pH 9.0, 0.1%
Triton X-loo, l.SmM MgC~). Primer sequences are outlined in Figure 3.3.
Cycling parameters: Amplification was perfonned on an MJ PTC-lOO thennal cycler.
All samples were heated to 9SoC for 5 minutes (Hot-start) to ensure complete
denaturation and subjected to 30 cycles of 9SoC for I min, SsoC for I min, 72°C for 1
min followed by a fmal extension step of 72°C for 10 minutes. PeR optimisation was
performed on primer pairs which did not give good PeR yield under these conditions.
Optimisation involved perfonning the PeR reactions according to the above conditions
however, either the concentration ofMgC~or the annealing temperature was altered.
3.2 (10) BAT-DR AMPLIFICATION FOR REPLICATION ERROR
ANALYSIS:
PCR amplification with the BAT-IIR primers was performed essentially u
described above, however the reaction volume was reduced to lotJ1 and the dNTP mix
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concentration was reduced to O.02mM. In addition 2tJ.Ci of [a32P]-dCTP
(3000cilmmol) was included in the reaction. The optimum cycling parameters included
30 cycles of 95°C for 1 minute, sooC for 30 seconds, 72°C for 30 seconds and a final
extension step of 72°C for 10 minutes. Samples were diluted 1:100 with 95%
fonnamide loading dye (95% formamide, 0.025% Bromophenol blue, 0.025% Xylene
cyanol) and denatured by heating at 95°C for 5 minutes. Samples were subsequently
loaded onto a 6% denaturing (7M urea) polyacrylamide gel and electrophoresis was
carried out for 3-4 hours at 60 Watts. Following electrophoresis autoradiography was
perfonned by exposing gels to X-ray film for 5-12 hours (depending on the signal
intensity) at -70°C.
3.2 (IV).
ANALYSIS:
BAT-26 AMPLIFICATION FOR MICROSATELLITE
,,:
PCR amplification with the BAT-26 primers was perfonned essentially u
described above however the reaction volume was reduced to 10J1l and the dNTP mix
concentration was reduced to O.02mM. In addition 2tJ.Ci of [a32P]-dCTP
(3OOOCilmmol) was included in the reaction. The optimum cycling parameters included
30 cycles of 95°C for 1 minute, 52°C for 30 seconds, 72°C for 30 seconds and a final
extalSion step of 72°C for 10 minutes. sampl~ were diluted 1:100 with 95.,
fonnamide loading dye (95% fonnamide, 0.025% Bromophenol blue, 0.025% Xylene
cyanol) and denatured by heating at 95°C for ~ minutes. Samples were subsequently
loaded onto a 6% denaturing (7M urea) polyacrylamide gel and electrophoresis was
carried out for 3-4 hours at 60 Watts. Following electrophoresis autoradiography was
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performed by exposing gels to X-ray film for 5-12 hOUlS (depending on the signal
intensity) at -70°C.
3.2 (V) PCR AMPLIFICATION OF THE BAT-40 LOCUS:
PeR amplification of the Bat-40 locus for microsatellite analysis was performed
as for Bat -26 however an annealing temperature of 52°C was required. Samples were
loaded onto a 6% denaturing polyacrylamide gel (7M urea) and analysed as for the Bat-
26 locus. The optimum cycling parametezs included 30 cycles of 95°C for 1 minute,
50°C for 30 seconds, 72°C for 30 seconds and a final extension step of 72°C for 10
minutes. Samples were diluted 1:100 with 95% formamide loading dye (95%
formamide, 0.025% Bromophenol blue, 0.025% Xylene cyanol) and denatured by
heating at 95°C for S minutes. Samples were subsequently loaded onto a 6%
denatming (1M urea) polyacrylamide gel and electrophoresis was carried out for 3-4
houts at 60 Watts. Following electrophoresis autoradiography was performed by
exposing gels to X-ray ftlm for 5-12 hours (depending on the signal intensity) at -700C.
3.2.(VI). MICROSATELLITE INSTABILITY ANALYSIS:
Samples were loaded onto gels in pairs of normal mucosa DNA products
adjacent to matched tumour DNA products from the same patient The sim of the
resulting products were compared and any discrepancie3 between pairs of samples wem
scored as positive for microsatellite imtability.
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Primer
BAT 26 (f)
BAT26(r)
-" .,. ",
Sequence
S' lUA CfA CIT ITO ACf TCA GCC 3'
S' AATCATTCAACA TITITAACC 3'
Sim
21mer
21mer
BAT40(f)
BAT40(r)
BATRll (f)
BATRll (r)
S' ACAACCCTGCITTTGITCCf 3' 20mer
S'GTAGAGCAAGACCACCITG 3' 19mer
S' ClTTATTCTGGAAGA TGCTGC 3' 21mer
S' GAA GAA AGT ere ACC AGO C 3' 19mer
Figure 3.3 Nucleotide sequences of the primers employed to amplify the poly A 1raCt
repeat loci at the BAT 26 , BAT 40 and the TGF-~Rll Loci.
3.3. RESULTS
MICROSATELLITE INSTABILITY ANALYSIS.
The replication error phenotype (RER) status of 20 sporadic colon cancel'
patients and 18 HNPCC patients were analysed by comparing the mobilities of PeR
products from two repeat loci in matched normal and tumour DNA from these
individuals. The markers used to assess the RER status include BAT 26 which
amplifies a 26bp polyA tract of the 3' intron of exon S of the hMSH2 gene (Lui et al.,
1995; Parsons et al., 1995) and BAT 40 which amplifies a 40bp repeat of an intron of
the 3-B-hydroxysteroid dehydrogenase gene (parsons et al., 1995). These markers
were selected as it has been demonstrated that larger rePeat sequences display higher
frequencies of instabiliti~than smaller repeat sequences (parson et al., 1995).
3.3 (I). INSTABILITY ANALYSIS AT THE BAT 26 LOCUS
. Matched nonnal and tumour tissue DNA from 20 sporadic colon cancer patients
and 18 HNPCC patients were analysed for instability at the BAT 26 locus. Samples
were amplified by PeR with [u-32p]-dCTP incOrPOration and products were separated
by electrophoresis in a 6% denaturing polyacrylamide gel
Figure 3.4 displays the autoradiograph of the polyacrylamide gel analysis of PeR
products amplified from the BAT 26 locus. Lanes were loaded in pairs with nonnal and
1WnoUr DNA respectively, the size of the normal product was compared to the tumour
DNA to detenniDe instability. Of the 38 samples analysed (not all shown) instability
was observed in 8 samples at this locus - the instabilities were observed in 4 HNPCC
samples (IV:I-BI, D:4-HI, D:4-F and n:I-W3) and 4 sporadic colon cancer samples (3,
II, 16 and 19).
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3.3 (0). ANALYSIS OF INSTABILITY AT THE BAT 40 LOCUS
Matched nonnal and tumour DNA from the 20 sporadic colon cancer patients
and 18 HNPCC samples was analysed for instability at the BAT 40 locus. The
autoradiograph of polyacrylamide gel electrophoresis of the amplified samples is shown
in Figure 3.5. DNA instability was observed in 7 sampl~ (only samples with
instabilities are shown) these include three HNPCC samples (IV:I-Bl, ll:4-Hl, ll:l-
W3) and 4 sporadic colon cancer samples (3, 16, 17 and 19).
3.3. (lO).MICROSATELLITE INSTABILITY AT THE BAT 2R LOCUS
The BAT- IIR oligonucleotide primers amplify a IObp POlyA tract of the TGF-B-
Rll gene. This intergenic repeat locus was analysed for instability in matched normal
and tumom DNA from 20 sporadic colon cancer sampl~ and 18 HNPCC samples.
Radiolabelled [a-32p]-dClF PeR products were separated by electrophoresis in a 6%
polyacrylamide gel. Analysis of the autoradiograph (Figure 3.6) reveals no
differences in the sm of the polyA tract between normal and tumour DNA in any
sample. This suggests that the 10bp polyA tract of the TGF-B-Rll gene is stable in the
Irish colon cancer samples analysed and is not implicated in the twnourigenic pathway
(Table 3.1).
3.3.(IV). DIFFICULTIES WITH mE ANALYSIS OF THE RER
PHENOTYPE.
The ability to detect repeat sequence instability is based on the comparison of
normal DNA with tumour DNA DNA instability at repeat sequences is caused by either
1he expansion or contraction of a repeat sequence in tumour DNA which is not present
in DNA from the matched normal tissue. In order to accurately compare the tumour
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DNA with nonnal DNA it is essential that both samples are independent and do not
contain any contaminating DNA The tumour DNA employed in the analysis was
obtained from tumour biopsy samples or in some cases from archival paraffm embedded
tissues (PET). Accurate removal of purely tumour DNA requires sensitive identification
and microdissection of the tumour tissue away from the nonnal tissue. 1be samples
used in this study were carefully excised either during surgery or in the histology
laboratory at Cork university hospital. However it is difficult to assess the purity of the
sample and in some cases contamination of the tumour DNA with normal DNA may
have occurred and DNA obtained from dissected tumour samples is likely to contain
DNA from normal mucosa. Analysis of repeat sequences in heterogeneous DNA
samples is observed as the presence of repeat sequences of increased~ (instability) in
addition to the normal repeat sequence. This phenomenon was observed in the analysis
of instability at the BAT 26 and Bat 40 loci perfonned in the Irish samples investigated,
which suggests that the tumour samples do contain cells from the normal colonic
mucosa.
3.3.(V). REPEAT SEQUENCE INSTABILITY AND K·RAS GENE
DEFECTS
In order to establish the relationship between instability and K-ras gene
mutatioDS, results of the mutation analysis of the K-ras gene from chapter 2 were
compared with the instability results obtained. Instability at the BAT 26 locus was
observed in 4 samples (3, 11, 16 and 19) and at die BAT 40 locus in three similar
samples (3, 16 and 19) and one additional sample (17) which did not display
microsatellite instability at the BAT 26 locus. K-ras gene analysis identified mutations
in 5 sporadic colon C8JlCC2' samples (2, 10, 14, 40 and 44) however there was DO
correlation between samples exhibiting instability and K-ras gene mutations (Table 3.3).
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3.3.(VI). REPEAT SEQUENCE INSTABILITY AND HNPCC GENE
MUTATIONS
In order to determine the relationship between instability and mismatch repair
gene defects in HNPCC patients the results of the analysis of the BAT 26 and BAT 40
loci were compared with the results of the mutation analysis of hMSH2 and hMLHI in
18 Irish HNPCC families (chapter I). Analysis of the BAT 26 locus identified four
samples with instability- individual IV:I of pedigree BI, ll:4 of pedigree HI, 11:1 of
pedigree W3 and ll:4 from pedigree F. Analysis of the mismatch repair gene mutation
data reveals that mutations in either hMSH2 or hMLHI were identified in the four
samples. An exon S splice site mutation of hMSH2 was detected in pedigree BI, an
exon 17 mutation of hMLHI was present in pedigree HI, pedigree W3 exhibited an
exon 8 hMLHI mutation and an exon S mutation was identified in pedigree F.
Further comparisons with samples which displayed instability at the BAT 40
locus revealed that the three samples (IV:I-BI, n:4-HI and II:I-W3) correspond to
mutation positive samples and displayed BAT 26 instability also. Further evaluation of
samples which display instability reveals that they an satisfy the Amsterdam criteria for
HNPCC pedigree8 and no instability was observed in atypical HNPCC pedigree8
suggesting that this subset of HNPCC pedigree8 may have an altema1ive tumourigenic
pathway.
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3.4. DISCUSSION
The phenomenon of microsatellite instability bas been associated with mismatch
tepair gene defects in sporadic and hezeditary colon cancez (Aaltonen etal., 1995; Lui et
al., 1995). Genetic models to explain the pathogenic differences between RER+ and
RER- tumours have been postulated (Fearon et al., 1990; Tannergard et al.,I997).
It has been proposed that RER+ tumours develop through the mismatch repair
pathway in 1bat mutations in mismatch repair genes which occur at a very early stage
JeSuit in a mutator phenotype within the cell, the mutator phenotype results in multiple
mutations in other genes which ifessential in the regulation of cellular growth, result in
the Progression of tumourigenesis. The most obvious manifestation of the RER
phenotype is observed as instability at repeat sequences u tIae regions ate the most
frequent sites of DNA Polymerase slippage (Aaltonen et al., 1993; Parsons et al., 1995;
Loeb 1994; Thibodeau et al., 1993). ,<" ; ,
The RER - pathway is not characterised by MI as it is believed that mismatch
repair gene defects may not have a major causative role as in RBR+ tumOlUS. This
model is based on the classical K-ras, APe, p53 tumorigenic pathway in which the
accumulation of mutations in a number of specific genes iI required for tumour
development (Fearon et al., 1990). The accumulation ~ mutations in such genes
provide a selective growth advantage to the cell wi1h progression to carcinoma (Fearon
and VogelsteiD, 1990).
Due to the association of die RBR+ phenotype with a1ta'aIiona It repeat
sequences. TOF-8-RII which contains an intragenic repeat sequence baa been
implicated in the disease and it has been suggested 1hat it may play a vital role in the
RBR+ tumourigenic pathway (Markowitz et al., 1995).
In order to investigate the RER+lRER- tmnourigenesis pathways in 1be Irish
colon cancer population, instability was analysed It two loci and at tbe TGFB-Rll
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intergenic repeat locus in the Irish HNPCC and sporadic colon cancer samples. The
HNPCC samples had been p:eviously screened for mutations in the hMLHl and
hMSH2 mismatch repair genes (chapter 1) and the sporadic samples had been analysed
previously for K-ras gene mutations (chapter 2). The analysis of instability at repeat
sequences and the various cancer genes in these samples facilitated the comparison of
the factors implicated in the two tumorigenic pathways.
3.4. (II). ANALYSIS OF THE HNPCC POPULATION
Results of the mutation screening of hMSH2 and hMLHl in 18 Irish HNPCC
pedigrees are presented in chapter 1, briefly, mutations were identified in 5 familie8 3 in
the hMSH2 gene and 2 in the hMLHI gene. Analysis of the BAT 26 locus identified 4
HNPCC patients with instabilities, these samples correspond to samples in which a
mismatch repair gene mutation was identified (I:V-BI, D:4-HI, D:4-F and D:I-W3).
Analysis of the BAT 40 locus identified 3 samples with instabilitir3 and they correspond
to patients with mismatch repair gene mutations and overlap with samples displaying
BAT 26 instabilities (I:V-BI, D:4-HI and II:I-W3).
In summary, analysis of the HNPCC patients identified mismatch repair gene
mutations in 5 HNPCC pedigrees (see chapter 1), assessment of the RER phenotype in
the same HNPCC patients identified abnonnalities at two loci in three samples and one
locus in ODe patient, however there was no evidence for instability at either locus in a
single sample which did exhibit a mismatch repair mutation.
Further assessment of RER da1a reveals a correJation betweea samplel
exhibiting instabilities and f3IDiJies which satisfy the Amsterdam selection criteria for
HNPCC pedigrees. Of the 18 HNPCC pedigrees analysed, 8 m:e typical in that they
satisfy an the Amsterdam criteria and 10 are atypical in that they fail to satisfy all the
criteria. Due to the fact that mismatch repair gene mutations in Irish HNPCC patients
wt2'e confined to typical HNPCC pedigrees it follows that instability at repeat sequences
should be associated more frequently with these families. The correlation serves to
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substantiate the belief that the RER phenotype observed in tumour samples is a
manifestation of mismatch repair gene defects and that in families which strictly satisfy
the Amsterdam criteria- mismatch repair gene defects are most likely the major factors in
tumourigenesis.
-. Based on the premise that the RER+ phenotype is designated when a minimum
of two loci display instability in a sample, 3 of 18 HNPCC (16%) samples exhibited
this phenotype. However, when only the typical HNPCC pedigrees are analysed 3 of 8
(37.5%) display the RER+ phenotype. 'These results are somewhat lower than the
reported data for HNPCC pedigrees (70%) (Aaltonen et al., 1993), however this may
be due to the fact that only two loci were analysed, and the sample size was small. Tbe
results do however suggest that instability at repeat sequences is a common feature of
tumours which barbour mutations in either hMSH2 or hMLHl and are not common in
atypical HNPCC pedigrees in the Irish samples studied here.
3.4.(11). MICROSATELLlTE INSTABILITY IN SPORADIC COLON
CANCER.
In order to determine the incidence of instability in the Irish sporadic cancez
patients, 20 nonnal and tumour DNA samples were analysed for instability at the BAT
26 and the BAT 40 loci. Four tumour samples displayed altered migration at the BAT
26 repeat sequence when compared to matched normal DNA and three of these samples
also displayed instability at the BAT 40 locus. In addition 1 sample which did not
display instability at the BAT 26 locus did display abnormalities at the BAT 40 locus. It
has been reported that 15% of sporadic colon cancer samples exhibit the RER
phenomenon (Aaltonen et al., 1993; Ionov et al., 1993), this compares favourably with
the results obtained in the Irish samples studied here 4/20 (20%). However as the
sample size is rather small and only two loci were examined it would be necessary to
perform further analysis to verify the incidence of instability in sporadic colon cancez
samples.
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Sporadic tumours with microsatellite instability have characteristics in common
with HNPCC tmnour in that they are often located in the proximal colon (lonov ~t al.,
1993; Thibodeau et al., 1993; Aaltonen et al., 1993), are poorly differentiated (Ionov et
al., 1993) and display diploidy (Aaltonen 1993), furthennore they show far lower
frequencies of mutations in K-ras (lonov et al., 1993) and p53 (Kim et al., 1994) and
infrequent loss at 5q, 17p and ISq (Thibodeau ~t al., 1993). It bas been suggested 1bat
in the absence of mismatch repair gene defects and repeat sequence instability, tmnours
develop 1hrough an alternative pathways which involves the accumulation of mutations
in a number of essential genes including K-ras, APe and p53 (Tannergard et al., 1997).
In order to determine if there is a negative correlation between MI and K-ras gene
mutations the results of the K-ras mutation analysis presented in chapter two were
compared with the MI data on the same patients. K-ras gene mutations were identified
in five individuals (2, 10, 14,40 and 44), however microsatellite instability observed in
samples 3, 11, 16, 17 and 19 only. These results suggest that there is a negative
correlation between K-ras gene defects and MI and provides evidence to corroborate the
hypothesis that a distinct MI pathway for tumourigenesis exists and that the K-ras,
APe, p53 pathway does not exhibit MI as a characteristic phenomenon.
3.4.(IV).mE TRANSFORMING GROWm FACTOR BETA GENE AND
COLON CANCER.
The 1UF-B-Rll gene has been implicated in the RER+ mismatch repair defect
pathway oftumourigenesis (Markowitz et al., 1995). Mutations in a IObp polyA 1raCt
of the gene have been identified in 70% of RER+ colon cane« tumours (sporadic and
HNPCC) and are associated with mutations of the mismatch repair genes (parsons et
al., 1995; Togo nal., 1996; Markowitz nal.., 1995). Analysis of the IObp polyA tIaCt
at nucleotides 7(1)-718 (BAT -RII) of the TGF-B-RII gene failed to identify instabili~
in the 20 sporadic colon cancer samples and in 18 Irish HNPCC samples. These results
suggest tbat although mutations in TGF-B-Rll may play a role in advancing
tmnourigenesis in some fonDS of colon cancers, mutations in this gene are not
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associated with RER or MMR gene mutations in any of the sporadic or HNPCC
samples analysed here.
• f
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